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ABSTRACT 
The incidence and prevalence of chronic kidney disease (CKD) has escalated in the past 
decade due to an ageing population, increased prevalence of diabetes and cardiovascular 
disease. This presents diverse challenges to the healthcare system. One such challenge relates 
to medication prescribing practices for patients with CKD. The process of selecting, 
prescribing and maintaining the correct drug dosing is challenging, partly because of CKD-
induced changes in drug pharmacokinetics and pharmacodynamics. Further, there is high 
occurrence of chronic comorbidities and resultant multiple drug prescribing in patients with 
CKD. Providing optimal care to patients with CKD is an area of concern for health care 
professionals as there is evidence of suboptimal prescribing, particularly in older people. Age-
related heterogeneity coupled with overall decline in bodily function puts older people at higher 
risk of drug toxicity. Identifying ways for optimising prescribing and minimising harm in this 
vulnerable population is increasingly a priority for health care providers and policy makers.   
The overall aim of this thesis was to determine how to improve use of high-risk 
medications in patients with CKD in community settings. Five connected studies were 
conducted to address the overall aim and quantify the extent of prevalence of inappropriate 
prescribing of renally-cleared drugs and explore the factors associated with it. We also aimed 
to identify the system-level and practice-level confounding factors that serve as barriers to 
implementing evidence-based guidelines in CKD care and to determine the intervention 
strategies most likely to have an effect in overcoming the observed barriers. The findings of 
this thesis provide a basis for designing intervention programs to optimise prescribing in 
patients with CKD in community settings.  
The first part of this thesis quantified the extent of the prevalence of inappropriate 
prescribing of renally-cleared drugs in elderly patients living in the Australian community and 
aged care settings, and determined the factors associated with inappropriate prescribing. A key 
observation from this study was that, despite the existence of published guidelines for dosage 
adjustments based on renal function, aged care residents and community-dwelling older people 
are often prescribed renally-cleared medicines that are either contraindicated or above the 
recommended dosage. Over one-quarter (n=1135 out of 4035; 28.1%) of the patients prescribed 
the renally-cleared drugs examined had evidence of inappropriate prescribing of at least one of 
the drugs, based on renal function. The drugs/drug class most commonly prescribed 
inappropriately were perindopril, fenofibrate, glibenclamide, gliptins, metformin, olmesartan, 
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bisphosphonates and strontium. The factors independently associated with patients being 
prescribed one or more potentially inappropriate renally-cleared drugs were; advancing age 
(odds ratio (OR)=1.06 per year increase, 95% confidence interval [CI] 1.05-1.07, P<0.001), 
the total number of renally-cleared drugs prescribed (OR=1.44 per unit increase, 95% CI 1.29-
1.61, P<0.001), presence of diabetes (OR=1.51, 95% CI 1.30-1.76, P<0.001), presence of heart 
failure (OR=1.38, 95% CI 1.13-1.69, P<0.005) and living in aged care facilities (OR=1.28, 
95% CI 1.06-1.55, P<0.05). 
The second part of this thesis explored the factors contributing to inappropriate 
prescribing in detail. The asymptomatic nature and opportunistic diagnosis of CKD are 
considered to be some of the major reasons for the higher prevalence of inappropriate 
prescribing. Other contributing factors reported include prescribers’ lack of knowledge of 
medications requiring dosage adjustment, the presence of renal impairment being overlooked 
by prescribers, underestimation of potential adverse events, and the lack of evidence-based data 
to guide prescribers on precautions and dosage adjustments. Moreover, a lack of quantitative 
data in the available drug information sources, and contradiction and inconsistency in dosing 
information may augment the problem of dosing error. Based on this background, we evaluated 
five standard drug information sources (Australian Medicines Handbook, British National 
Formulary, American Hospital Formulary System, Monthly Index of Medical Specialties, Drug 
Prescribing in Renal Failure) for the availability and concordance of renal dosing 
recommendations for 61 drugs recommended to be used with caution in renal impairment. We 
observed a lack of consistency among the sources regarding the definition and categorisation 
of CKD. Only a slight agreement was observed in the renal dosing recommendations among 
the sources (Fleiss Kappa: 0.3). Qualitative data were not well defined, and there was a lack of 
consistency in quantitative values. Some drugs marked as contraindicated in one source were 
not mentioned as such in others. Also, drugs considered as not requiring dosage adjustment in 
one source had explicit recommendations in other sources. We concluded that a lack of data to 
guide the prescribers on dosage adjustments and lack of consistency among the standard 
information sources could potentially contribute to inappropriate prescribing. 
In the third part of the thesis, we investigated the extent to which renal dosing 
information was available in the manufacturer’s product information (PI) and determined the 
concordance in renal dosing recommendations across the 155 brands of 27 drugs. For each 
brand, the PI was consulted and data referring to renal impairment was collated. The renal 
dosing recommendations varied significantly among different brands of the same drugs. Also, 
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there was inconsistency in use of CKD terminology and classification of renal impairment. 
There was generally a lack of detailed information in the PI regarding the use of drugs in 
patients with renal impairment. The majority of PI documents (88 of 155 PI; 57%) provided 
quantitative recommendations regarding dosage adjustments for renal impairment, but this was 
often not detailed enough to help users make an informed decision. For 37 PI documents (24%), 
an altered dosage regimen was proposed without a quantifiable measure of renal function 
reported in the dose recommendation. The results of pharmacokinetic studies in patients with 
renal impairment were not presented in 59 PI documents (38%). Twenty brands did not have 
full PI and advice such as “contact the manufacturer” was given. Four PIs mentioned the lack 
of data regarding use in patients with renal impairment and thus recommended avoiding the 
drug in renally impaired patients. We concluded that a lack of data to guide the prescribers on 
precautions and dosage adjustments and lack of consistency among the PIs could potentially 
contribute to inappropriate prescribing.  
In the fourth part of the thesis, we determined the agreement among the Cockcroft-
Gault, the Modification of Diet in Renal Disease (MDRD) and the CKD-Epidemiology 
Collaboration (CKD-EPI) equations, if hypothetically used in dosing of renally-cleared drugs 
in primary care settings. There was a significant difference in the kidney function values 
estimated from the three equations. There was a good overall agreement among doses rendered 
using the equations. Dosing based on either CrCl or an eGFR with body surface area 
normalisation removed appeared acceptable and practicable for the purpose of dosing of non-
critical drugs in the primary care settings. However, it is worth noting that in some instances 
there were potentially important discrepancies among the doses rendered from the equations 
so caution should be exercised. 
In the fifth part of the thesis, we conducted a survey of general practitioners (GPs) to 
determine what sort of implementable strategies are most likely to have an effect on GPs to 
improve renal dosing in patients with CKD. There was a low familiarity with CKD 
management guidelines and a general lack of confidence in identifying and performing dosage 
adjustment of renally-cleared drugs among the GPs. There was a general scepticism concerning 
the usefulness, reliability and applicability of the information sources for renal dosing. The 
major barriers to using guidelines were lack of easy access during consultations and ambiguous 
recommendations on renal dosing between the different sources. The factors responsible for 
inappropriate prescribing from the GPs’ perspective were a lack of awareness on the 
availability of information sources and a lack of practice of routine monitoring of renal 
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function. The most favoured interventions were decision support systems, online education 
training and medication reviews by pharmacists. 
In the last part of the thesis, we also conducted a systematic review to explore the nature 
and types of interventions conducted by pharmacists for patients with CKD and the outcomes. 
Pharmacist-mediated drug use evaluation and monitoring appeared promising in decreasing the 
rate of over dosing, usage of unnecessary drugs and improving physician adherence to dosing 
guidelines. The high level of acceptance of pharmacists’ recommendations by the physicians 
indicates the greater opportunity for pharmacists to be involved in CKD care. 
In conclusion, optimising prescribing in patients with CKD requires accurate 
identification of CKD in clinical settings and individualisation of medication prescribing based 
on the patient’s renal function, pharmacokinetic parameters and goals of care. Updating the 
information sources to present the key elements in an unambiguous format, in conjunction with 
efforts to build consensus among the standard information sources, seems necessary. As a 
result, GPs can easily incorporate the recommendations into daily practice. Regular updating 
of the content of drug information sources is also warranted. An emphasis should be placed on 
conducting and disseminating large population-based studies focused on determining the 
correct drug dosage based on renal function. The provision of more complete pharmacokinetic 
data in special groups, such as those with renal impairment, should be compulsory for the 
registration of new drugs. An expiry date should be assigned for PIs in order to enforce 
upgrading of the information over time. Improved dissemination of existing guidelines, online 
education to increase awareness of dosage problems in patients with CKD and adopting 
decision support systems to aid GPs in identifying and dosing renally-cleared drugs, also 
appear warranted. 
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Chapter 1 INTRODUCTION 
1.1 Thesis background  
Chronic kidney disease (CKD) is one of the most common causes of preventable death 
in Australia. It is an important therapeutic problem due to its increased prevalence and a close 
association with substantial mortality and morbidity.1 CKD is characterised by the occurrence 
of kidney damage and the progressive and irreversible loss of a patient’s kidney function over 
a period of 3 months or more.2 The major health outcomes of CKD include complications 
associated with impaired kidney function, development of cardiovascular disease (CVD) and 
progression to kidney failure.3 It is a global public health problem affecting more than 50 
million people worldwide, with more than 1 million of them receiving kidney replacement 
therapy.4 The incidence and prevalence of CKD has escalated in the past decade with the 
increased prevalence of risk factors such as diabetes and hypertension.5 However, early 
diagnosis, optimal use of medications, treatment of comorbid conditions, management of 
complications, patient education and preparation for kidney replacement therapies, have all 
been associated with better outcomes in patients with CKD.2 6 At each CKD stage, patients 
benefit from measures that delay or prevent the progressive loss of kidney function, such as 
appropriate selection of medication and the reduction of cardiovascular risk factors.3 
Avoidance of nephrotoxic drugs and dose modification of renally-cleared medications play a 
crucial role in preventing and delaying the drug-related adverse outcomes in patients with 
CKD.7  
There have been national and international attempts to improve the detection and 
management of CKD.8 Various national and international nephrology bodies have released 
CKD management guidelines in recent years. Specialised texts have been designed to guide 
the dosing of medications in patients with CKD. However, despite their wide promulgation, a 
growing body of evidence suggests CKD is underdiagnosed and under-treated.9 10 Studies have 
indicated that inappropriate prescribing of renally-cleared medicines is common in patients 
with renal impairment both in Australia and internationally.9-15 
There is a need to identify and understand the factors that serve as enablers for 
inappropriate prescribing in order to improve the usage of high-risk medications in patients 
with CKD. It is essential to understand barriers to implementing evidence-based guidelines in 
CKD care. This will assist in developing strategies to enhance the uptake of the guidelines in 
the clinical setting. Understanding what sort of intervention strategies would potentially have 
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an effect on GPs would facilitate designing and implementing structured intervention programs 
aimed to improve the overall prescribing and quality of care in CKD. 
This thesis reports on work that investigated the extent of inappropriate prescribing of 
renally-cleared drugs in elderly patients in the Australian community and determined the 
associated factors. This thesis also identifies the system-level and practice-level confounding 
factors that serve as barriers to implementing evidence-based guidelines in CKD care. 
 
1.2 Aim of the thesis 
The general aim of this thesis was to investigate the magnitude of the issue and 
determine how to improve use of high-risk medications in patients with CKD in the community 
setting.  
The aims of the specific studies were as follows. 
i. Evaluate the extent of inappropriate prescribing of renally-cleared drugs in 
elderly patients in the Australian community and determine the associated 
factors. 
ii. Examine the standard drug information sources for the availability and 
concordance of renal dosing recommendations. 
iii. Investigate the nature and the extent to which renal dosing information was 
available in the manufacturer’s product information (PI) and determine the 
concordance in renal dosing recommendations across the various brands of the 
same drug. 
iv. Determine the agreement among the Cockcroft-Gault, the Modification of Diet 
in Renal Disease (MDRD) and the CKD-Epidemiology Collaboration (CKD-
EPI) equations, if hypothetically used in dosing of renally-cleared drugs in 
primary care settings. 
v. To understand the options available to GPs to assist in managing medications 
in patients with CKD and to assess GPs’ views on applicability, utility and 
potential barriers to using the available guidelines and information sources for 
drug dosing purposes in primary care settings. 
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Figure 1.1 Thesis Structure 
 
1.3 Rationale of the thesis 
Studies have examined the dosing appropriateness of primarily renally-cleared medicines in 
hospital and nursing homes settings, and recommended the need for general education and 
raising awareness of medications requiring dosage adjustment, along with the need for routine 
assessment of renal function.9-15 However, the prevalence of inappropriate prescribing in 
patients with renal impairment in community settings has received relatively little attention, 
particularly in Australia; there is limited data on the prevalence of inappropriate prescribing of 
renally-cleared drugs in older community-based patients. The research outlined in this thesis 
investigated the extent of inappropriate prescribing of renally-cleared drugs in elderly patients 
in the Australian community setting. 
A clear understanding of the factors that influence prescribing and guideline adoption 
is essential for improving the usage of medications, and ensuring optimal care and outcomes 
for patients with CKD. This thesis explored these factors in greater depth than previously 
reported. There is limited information available on the potential barriers to optimal 
management of medications in CKD from the prescriber’s perspective. Little is known about 
the information sources that GPs use when deciding on drug doses for patients with CKD. To 
date, there have not been any studies conducted to identify GPs’ perspectives regarding the 
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applicability and utility of these guidelines in patients with CKD in Australia. We were 
interested in undertaking a survey to understand the options available to GPs to assist in 
managing medications in patients with CKD and to assess GPs’ views on applicability, utility 
and the potential barriers to using the available guidelines and information sources for drug 
dosing purposes in primary care settings.  
Studies have reported a knowledge gap, limited educational and administrative 
resources for CKD management and a lack of awareness of estimated glomerular filtration rate 
(eGFR) and its correct usage as some of the reasons for suboptimal CKD management practices 
in the primary care settings. 16-22 23 24  This thesis elaborates more upon the results of these 
studies by examining factors beyond those of GPs’ knowledge and understanding, to identify 
system-level and practice-level confounding factors that serve as barriers to implementing 
available evidence-based guidelines for prescribing in patients with CKD. 
This thesis determines the type of strategies that are most likely to have useful input in 
GPs’ care of patients in order to improve prescribing in patients with CKD. The findings and 
benefits of this research will accrue indirectly and in the long term as this provides a framework 
for designing intervention programs in the primary care settings, aimed to reinforce knowledge 
about CKD and the available guidelines, drug use problems in CKD, and to improve the quality 
of care in CKD. 
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Chapter 2 LITERATURE REVIEW 
2.1 Chapter Introduction 
This chapter presents a background review on CKD covering the definition, 
classification, causes, and its risk factors. Additionally, CKD epidemiology, and its 
comorbidities and complications, will be reviewed. This is followed by an overview on the 
effect of renal impairment on drug pharmacokinetics and drug dosing considerations for 
patients with CKD with a focus on drugs that need to be used with caution. Emphasis will be 
placed on the methods used to assess renal function, a step by step approach to dose adjustment 
and the most commonly used CKD management guidelines and information sources developed 
to guide prescribers in renal dosing. 
CKD is a general term that encompasses all degrees of decreased renal function, from 
patients at risk of damage to kidney failure through mild, moderate, and, severe impairment. 
CKD is recognised as a significant global health problem and should be managed in its early 
stages. CKD can be detected with routine laboratory tests and early intervention can prevent 
and delay its progression, reduce complications and therefore, improve both the likelihood of 
survival and quality of life for CKD patients. With a growing elderly population and increasing 
numbers of patients with diabetes and hypertension, the prevalence of CKD will continue to 
rise. As a result, primary health care practitioners will be confronted with the management of 
complex medical problems that are unique to CKD patients. 
 
2.2 Chonic Kidney Disease 
2.2.1 Definition and classification 
Glomerular filtration rate (GFR) is accepted as the best overall measure of kidney 
function.2 The normal level of GFR varies according to age, gender and body size. Normal 
GFR in young healthy adults is approximately 120 to 130 mL/min/1.73 m2. A GFR level of 
less than 60 mL/min/1.73 m2 indicates a loss of half or more of the adult level of normal kidney 
function.6 Below this level the risk of complication of CKD increases. In the past, the definition 
of CKD has been vague , with use of imprecise terminology such as ‘pre-dialysis’, ‘pre-end-
stage renal disease’ ‘chronic renal insufficiency’, ‘chronic renal disease’, ‘chronic renal 
impairment’ and ‘chronic renal failure’ and has been categorised mainly by cause.25 CKD 
should in principle, be classified in accordance with severity, diagnosis, treatment and 
prognosis, and consistently linked with “clinical action plans” to facilitate management.26 In 
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2002, the Kidney Disease Outcomes Quality Initiative (KDOQI) of the National Kidney 
Foundation (NKF) established a classification system for CKD that has been accepted and used 
worldwide.2 “This classification defines CKD as a measured GFR or eGFR1 of less than 60 
mL/min/1.73 m² for three months or more, with or without kidney damage, or kidney damage 
for three or more months, as defined by structural or functional abnormalities of the kidney, 
with or without decreased GFR, manifested by either: pathologic abnormalities, or markers of 
kidney damage, including haematuria or albuminuria or abnormalities in imaging tests.2” This 
evidence-based classification categorises CKD into five stages according to the level of kidney 
function with a clinical action plan, as shown below in Table 2.1. The Kidney Health Australia 
CARI (Caring for Australians with Renal Impairment) guidelines further categorise the stage 
3 CKD into stage 3A (GFR=45-59 mL/min/1.73 m2) and stage 3B (GFR= 30-44 mL/min/1.73 
m2).26 
 
Stage Description GFR (mL/min/1.73m2) Clinical action* 
 At increased risk 
≥90 
(with CKD risk factors) 
Screening, CKD risk reduction 
1 
Kidney damage with 
normal or ↑GFR 
≥90 
Diagnosis and treatment, 
Treatment of comorbidities, 
Slowing progression, 
CVD risk reduction 
2 
Kidney damage with 
mild ↓GFR 
60-89 Estimating progression 
3 Moderate ↓GFR 30-59 
Evaluating and treating 
complications 
4 Severe ↓GFR 15-29 
Preparation for kidney 
replacement therapy 
5 Kidney Failure  <15 (Dialysis) 
Replacement (if uraemia is 
present) 
GFR: Glomerular Filtration rate, CVD: cardiovascular Disease 
Table 2.1 Classification of CKD 
*Includes action from preceding stage, shaded area identifies patients who have CKD, unshaded area delineates individuals 
who are at increased risk for developing CKD.  
 
                                                          
1 eGFR stands for estimated Glomerular Filtration rate, derived using the GFR predicting equations that 
combine serum creatinine value with patient factors such as age, gender and weight. 
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2.2.2 Causes and risk factors  
The causes for CKD, as defined above, are not well established. However, the causes 
for end stage renal disease (ESRD) as encountered in Australia are; diabetic nephropathy (32% 
of all new patients), glomerulonephritis (24%), hypertension (14%) and reflux nephropathy 
(3%). (Figure 2.1) The major risk conditions for patients with CKD are hypertension, diabetes, 
obesity and dyslipidaemia.27  
 
Figure 2.1 Causes of end stage renal disease 
Source Collins et al (2009)27 
 
The various risk factors for CKD are as follows.28 
Socio-environmental factors: Socioeconomic status, nature of environment, availability of 
health care28 
Biomedical risk factors: Diabetes, high blood pressure, metabolic syndrome, obesity, urinary 
tract infections, kidney and urinary stones, glomerulonephritis, streptococcal infections, drug 
toxicity28 
Behavioural risk factors: Tobacco smoking, physical inactivity, poor diet28 
Predisposing factors: Age, gender, ethnicity, family history, genetic makeup28 
 
2.2.3 Clinical presentation 
Patients usually present themselves to their physicians when a significant loss of kidney 
function occurs. Up to 90% of the renal function can be lost before the clinical symptoms of 
CKD become apparent; therefore, routine screening and monitoring is important.29 Patients 
with CKD may not notice any symptoms until they reach ESKD requiring dialysis or a 
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transplant (GFR <15 mL/min/1.73m2). The symptoms of ESKD include lethargy, nocturia, 
malaise, anorexia, nausea, pruritus, restless legs and dyspnoea.30 
 
2.2.4 Comorbidities and complications 
Diabetes, hypertension, cardiovascular disease, and anaemia are common in patients 
with CKD and managing them is a challenge.31 The prevalence of these comorbidities increases 
as CKD progresses (Figure 2.2).32 Most patients (86%) with advanced CKD have at least one 
comorbidity.33 Early detection and intervention has shown to reduce the progression of CKD 
and its complications, and primary care providers have an important role in the diagnosis and 
management of comorbidities in patients with CKD.34 It is essential to regularly check for the 
known complications of CKD and to monitor treatment targets.  
 
Figure 2.2 Prevalence of comorbidities by CKD stages32 
 
Hypertension 
Hypertension is both a cause of CKD and a complication of CKD, and can be difficult 
to control. Hypertension is associated with accelerated progression of CKD, increased risk of 
developing and worsening of coronary heart disease and stroke.35 The prevalence of 
hypertension is 84% in patients with stage 4–5 CKD, compared with 23% of adults without 
CKD.32 In addition, up to 75% of patients with CKD have blood pressure levels > 140/90 mm 
Hg, more than 10 mm Hg above the current treatment target in CKD. CKD with hypertension 
is a compelling indication for the use of angiotensin-converting enzyme inhibitors (ACEIs) or 
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angiotensin receptor blockers (ARBs) as first-line therapy.36 With the initiation of treatment 
with ACEIs or ARBs, GFR may reduce and the potassium level may rise.37 If the acute decrease 
in GFR is less than 25% below the baseline level and stabilises within two months, the 
medication should be continued. If the reduction in GFR is greater than 25% below baseline 
value, these drugs should be stopped and the patient should be examined for bilateral renal 
artery stenosis.38 If the serum potassium concentration is greater than 6 mmol/L despite dose 
reduction, diuretic therapy and dietary potassium restriction, then the medication should be 
stopped. Combined therapy of ACE inhibitor and ARB is not recommended.38 
 
Hyperkalaemia 
Almost one-fourth of patients with stage 5 CKD experience a life-threatening episode 
of hyperkalaemia that requires emergency treatment. The incidence of hyperkalaemia is low in 
patients with stage 3 CKD but may develop with ACEI or ARB therapy. In more severe CKD, 
use of ACEIs or ARBs and the presence of diabetes have been found to be associated with the 
increased frequency and severity of hyperkalaemia.39 Measures to lower serum potassium 
should be initiated if the concentration exceeds 5 mmol/L. Reduction of ACEI, ARB, and beta-
blocker dosages and the use of loop diuretics or a combination of loop and thiazide diuretics, 
and treatment with alkali replacement in patients with acidosis also can effectively manage 
hyperkalaemia. 
 
Diabetes 
Patients with diabetes are at an increased risk for CKD and cardiovascular events. The 
patients with diabetes require intensive blood glucose control in order to reduce the risk of 
developing microalbuminuria, macroalbuminuria and/or overt nephropathy.40 Glycaemic 
control is challenging in patients with CKD because of increased sensitivity to medications and 
adherence issues related to the complexity of the regimen.41 Patients with stage 3–5 kidney 
disease have an increased risk of hypoglycaemia due to decreased medication clearance and 
impaired kidney gluconeogenesis.42 Therefore, glucose levels should be monitored closely and 
treatment should be adjusted slowly to reduce the risk of hypoglycaemia.  
Drugs for diabetes should be used with correct dose adjustment. The Australian 
Medicine Handbook recommends avoiding glibenclamide in patients with CKD.43 
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Glibenclamide and other long-acting sulfonylureas are more likely to induce serious 
hypoglycaemia in CKD patients.44 45 Some of the metabolites of glibenclamide that have 
hypoglycaemic activity are likely to accumulate in patients with CKD and this increases the 
risk of hypoglycaemia.45-47 Brier et al reported an increase in elimination half-life of 
glibenclamide from 3.3 hours to 5.0 hours in haemodialysis patients.48 Several studies have 
reported decreased elimination of glibenclamide in patients with CKD resulting in increased 
risk of hypoglycaemia and have recommended using caution in patients with CKD .49-51  
Metformin is contraindicated in severe renal impairment and has been recommended to 
be used with caution in mild to moderate impairment due to the risk of lactic acidosis.43 As 
metformin is entirely cleared by the kidneys, it may accumulate when renal function decreases, 
with the potential for exposure-dependent toxicity that could precipitate lactate accumulation.52 
53 However, several observational studies have failed to show a consistent link between 
metformin and lactic acidosis.54-57 The incidence of lactic acidosis associated with metformin 
therapy in CKD patients is usually low and metformin is not necessarily responsible when 
lactic acidosis occurs in patients taking this medication.55 58 Studies show that although drug 
levels are higher in those with kidney dysfunction, levels are still maintained largely within the 
therapeutic range and lactate levels are not substantially increased when metformin is used in 
patients with renal impairment.53 59 60 A recent review also reported that the rate of lactic 
acidosis in patients taking metformin was similar to people with diabetes mellitus who did not 
take metformin.55 There have been increasing calls to update the metformin-prescribing 
guidelines to allow for use of this drug in patients with mild to moderate CKD.61 62 However, 
to date there are no randomised controlled trials conducted in patients with mild to moderate 
CKD to determine if metformin is safe. 
 
Mineral and bone disorder 
The metabolism of calcium, phosphate, parathyroid hormone (PTH) and vitamin D are 
adversely affected due to renal impairment.63 When GFR falls below 60 mL/min/1.73m2, the 
renal clearance of phosphate is decreased. This results in a higher level of serum phosphate. 
With the decline of kidney function, there is decline in the level of calcitriol, the most active 
form of vitamin D, which is synthesised in the kidney. Subsequently, the calcium level falls as 
there is less calcitriol dependent calcium uptake from the gastrointestinal tract. The cumulative 
effect of elevated phosphate level, and diminished calcium and vitamin D level, stimulates 
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parathyroid hormone production.64 The elevated levels of PTH increase the resorption and 
release of mineral from bone. This leads to an increased risk of fracture.65 
 
Anaemia  
The prevalence of anaemia increases markedly with decreasing GFR. Anaemia related to CKD 
usually occurs at GFR less than 60 mL/min/1.73m2 and is more prominent in patients with 
severe CKD.32 Anaemia of CKD is related to reduced erythropoietin production by the kidney. 
Treatment with erythropoietin agents improves health-related quality of life but it has been 
found to increase risk of stroke and other cardiovascular events. CKD patients with anaemia 
should be evaluated for iron deficiency and treated with oral or parenteral iron when indicated 
before using erythropoietin agents 66 
 
Cardiovascular disease  
About 63% of patients with advanced CKD encounter cardiovascular events compared with 
5.8% of adults without CKD.32 Patients with CKD are more likely to die from cardiovascular 
diseases than progress to dialysis, and cardiovascular events account for 45% of deaths in 
dialysis patients.35 Conditions like hypertension, dyslipidaemia, diabetes, anaemia and other 
metabolic abnormalities increase the likelihood of occurrence of cardiovascular events in 
patients with CKD. Prevention and treatment of cardiovascular disease in CKD involves 
addressing these factors.  
 
Dyslipidaemia  
CKD is associated with substantial abnormalities of lipid metabolism, including increased low-
density lipoproteins, triglycerides, very-low-density lipoproteins, and reduced levels of high-
density lipoprotein cholesterol.67 Dyslipidaemia is more severe in individuals with proteinuria, 
particularly those with nephrotic syndrome. Dyslipidaemia should be treated as per CVD 
recommendations and targets.67 
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Other comorbidities 
In addition to the comorbidities outlined above, patients with CKD are more likely than those 
without CKD to have acidosis, osteoporosis, depression, and sexual dysfunction.68 69 
Identifying and treating these comorbidities may significantly improve quality of life for 
patients with CKD. Depression can affect 1 in 5 people with CKD and 1 in 3 individuals on 
dialysis.68 It has detrimental effects on mortality, rates of hospitalisation, medication and 
treatment adherence, nutrition, and overall quality of life.  
 
2.3 An overview of CKD in Australia 
CKD is the 9th leading cause of death in Australia.70 CKD is a stronger risk factor for 
coronary events and all-cause mortality than diabetes.28 One in 10 Australian adults have 
indicators of CKD including reduced kidney function and/or albumin in the urine. 
Approximately 1.7 million Australians aged 18 years and over had some biomedical signs of 
CKD.70 71 Fewer than 10% of people with CKD are aware they have this condition. This equates 
to over 1.5 million Australians being unaware that they have indicators of CKD.28 Risk factors 
for chronic kidney disease are highly prevalent in Australia and the number of Australians at 
risk is increasing. Indigenous Australians in particular are at high-risk. Aboriginal and Torres 
Strait Islanders have a greater prevalence of CKD and are approximately 10 times more likely 
than non-Indigenous Australians to develop end stage renal disease.72 It is most prevalent in 
remote areas and is strongly correlated with socioeconomic disadvantage.72  
 
 
Figure 2.3 Prevalence of treated end stage kidney disease in Australia, by age and sex 2013 
Source: AIHW analysis of Australia and New Zealand Dialysis and Transplant Registry data70 
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There were over 1.6 million hospitalisations where CKD was the principal and/or additional 
diagnosis in 2013-14.73 This represented 17% of all hospitalisations in Australia.73 Dialysis 
accounted for the majority of (81%) of these hospitalisations (Figure 2.4). 
 
 
Figure 2.4 Reason for hospitalisations in Australia 
Source: Australian Institute of Health and Welfare73 
 
CKD accounts for 1 in 10 deaths in Australia.73 It was an underlying or associated cause of 
15,900 deaths recorded in 2013.73 The frequency of hospitalisation and CKD-associated death 
was 3 to 5 times higher among Aboriginal and Torres Strait Islander Australians compared 
with non-Indigenous people.72  
 
2.4 Effect of Kidney disease on drug pharmacokinetics 
Pharmacokinetic parameters like hepatic clearance, absorption, and renal clearance 
(tubular secretion, reabsorption, glomerular filtration rate) are affected adversely due to renal 
dysfunction.74 75 This alters the total clearance of drugs eliminated primarily by the kidney and 
guided dosing should be considered when prescribing these drugs to patients with CKD.76 
Renal impairment can also enhance the accumulation of active metabolites, which can lead to 
exaggerated therapeutic effect or undesirable pharmacologic activity or toxicity.75 
 
2.4.1 Effect on absorption 
Renal dysfunction induces various physiological changes in the gastrointestinal tract, 
such as increased gastric pH, gastroparesis, bowel wall oedema, vomiting, diarrhoea, and 
reduced intestinal metabolism and transport. The aetiology of these changes are usually 
multifactorial.77 For medications (such as furosemide, ketoconazole and ferrous sulphate) that 
are most soluble in an acidic environment, increased gastric pH often reduces drug dissolution 
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and ionization resulting in reduced bioavailability.75 77 78 Gastroparesis is a common 
manifestation in CKD, which can result in delayed gastric emptying and may prolong the time 
to maximum drug concentration.77-79 These delays are important for drugs such as short-acting 
sulfonylureas.75 Bowel wall oedema has also been reported as a potential cause of diminished 
oral absorption in patients with CKD.74 75 77 79 Vomiting and diarrhoea are also common in 
patients with CKD, and can reduce the amount of drug absorbed.74 75 CKD is associated with 
decreased activity of intestinal cytochrome P450 enzyme activity.80 This can have a profound 
effect by increasing overall oral absorption.77 79 
 
2.4.2 Effect on distribution 
CKD-induced alteration in protein binding adversely affects the distribution of drugs 
and has significant clinical implications. CKD manifested uraemia results in lower 
concentration of albumin, a plasma protein to which the acidic drugs bind to. This 
hypoalbuminemia can result in an increased level of free concentration of acidic drugs such as 
barbiturates, furosemide, salicylates, warfarin, valproate, cephalosporin, penicillin and 
phenytoin. The plasma concentration alkaline drugs such as propranolol, morphine, oxazepam, 
vancomycin, that bind to α1-acid glycoprotein are elevated in renal dysfunction. Thus, the free 
fraction of alkaline drugs is often elevated in renal dysfunction.74 75 CKD-induced alterations 
in body composition, such as increased total body water and decreased muscle mass, have a 
significant effect on hydrophilic drugs. There is an increase in volume of distribution of these 
drugs due to oedema and ascites. This leads to a reduction in serum concentration. However, 
the muscle wasting and increased adipose tissue may reduce volume of distribution and may 
result in increased serum concentration of hydrophilic medication.75 
 
2.4.3 Effect on metabolism 
The kidney accounts for 15% of metabolic functions by the liver. Various metabolic 
enzymes are located in the cortex of the kidney. Both Phase I and Phase II reactions are 
profoundly affected by CKD.80 The hydrolysis and reduction reactions are slowed in patients 
with CKD. Methylation (dobutamine, 6-mercaptopurie, dopamine), glucuronidation 
(morphine, acetaminophen/paracetamol, oxazepam, lorazepam, naproxen), sulfation 
(salbutamol, minoxidil, dopamine), acetylation (dapsone, hydralazine, isoniazid, 
procainamide) are slowed in patients with CKD. Reduction in overall metabolic rate leads to 
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increased concentration of parent drug in plasma, causing potential toxicity and various adverse 
drug outcomes.77 79  
 
2.4.4 Effect on excretion 
The kidney is a major site for elimination of drugs. The renal elimination of drugs 
depends upon the GFR, which in turn is affected by the protein binding of drugs.76 Drugs bound 
to protein are not filtered through the glomerulus. The filtration of drugs depends upon the 
concentration of the free drugs in plasma. In patients with CKD, there is a higher level of free 
drug in plasma but the GFR is decreased. Resultantly, the elimination half-life of the drug is 
prolonged. This leads to accumulation of the drug or of toxic metabolite or biological active 
metabolite of the drugs in the body.76 A metabolite of pethidine, norpethidine (or 
normeperidine) has lower analgesic activity but its accumulation has adverse effects on the 
CNS, leading to convulsions.81 
 
2.5  Methods to determine renal function  
Accurate estimation of kidney function is an important component in the multifactorial 
care of patients with CKD.82 Knowledge of kidney function is essential for CKD staging and 
influences all aspects of pharmacological and non-pharmacological therapy.82 GFR, defined as 
the rate (volume per unit of time) at which filtrate is formed by the glomerulus, is considered 
the best indicator of overall kidney function and therefore its assessment has become an 
important clinical tool in the daily care of patients. 
GFR cannot be measured directly, but instead it can be assessed by the renal clearance 
of a filtration marker that achieves stable plasma concentration, is inert, and is freely filtered 
by the glomeruli but not reabsorbed, secreted, or metabolized. Such an ideal endogenous 
marker does not exist. Serum creatinine, one of the clinically useful analytes endogenously 
produced by the muscle and excreted by the kidney (others are serum urea and, more recently, 
serum cystatin C), has long been used by clinicians as a marker of kidney function.83 It is most 
useful for assessing minor changes in kidney function over time in the same individual.84 
However, serum creatinine should not be used alone as a measure of kidney function as it is 
influenced by a range of factors, such as age, gender, ethnicity, muscle mass, diet, drugs, and 
disease state.85  
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The isolated use of serum creatinine concentration may not reflect the actual degree of 
kidney function in an individual as the the inverse relation between serum creatinine and GFR 
is nonlinear, particularly when patients have near-normal renal function. The serum creatinine 
concentration may be in the normal range while the patient’s GFR may be markedly reduced, 
indicating impaired kidney function. This is common in older people who have decreased 
muscle mass along with overall decline in GFR.85 Serum creatinine does not increase beyond 
normal limits until more than 50% of GFR has been lost (Figure 2.5). 
 
 
Figure 2.5 Curvilinear relationship between GFR and serum creatinine86 
Note that, on the right side of the graph, relatively large reductions in GFR result in only minor changes in serum creatinine, 
while the opposite relationship is demonstrated at the top of the graph. 
 
An alternative to this approach is the measurement of creatinine clearance. 
 
2.5.1 Measurement of Creatinine Clearance (CrCl) 
GFR can be measured directly from the urinary clearance of an endogenous filtration 
marker such as creatinine derived from a 24 hr urine collection.87 This is called 24-hour 
creatinine clearance (CrCl) measurement. This determination does not require highly trained 
personnel or expensive assays and can be performed by standard laboratories. 
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However, this method is limited by the difficulties in obtaining accurate urine collection 
and the associated delay in the reporting of the results.88 It is often susceptible to error because 
of analytical interference of concomitant disease state and concurrent medications in the assay. 
This method, however, is widely available and familiar to the health care community. 
 
2.5.2 Measurement of GFR using exogenous markers 
GFR can be measured using exogenous substances, such as inulin and iohexol.87 The 
inulin clearance measurement has been the gold standard of GFR evaluation. Inulin is an ideal 
filtration marker as it is simply filtered in the glomeruli and neither reabsorbed nor secreted.89 
Due to the limited availability of the substance and the labour intensity of the assay, this is 
rarely performed except for research purposes.90 A few modifications to this procedure were 
introduced, such as use of radiolabelled markers such as iothalamate, iohexol, 
diethylenetriamine pentaacetate (DTPA), and ethylenediamine tetraacetate (EDTA).91 The 
plasma clearance of these radiolabelled markers was measured and there was no need for urine 
collections. Some of the limitations associated with this procedure are that some of the markers 
are not completely eliminated by GFR, but are also secreted by the tubules. The extrapolation 
of the area under the curve is required to calculate the plasma clearance of the exogenous 
markers. This is often unreliable in patients at moderate to severe stages of CKD or with 
oedema. In clinical practice, these methods are not feasible as the procedures are cumbersome, 
expensive and subject to error unless done under carefully controlled conditions. 
 
2.5.3 Estimating GFR using serum creatinine based equations 
GFR measurement using clearance of exogenous filtration marker is complicated in 
clinical practice as it requires substantial time and resources. Alternatively, GFR can be 
estimated in clinical practice from serum creatinine using prediction equations (eGFR).This 
method involves obtaining a blood sample to measure creatinine concentration and then 
combining it with patient factors using the GFR estimating equations to determine eGFR.92 
The advantage of this method is that the results are available for routine clinical practice and it 
is highly practical in routine individual drug dose calculations. For the majority of people, GFR 
estimating equations are, on average, more accurate than measured creatinine clearance and 
provide an unbiased assessment of measured GFR. The National Kidney Foundation Disease 
Outcomes Quality Initiative recommends using eGFR estimated from prediction equations 
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based on serum creatinine, mainly due to the inadequacies of serum creatinine and a 24-hr 
CrCl.2 The various equations to estimate GFR in clinical care settings are as follows: 
 
2.5.3.1 Cockcroft-Gault equation 
The Cockcroft-Gault equation predicts CrCl based on age, body weight, height, gender 
and plasma creatinine, together with correction factors.93 This equation was derived from a 
study population of 249 Caucasian men aged 18 to 92 years, with and without CKD.93 It is 
most widely used for estimating renal function and is the standard equation for calculating renal 
drug doses. The United States Food and Drug Administration (FDA) and Therapeutic Goods 
Administration (TGA) recommend using CrCl estimated by the Cockcroft-Gault equation for 
guiding the renal dosing of drugs and for conducting pharmacokinetic studies.94 95 
eCrCl = [((140‐age) x weight)/ (72 x Scr)] x 0.85 if female 
Note: eCrCl is expressed in mL/min, age is expressed in years, weight is expressed in 
kilograms, and Scr is expressed in mg/dL. 
Limitations to using this equation include the use of unstandardized creatinine assays and 
differing reference materials. The CG equation cannot be re‐expressed for isotope-dilution 
mass spectrometry (IDMS) traceable creatinine values. The creatinine method used in the 
development of the equation is no longer in use and samples from the study are not available. 
The CG equation underestimates GFR in the elderly and is less accurate in patients with normal 
kidney function. The CG equation provides CrCl that is not adjusted for body surface area 
(BSA). The requirement for weight and height to be provided restricts its ability to be reported 
by the laboratory. Modifications of the CG equation, such as the use of ideal versus actual body 
weight, were developed in an attempt to overcome the imprecision with the use of measured 
body weight.96 However, there is no evidence that these modifications are more accurate 
predictors of GFR or provide better drug‐dosing guidelines. 
 
2.5.3.2 Modification of Diet in Renal Disease (MDRD) 
The Modification of Diet in Renal Disease (MDRD) Study equation was derived from 
a study population of 1,628 men and women with CKD, aged 18 to 70 years, predominantly 
Caucasian, nondiabetic, and who were non‐kidney‐transplant recipients.97 MDRD is 
normalised for race, BSA, age, and sex; it is reported as mL/minute/1.73 m2. The MDRD Study 
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equation estimates GFR adjusted for BSA. Kidney function is proportional to kidney size, 
which is proportional to BSA. BSA of 1.73 m2 is the normal mean value for young adults. 
MDRD is primarily used for CKD staging in clinical practice. Given the MDRD equation was 
developed from a population of patients with CKD, it is imprecise and underestimates GFR at 
higher values, yielding false positives for CKD.98 Additionally, the MDRD equation has not 
been validated in individuals less than 18 years of age; individuals greater than 75 years of age; 
pregnant women; patients at extremes in body size; or in races other than Caucasian and 
African American.99  
The original MDRD Study equation is suitable for use with creatinine methods that do 
not have calibration traceable to IDMS. Calibration bias and measurement imprecision for 
plasma creatinine have a large impact on the eGFR.100 To overcome the error from instrument 
bias, standardisation of creatinine measurements to the reference IDMS method, was 
introduced. With this, a new factor of ‘175’ (as opposed to ‘186’) was used in the MDRD 
equation for creatinine assays that are IDMS-aligned.101 
Original MDRD equation97 
eGFR = 186 x (Standarised Scr)‐1.154 x (age)‐0.203 x (0.742 if female) x (1.212 if African 
American) 
Note: GFR is expressed in mL/min per 1.73 m2, Scr is serum creatinine expressed in mg/dL, 
and age is expressed in years. 
Re-expressed MDRD Study equation101 
eGFR = 175 x (Standardized Scr)‐1.154 x (age)‐0.203 x (0.742 if female) x (1.212 if African 
American) 
Note: GFR is expressed in mL/min per 1.73 m2, Scr is serum creatinine expressed in mg/dL, 
and age is expressed in years. 
 
2.5.3.3 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 
Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), the newest equation, 
normalises for race, BSA, age, and sex and is reported as mL/min/1.73 m2.102 In clinical 
practice, CKD–EPI is most commonly used for CKD staging. The CKD–EPI is a more accurate 
estimation of GFR than MDRD at all values. The CKD-EPI formula is a useful tool to estimate 
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GFR in all people, including various ethnic populations.102 The CKD-EPI formula has been 
validated as a tool to estimate GFR in some non- Caucasian populations, including South-East 
Asian, African, Indian and Chinese individuals living in Western countries.  A recent validation 
study confirmed that CKD-EPI formula (without the African American race correction factor), 
provides a reasonably unbiased and accurate estimate of GFR in Indigenous Australians.103 
CKD-EPI equation102 
For females with SCr ≤ 62μmol/L: = 144 × (SCr in μmol/L ×0.0113/0.7)-0.329 × (0.993) age in years 
For females with SCr > 62 μmol/L= 144 × (SCr in μmol/L × 0.0113/0.7)-1.209 × (0.993) age in years 
For males with SCr ≤80 μmol/L= 141 × (SCr in μmol/L×0.0113/0.9)-0.411 × (0.993) age in years 
For males with SCr >80 μmol/L= 141 × (SCr in μmol/L ×0.0113/0.9)-1.209 × (0.993) age in years 
The K/DOQI clinical practice guideline recommends using eCrCl calculated from the 
Cockcroft Gault equation or eGFR calculated from the MDRD or CKD-EPI study equation for 
routine estimation of kidney function.2 However, both eGFR and eCrCl estimates may not be 
accurate in individuals at extremes of body size or muscle mass, particularly in populations 
with reduced muscle mass, including the frail, elderly and critically ill patients.104 In these 
individuals for whom serum creatinine based estimates may be inaccurate, direct measurement 
of CrCl using 24-hr method or measurement of GFR using exogenous filtration markers should 
be considered.105 Similary, when dosing medications with narrow therapeutic indices or with 
high toxicity it is recommended to use measured GFR. The Australasian Creatinine Consensus 
group suggests that the eGFR calculated with the MDRD or CKD-EPI formula is acceptable 
to assist with drug dosing decisions in general practice.106 Therefore, in addition to the CrCl 
calculated using Cockcroft-Gault equation, eGFR estimated using MDRD and CKD-EPI 
equations will also be used for determining doses for renally cleared drugs in this thesis. In 
chapter six, the agreement among  all three equations in dosing of renally cleared drugs will be 
examined. 
Above discussed methods for estimating kidney function are essential to detect renal 
impairment and to determine the need for dose adjustment of renally cleared drugs. Dose 
adjustment can be achieved by a reduction in dose, or an extension of the dosing interval, or 
both. Knowledge of appropriate dosage adjustment method is important to ensure drug 
effectiveness and to avoid accumulation and drug toxicity in patients with CKD. 
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2.6 Drug dosing considerations for patients with CKD 
It is essential to understand the patient’s renal function while prescribing medicines that 
are renally excreted.76 The dose and the dosing interval of these medicines needs to be modified 
in patients with renal impairment, but the need for dosage adjustment is not always recognised. 
The impaired renal function can cause medicines or their metabolites to accumulate and 
potentially cause toxicity.82 This is common in medicines with a narrow therapeutic index (e.g, 
digoxin, lithium).76 Renal function must be monitored in patients taking drugs that impair renal 
function or cause nephrotoxicity.76 107 Patients with pre-existing renal impairment are more 
prone to nephrotoxicity. Monitoring renal function is important regardless of the length of time 
a medicine has been used, as the dose needs to be changed as the patient ages (and renal 
function declines). Renal function must be assessed when: prescribing a new renally excreted 
or nephrotoxic medicine, even for drugs for chronic conditions.108 (Table 2.2) 
 
Analgesics 
codeine 
hydromorphone 
morphine 
oxycodone 
tramadol 
Genitourinary 
solifenacinb 
sildenafil 
tadalafil 
tolterodine 
vardenafil 
Blood 
dabigatran 
enoxaparin 
rivaroxaban 
Endocrine 
glibenclamide 
glimepiride 
gliptins 
metformin 
Neurological 
baclofen 
gabapentin 
galantamine 
levetiracetam 
memantine 
methysergide 
paliperidone 
pramipexole 
pregabalin 
topiramate 
varenicline 
Psychotropic 
acamprosate 
amisulpride 
benzodiazepines 
bupropion 
desvenlafaxine 
duloxetine 
lithium 
reboxetine 
venlafaxine 
Cardiovascular 
ACE-Is 
ARBs 
atenolol 
bisoprolol 
digoxin 
fenofibrate 
Gastrointestinal 
H2-antagonists 
Musculoskeletal 
allopurinol 
bisphosphonates 
colchicine 
strontium 
ranelate 
teriparatide 
Table 2.2 Drugs requiring dosage adjustment in renal impairment 
This list contains drugs used commonly in Australian community setting. Therefore, it does not include antibiotic, antifungal 
or antiviral medicines, or those medicines predominately used in hospital settings 
Source. Veterans Mates Therapeutic brief108 
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Medicines that may accumulate and require renal function monitoring 
Drugs and their metabolites may accumulate and contribute to exaggerated 
pharmacologic effects or adverse drug reactions in patients with CKD, especially if the 
medicine has a narrow therapeutic index (e.g. digoxin, lithium). Potential adverse effects can 
be prevented by reducing the dose, extending the dose interval, or by prescribing an alternative 
medicine that is less likely to accumulate.109 It is necessary to consider that fixed dose 
combination products may also contain one or more active ingredients that are renally excreted. 
Some of medicines commonly prescribed in general practice that require dose modification on 
the basis of renal function monitoring are presented below. 
 
Metformin 
Metformin may accumulate in patients with renal impairment. This increases the risk of lactic 
acidosis, a rare but potentially fatal adverse drug reaction. This risk is highest in patients with 
comorbidities manifested by hypoxemic conditions, such as acute myocardial infarction, severe 
infection, respiratory disease, and liver disease.76 Australian guidelines recommend a total 
maximum daily dose of 2000 mg for patients with a GFR of 60–90 mL/ min, and 1000 mg for 
patients with a GFR of 30–60 mL/min.110 Metformin is not recommended for patients with a 
GFR <30 mL/min. 
 
Dabigatran 
Renal impairment may cause accumulation of dabigatran and lead to major bleeding and 
death.111 It is recommended to assess renal function in all patients before starting dabigatran. 
Dabigatran is contraindicated in patients with GFR<30 mL/min.112 For patients taking 
dabigatran, renal function should be assessed in situations where a decline in renal function is 
suspected (eg. hypovolaemia, dehydration, concurrent use of nephrotoxic medicines); in older 
patients or those with moderate renal impairment taking dabigatran, renal function should be 
assessed at least once per year.108 112 
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Bisphosphonates 
Bisphosphonates are not recommended for treating osteoporosis in patients with a GFR <30–
35 mL/min.43 There is a high risk of renal failure associated with zoledronic acid, especially in 
patients co-prescribed diuretics or other potentially nephrotoxic medicines.113 Drugs like 
strontium ranelate and teriparatide used to treat osteoporosis are also not recommended in 
patients with a GFR <30 mL/min. 
 
Sulphonylureas 
Renal impairment increases susceptibility of a patient to hypoglycaemia associated with 
sulphonylureas and their metabolites. Short-acting sulphonylureas (eg. glicazide, glipizide) are 
preferred choices for patients with renal impairment, as these drugs do not have an active 
metabolite and dose reduction is not usually necessary.43 109  
 
Opioids 
A variety of opioids (codeine, tramadol, morphine, hydromorphone) have active metabolites, 
which can accumulate in renal impairment, causing central nervous system or respiratory 
depression; therefore, a dose reduction is necessary.114 It is recommended that the initial dose 
of oxycodone should be reduced in patients with a GFR <30 mL/min. Immediate release 
products needs to be dosed less frequently.43 Extended release products (eg. controlled release 
oxycodone) are potentially more difficult to titrate to appropriate clinical effect in those with 
renal impairment. 
 
Allopurinol 
The active metabolite of allopurinol, which is primarily renally cleared, accumulates in renal 
impairment causing adverse effects.109 Therefore, dose adjustment is warranted. An initial dose 
of 100 mg on alternate days is recommended for patients with a GFR <10 mL/min, or if 
possible, the medicine should be avoided in this situation.43A maintenance dose of 100 mg/day 
is sufficient for the majority of older patients. 
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Medicines that can reduce renal function or cause nephrotoxicity 
There are a number of commonly used medicines that can impair renal function or cause 
nephrotoxicity such as Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin 
Receptor Blockers (ARBs) and Non-Steroidal Anti-Inflammtory Drugs (NSAIDs). In patients 
with renal impairment, drugs with toxic metabolites should be avoided, the least nephrotoxic 
agents should be used, and alternative medications should be prescribed if necessary to avoid 
potential drug interaction. In severe renal impairment, the remaining functional nephron units 
work harder to compensate for the loss of other nephrons. These residual nephrons are more 
susceptible to nephrotoxic injury due to their increased workload. If the use of nephrotoxic 
drug cannot be avoided, then therapeutic drug monitoring and renal function monitoring is 
mandatory. 
 
ACEIs and ARBs 
Renal impairment affects the excretion of most ACEIs and increases the risk of 
hyperkalaemia; therefore, dose adjustment may be necessary. Renal function and electrolytes 
level should be measured when initiating treatment with ACEIs or ARBs and these tests should 
be repeated after 1-2 weeks.115 ACEIs or ARBs can cause an acute decline in GFR, even 
without pre-existing risk factors. This decline is more significant, especially in presence of 
congestive heart failure, diuretic or NSAID use.30 If the acute decline in GFR is greater than 
25% below baseline, then the medicine should be stopped and investigations for bilateral renal 
artery stenosis should be performed.43 
 
NSAIDs 
NSAIDs use is linked to three times higher risk for acute renal failure.116 Short-term NSAIDs 
use is well tolerated in absence of heart failure, diabetes, or hypertension and if the patient has 
normal renal function. Long-term use is not recommended as it can cause nephrotic syndrome 
with interstitial nephritis and chronic renal failure. The decline in GFR associated with NSAIDs 
may improve following treatment cessation.117 When NSAIDs are used together with either 
loop diuretics or ACEIs/ARBs, the risk of renal failure is further increased.118 For patients with 
renal impairment, paracetamol is considered suitable to use. Serum creatinine should be 
checked every 2 to 4 weeks in early treatment with NSAIDs. 
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Medicines causing biochemical changes 
Drugs such as amiloride, eplerenone, and spironolactone are contraindicated in patients with 
severe renal impairment and it is advised to monitor renal function and potassium levels if used 
in renal impairment, due to the increased risk of hyperkalemia.43 Products with a high sodium 
content (eg, some antacids) may cause sodium and water retention in patients with CKD. 
Excessive vitamin D replacement therapy, use of calcitriol have been found to precipitate or 
exacerbate renal impairment and increase the risk of hypercalcaemia and nephrocalcinosis in 
patients with CKD. 
 
Spironolactone 
Renal function monitoring for patients using spironolactone should be considered due to the 
risk of hyperkalemia.76 This is particularly the case when spironolactone is used in combination 
with ACEs and ARBs, NSAIDs or in patients with diabetes.109 In patients with a GFR less than 
30mL/min, spironolactone is best avoided. 
 
2.7 CKD management guidelines and resources  
Various professional nephrology bodies around the world have designed and 
disseminated CKD management guidelines to provide guidance and clinical tips to help 
identify, manage and refer CKD in general practice (Table 3.2) The recommendations are 
formed from existing evidence-based clinical guidelines, current research, and clinical 
consensus. It is recommended that GPs and other health professionals consult these guidelines 
in order to ensure a high standard of care for their patients. Some of the most commonly 
accessed  resources for information on drug use in CKD are shown below in Table 2.3. 
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Table 2.3 CKD management guidelines 
 
 
KDIGO Guideline: Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work 
Group 2012 clinical practice guideline for the evaluation and management of CKD 
http://www.kdigo.org/clinical_practice_guidelines/CKD.php 
CARI Guideline: Diagnosis, classification and staging of chronic kidney disease. July 
2012. 
http://www.cari.org.au/CKD_early_CKD/Diag_Classification_Staging_ECKD.pdf 
The Renal Association Guideline: for detection, monitoring and care of patients with 
CKD. 
http://www.renal.org/Clinical/GuidelinesSection/Detection-Monitoring-and-Care-of-
Patients-with-CKD.aspx 
Japanese Society of Nephrology Guideline: Evidence-based Practice Guideline for the 
Treatment of CKD. http://www.jsn.or.jp/en/guideline/pdf/guideline.2009.pdf 
National Institute for Health and Clinical Excellence (NICE) Guideline: Early 
identification and management in adults in primary and secondary care. 2008, Royal 
College of Physicians. 
http://www.nice.org.uk/nicemedia/live/12069/42116/42116.pdf 
Canadian Society of Nephrology Guideline: for management of chronic. CMAJ. 
2008;179(11):1154-62. 
http://www.cmaj.ca/content/suppl/2008/11/17/179.11.1154.DC1 
NKF KDOQI Guideline: CKD: evaluation, classification, and stratification. Am J Kid 
Dis.2002;39(2 Suppl 1): S11-266. 
http://www.kidney.org/professionals/KDOQI/guidelines_ckd/toc.htm 
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Table 2.4 Resources for information on drug use in CKD 
 
2.8 Approach to renal drug dosing 
Safe drug prescribing in patients with CKD can be complex and requires a stepwise 
approach. In order to ensure effectiveness, minimise further damage and prevent drug 
nephrotoxicity, the following recommendations may be useful.75 (Figure 2.6). 
  
Drug Prescribing in Renal Failure: Dosing Guidelines for Adults.  
http://acp.pdaorder.com/pdaorder/-/6059205375541/item?oec-catalog-item-id=1028 
FDA Centre for Food Safety and Applied Nutrition 
http://www.cfsan.fda.gov/ 
FDA MedWatch 
http://www.fda.gov/medwatch/index.htmL 
Medicine Plus  
Web site: http://www.nlm.nih.gov/medlineplus.htmL 
National Kidney Disease Education Program  
Web site: http://www.nkdep.nih.gov 
National Kidney Foundation 
Web site: http:www.kidney.org/ 
Kidney Check Australia Taskforce (KCAT) program. Kidney Health Australia 
Website: www.KCAT.org.au 
PDA=personal digital assistant, FDA= U.S Food and Drug Administration 
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Figure 2.6 Step by step approach to dosage adjustment in renal impairment58 
Step 1. Take patient history       
Record current medications, drug allergies & examination sensitivities. 
Physical examination: height, weight, extra-cellular volume status, jugular 
venous pulse, blood pressure & heart rate with orthostatic changes, edema, 
ascites.
Step 2. Determine the degree of renal impairment
Measure serum creatinine and calculate CrCl
Step 3. Review the medication list 
Ensure that all drugs are still required and that new medications have specific
indications. Evaluate for potential drug interactions.
Step 4. Choose less nephrotoxic drugs
If the use of nephrotoxic drugs cannot be avoided then therpeutic drug 
monitoring of renal function is mandatory
Step 5. Select loading doses
These are usually the same for patients with both 
normal and abnormal function. 
Step 6. Select a maintenance regimen
Either reduce the dose of the drug and maintain the usual dosing interval or
maintain the drug dose and extend the interval. Remember to titrate the dose
of the drug to patient effect, if applicable. For example, antihypertensives
are dosed upon blood pressure control, whereas antimicrobials are not
adjusted according to response.
Step 7. Monitoring drug levels. 
Monitor drug levels if monitoring is available to guide further therapy. 
Step 8. Reasses the patient 
evaluate drug effectiveness and the need for ongoing therapy. If 
nephrotoxic drugs are used, check the pateint's serum creatinine and 
CrCl again. 
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Initial patient assessment 
The first step is to have a detailed initial patient assessment that includes medical history, 
previous drugs, past medications, comorbidities, concurrent medications including over the 
counter drugs, body weight and height, laboratory data for renal function parameters, liver 
function tests and albumin concentration.74 75  
 
Evaluating the degree of renal impairment 
The second step is to evaluate the degree of renal impairment. GFR is the most reliable index 
and surrogate marker of overall kidney function; however, in clinical settings it is not possible 
to measure GFR, therefore calculation of eGFR using the MDRD equation to determine the 
CKD stage is required.2 Calculation of CrCl using Cockcroft-Gault equation to determine the 
appropriate drug dose adjustment is also necessary. Most medications may not require dose 
adjustment at CrCl>50 mL/min.  
 
Reviewing the Medication List 
Medications should be reviewed for any potential drug interactions and adverse effects.75 It 
should be ensured that the appropriate drugs have been prescribed for the given indication.119 
For patients with CKD or elderly patients with declining renal function, the doses of medicines 
for new and chronic conditions should be reviewed to ensure they are still suitable to the degree 
of renal function.77 Dose adjustment is necessary to avoid toxicity in patients who are elderly 
or have rapidly declining renal function.  
 
Choosing the drug that has no or Minimal Nephrotoxicity 
In chronic kidney failure, the nephrons are more susceptible to nephrotoxic injury due to 
nephrotoxic drugs. It is recommended to avoid the use of nephrotoxic drugs; however, if used, 
then therapeutic drug monitoring and renal function monitoring is recommended.75 120 121 
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Selecting the dose regimen  
Loading doses usually do not need to be adjusted in patients with CKD, except for drugs that 
have a large volume of distribution.122 The recommendation for adjusting dose regimen can be 
obtained from drug information sources. Some of the most commonly used information sources 
are the Australian Medicine Handbook,43 British National Formulary,123 Drug Prescribing in 
Renal Failure81 MIMS124 and the American Hospital Formulary System Drug Information.125 
The suggested methods for dose adjustments in these information sources are dose reduction, 
lengthening the dosing interval, or both. The dose reduction method involves reducing each 
dose while maintaining the normal dosing interval.76 This approach maintains a constant drug 
concentration, but is associated with a higher risk of toxicities if the dosing interval is 
inadequate to allow for drug elimination. Lengthening the dosing interval has been associated 
with a lower risk of toxicities but a higher risk of sub-therapeutic drug concentrations, 
especially toward the end of the dosing interval.76 
Information sources provide dose recommendations for individual drugs corresponding 
to different levels of CKD. The guidelines are divided into broad GFR categories usually 
encompassing up to a 10-fold range in renal function. Quantitative data on dose adjustment 
based on various categories of renal impairment is well suited for renal dosing purposes; 
however, not all drugs have quantitative data on dose adjustment in renal impairment. 
Therefore, regimens must be individualized further based on patient response and serum drug 
concentrations. Clinical judgement should be used and doses must be adapted to the specific 
patient’s situation. There are factors other than renal impairment that influence the choice of 
drug and its dose. The severity of the condition being treated, the toxicity of the drug, 
comorbidity, and the patient’s size, age, and gender, all have an influence on the dosing of 
CKD patients. It might be necessary to titrate the dose according to the patient's clinical 
condition or quantitative measures for example- international normalised ratio, heart rate, blood 
pressure. 
 
Monitoring Outcomes 
It is recommended to monitor drug levels if monitoring is available to guide therapy. For drugs 
with a narrow therapeutic index, such as aminoglycosides, digoxin and lithium, it is mandatory 
to monitor the drug level. For certain drugs like antihypertensive and oral hypoglycaemic, the 
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dose may be titrated based on pharmacodynamic response (e.g. monitoring of blood pressure, 
blood sugar and glycated haemoglobin).74  
 
2.9 Inappropriate prescribing  
Inappropriate prescribing has been defined as the use of a particular medicine that poses 
greater risk of harm than benefit, especially when safer and more effective options are available 
for the same condition.126 Inappropriate prescribing has become an area of major concern in 
patients with CKD, especially in older people.77 One of the most important prescribing 
problems in patients with CKD is medication dosing errors.122 It is generally acknowledged 
that certain drugs should be used cautiously or avoided completely in this patient group, if a 
safer alternative is available.75 Because of the pharmacokinetic and pharmacodynamics 
changes associated with CKD, the patients are more susceptible to adverse effects.107 In the 
case of patients with CKD, the most common form of inappropriate prescribing is the use of 
an inappropriately high dose based on the renal function or contraindicated drug.10 The concept 
of inappropriate prescribing recognises that there are no medications without any risk, whereby 
appropriate use of medications requires that the  benefits associated with its use outweigh the 
risks.127 
Various studies have been conducted to address the dose appropriateness and dose 
adjustment practice in hospital settings in Australia and overseas; however, there is very limited 
data in the community setting.128-133  
A cross-sectional study conducted in the Princess Alexandra Hospital, Queensland, 
Australia in patients with renal impairment found that 111 (44.8%) of 248 prescriptions of the 
targeted drugs were inappropriately high.128 
In a prospective study in a hospital setting in France, Solomon et al found that out of 
the 886 prescriptions for patients with CKD, 34% prescriptions were inappropriate.131 Among 
these, 14% were contraindicated and 20% were inappropriately high doses based on renal 
function. 
A longitudinal study analysing the inpatients record of four years in South Korea 
revealed that 5.3% of the prescribed drug doses were excessive based on the patient’s renal 
function.134 The rate of overdosing in patients with moderate to severe CKD was 28.2%. Out 
of the 56 drugs studied, 10 drugs including piperacillin, amoxicillin and ranitidine accounted 
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for 85.4% of the overdoses. Chertow et al analysed 17,828 prescriptions in a tertiary care 
hospital in the USA and reported that 70% of the prescriptions for nephrotoxic or renally-
cleared medications in renally impaired patient were inappropriate.135 Decloedt et al reported 
that out of 615 prescriptions for 97 patients with CKD, drug adjustment was required in 19% 
of cases and only 32% of the prescriptions had the correct dose adjustment in a hospital setting 
in Africa.136 
A high proportion of elderly patients, ranging from 12-43%, are reported to have been 
administered excessive doses of primarily renally-cleared medicines in various studies 
conducted in nursing homes and hospital settings around the world.9 10 12 Approximately 20–
50% of elderly people in the Australian community setting are prescribed one or more 
potentially inappropriate medicines, with higher rates seen in residential aged care facilities.132 
137-139 These studies examined the inappropriate use of medicines in elderly patients and was 
not confined to those where dose adjustment was required due to decline in renal function. In 
our thesis we will be examining the inappropriate use of medicines focusing on the elderly 
population who require dose adjustment due to decline in renal function. 
About 43% of the elderly patients received at least one of 20 renally-cleared drugs 
inappropriately in a cohort of 456 patients in four long-term care facilities in Canada.9 The 
drugs most frequently prescribed inappropriately were allopurinol, glibenclamide, ranitidine 
and metformin, and variables like age, weight, number of medications and the number of 
physicians prescribing in the facility were predictive for receiving an inappropriate prescription 
based on CrCl.9 
Approximately 12% of the patients had evidence of inappropriate prescribing of at least 
one of 21 renally-cleared drugs in a longitudinal study of 3804 elderly patients in 133 nursing 
homes in the USA and factors associated with potentially inappropriate prescribing were age 
older than 85 years, obesity and multiple comorbidities.10 In a cross sectional study conducted 
by Rahimi et al in the USA, 50% of the patients were prescribed with renally-cleared drugs and 
25% of them had at least one medication dosed incorrectly for renal function.12 A recent study 
in aged care residents in Australia has recognised metformin and perindopril as the top most 
inappropriately prescribed drugs in aged care settings.140. The inappropriate prescribing of oral 
hypoglycaemics, angiotensin receptor blockers (ARBs), angiotensin-converting-enzyme-
inhibitors (ACEIs) and drugs for the treatment of bone diseases for elderly patients with renal 
impairment has been noted in various studies.9 11 133 
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2.10 Next Step 
This chapter suggests that despite the availability of CKD management guidelines and 
information sources to help guide renal dosing, patients with renal impairment continue to be 
exposed to inappropriate prescribing around the world. In Australia, a high proportion of 
elderly patients are reported to have been administered inappropriate prescribing in various 
studies conducted in nursing homes and hospital settings, and this proportion was higher in 
nursing home patients. In the next section, we quantify the extent of inappropriate prescribing 
for renally-cleared drugs in elderly patients in Australian community settings and residential 
aged care facilities, and determine the factors associated with inappropriate prescribing. 
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Chapter 3 POTENTIALLY INAPPROPRIATE PRESCRIBING OF RENALLY-CLEARED DRUGS 
IN ELDERLY PATIENTS IN COMMUNITY AND AGED CARE SETTINGS 
The literature outlined in Chapter 2 discussed the various CKD management guidelines and 
the recommended approach to drug dosing in patients with CKD. Evidence suggests that older 
people are more vulnerable to inappropriate prescribing as they often have multiple 
comorbidities, aged related heterogeneity, and an overall decline in renal function, for which 
clinicians, using evidence-based guidelines, should prescribe the recommended therapy with 
dose adjustment. The aim of this chapter was therefore to determine the prevalence of 
inappropriate prescribing for renally-cleared drugs in elderly patients and determine the factors 
associated with inappropriate prescribing. 
3.1 Abstract 
Background 
Limited data is available on the prevalence of inappropriate prescribing for renally-cleared 
drugs in elderly patients in Australia. 
Objectives 
To quantify and compare the extent of inappropriate prescribing (defined as at least one drug 
prescribed in excessive dose or when contraindicated with respect to renal function) for renally-
cleared drugs in elderly patients across the community and aged care settings, and to determine 
factors associated with patients being prescribed one or more potentially inappropriate renally-
cleared drugs. 
Methods 
This retrospective study examined de-identified Home Medicines Review (HMR) and 
Residential Medication Management Review (RMMR) cases pertaining to 30,898 patients 
aged 65 years and over. Only 25% (n=7625) of these patients had documented information on 
renal function. Among them, 4035 patients were prescribed at least one of the 31 renally-
cleared drugs examined in the study. For these patients, details including demographics, 
medications, medical conditions and pathology test results were extracted. The creatinine 
clearance (CrCl) was estimated using the Cockcroft-Gault formula and the prevalence of 
inappropriate prescribing for the 31 drugs was examined, based on conformity with the 
recommendations in the Australian Medicines Handbook. Multivariate logistic regression was 
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performed to determine the factors associated with patients being prescribed one or more 
potentially inappropriate renally-cleared drugs.  
Results 
The mean age (SD) of the HMR (n=3315; 59% female) and RMMR (n=720; 68% female) 
patients were 78.3±7.2 and 86±7.3 years, respectively. Over one-quarter (n=1135 out of 4035; 
28.1%) of the patients prescribed the renally-cleared drugs examined had evidence of 
inappropriate prescribing of at least one of the drugs, based on renal function. The drugs/drug 
class most commonly prescribed inappropriately were perindopril, fenofibrate, glibenclamide, 
gliptins, metformin, olmesartan, bisphosphonates and strontium. The factors independently 
associated with patients being prescribed one or more potentially inappropriate renally-cleared 
drugs were; advancing age (odds ratio (OR)=1.06 per year increase, 95% confidence interval 
[CI] 1.05-1.07, P<0.001), the total number of renally-cleared drugs prescribed (OR=1.44 per 
unit increase, 95% CI 1.29-1.61, P<0.001), presence of diabetes (OR=1.51, 95% CI 1.30-1.76, 
P<0.001), presence of heart failure (OR=1.38, 95% CI 1.13-1.69, P<0.005) and living in aged 
care facilities (OR=1.28, 95% CI 1.06-1.55, P<0.05). 
Conclusions 
Inappropriate prescribing of renally-cleared drugs is common in older Australians. Intervention 
studies to improve prescribing of renally-cleared drugs in the elderly appear warranted. 
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Key Points 
 Aged care residents and community dwelling older people are often prescribed renally-
cleared medicines that require dose adjustment based on renal function, outside of the 
recommended guidelines. 25.9% of the HMR patients and 37.9% of RMMR patients 
received inappropriate prescribing for at least one of the renally-cleared drugs examined 
in the study. 
 The drugs/drug class most commonly prescribed inappropriately were perindopril, 
fenofibrate, glibenclamide, gliptins, metformin, olmesartan, bisphosphonates and 
strontium. 
 The factors independently associated with patients being prescribed one or more 
renally-cleared drugs inappropriately were advancing age, the total number of renally-
cleared drugs prescribed, presence of diabetes, presence of heart failure and living in 
aged care facilities. 
 It is essential to consider renal function when prescribing renally-cleared drugs to 
elderly patients. The need for dosage adjustment should be determined by measurement 
of the renal function and the optimal dose should be determined by consulting standard 
drug information sources.  
 Designing an intervention program targeted towards improving the prescribing of these 
medications seems necessary. 
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3.2 Introduction 
Providing optimal care to the aging population has been, and is increasingly, an area of 
concern for health care professionals.141 The process of selecting, prescribing and maintaining 
the correct drug dosing is challenging in the elderly, partly because of the high prevalence of 
chronic disease states and resultant multiple drug prescribing.142 143 Furthermore, age-related 
heterogeneity coupled with overall decline in bodily function put these patients at high-risk of 
toxicity.144 145 The glomerular filtration rate (GFR) decreases gradually at an average rate of 
0.8 mL/min/1.73 m2/year after age 40 years and this decline accelerates after about age 65 to 
70 years.146-148 Therefore, optimal drug selection and dosing modification should be carried out 
in elderly patients in order to avoid the occurrence of adverse drug events (ADEs), particularly 
for renally-cleared drugs.85 149  
The need for drug dosage adjustment can be determined by measurement of the renal 
function of patients.150 Previous overseas studies conducted in hospital settings and nursing 
homes have revealed that a high proportion of elderly patients are administered excessive doses 
of primarily renally-cleared medicines.9-15 Subsequently, the problem of dose 
inappropriateness has been addressed to some extent, by general education and raising 
awareness of medications requiring dosage adjustment and the need for routine assessment of 
renal function.12 Approximately 20–50% of elderly people in the Australian community setting 
are prescribed one or more potentially inappropriate medicines, with higher rates seen in 
residential aged care facilities.132 137-139 Pharmacist conducted medication reviews have found 
to be effective in reducing the use of potentially inappropriate medicine for elderly people in 
the Australian community.139 However, the prevalence of inappropriate prescribing in patients 
with renal impairment in community settings has received relatively little attention; particularly 
in Australia, where there is limited data on the prevalence of inappropriate prescribing of 
renally-cleared drugs in older community-based patients.  
Given this background, we conducted this study to quantify and compare the extent of 
inappropriate use of renally-cleared drugs in older patients across the community and aged care 
settings, and to determine the factors associated with patients being prescribed one or more 
potentially inappropriate renally-cleared drugs.  
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3.3 Methods 
3.3.1 Ethics and data source 
Ethical approval for the study protocol was granted by the Tasmanian Health and 
Medical Human Research Ethics Committee Tasmania, Australia (H0012386). This 
retrospective study examined a sample of de-identified Home Medicines Review (HMR) and 
Residential Medication Management Review (RMMR) cases pertaining to older Australians. 
HMR and RMMR are community-based collaborative services provided by general 
practitioners (GPs) and accredited pharmacists.151 HMR services are provided to the 
community-dwelling older individuals whereas RMMR services are available to all permanent 
residents of Australian Government-funded aged care facilities. When requested by a GP, an 
accredited pharmacist conducts an HMR/RMMR. Information about the patient’s medicines is 
collated and a comprehensive assessment is undertaken to identify, resolve and prevent 
medication-related problems. A report of this assessment is provided to the GP. Based on this 
report, the GP and the patient develop and implement a medication management plan.  
 
3.3.2 Data extraction 
The RMMR and HMR services were conducted by accredited pharmacists in 
collaboration with GPs between January 2010 and June 2012. These de-identified cases were 
extracted from the database of Medscope, an IT company providing decision support solutions 
for accredited pharmacists performing medication reviews. Approximately 12% of Australian 
accredited pharmacists performing medication reviews utilise this system. This database 
includes information on each patient’s medical conditions, medication and biochemical 
parameters. Demographic data (age, sex, weight), medical conditions, pathology test results 
and medications (including doses) were extracted into a database developed in Access 2010 
(Microsoft Corporation, Redmond, USA). 
 
3.3.3 Inclusion criteria 
All individuals aged 65 years and older, who had their serum creatinine reported and 
were prescribed one or more of the drugs under review, were included in the study. We used a 
list of 31 renally-cleared drugs that are prescribed commonly in the community setting and 
recommended to be avoided or used with dose adjustment in older patients by the Department 
of Veterans’ Affairs (DVA), Australia (Appendix 1).152 
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A total of 30,898 elderly patients (aged 65 years or over) were identified in the database. 
Those who had their renal function reported (n=7625) were selected for further analysis. Out 
of these, a total of 4035 patients who were taking at least one of 31 renally-cleared drugs in our 
list, were included in the final sample. The creatinine clearance (CrCl) was estimated using the 
Cockcroft-Gault (CG) equation.93 For 1604 patients (1417 HMR, 187 RMMR) whose CrCl 
could not be estimated due to lack of reported weight, the laboratory eGFR provided in the 
database was used. For each drug, prescriptions were marked as “appropriate dosage” when 
the prescribed dose was in conformity with the adjustment specified in Australian Medicines 
Handbook (AMH)153 with regard to the patient’s renal function. Prescriptions were considered 
as “inappropriate dosage” when the dose exceeded that recommended for the patient’s renal 
function. Prescriptions were considered as “contraindicated” if AMH recommended avoiding 
use in renal impairment based on the patient’s renal function. Both “inappropriate dosage” and 
“contraindicated” were treated as inappropriate prescription. Inappropriate prescribing is 
defined as a situation where risk from the adverse effects of a prescribed medication outweighs 
the desired clinical benefits of treating a particular condition.127 It includes over-use of 
medications at a higher frequency or for longer durations than clinically indicated and the use 
of multiple medicines that have recognised drug-drug interactions.154 For our study purpose, 
we defined potentially inappropriate prescribing as use of a contraindicated medication or 
inappropriately high dose according to the renal function. Similar definitions for inappropriate 
prescribing in renal impairment have been reported in past studies.9 10 155 For example, 
metformin prescribed at a dose of 2000 mg one daily to a patient with a calculated CrCl of 
greater than 60 mL/min would be considered appropriate, whereas the same prescription in an 
individual of CrCl less than 60 mL/min would be inappropriate. 
 
3.3.4 Statistical analysis 
All statistical analyses were conducted using IBM SPSS Statistics for Windows, 
Version 20.0. Armonk, NY: IBM Corp. and Excel 2010 (Microsoft Corporation, Redmond, 
USA). Descriptive statistics were presented as median, mean, standard deviation and range, 
depending on normality. Univariate analysis (Mann-Whitney and Chi square test) followed by 
multivariate logistic regression, were performed to determine factors associated with patients 
being prescribed one or more potentially inappropriate renally-cleared drugs. 
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The dependent variable was presence or absence of inappropriate prescribing for at least 
one of the 31 drugs examined, based on the patient’s renal function. The independent variables 
included age, sex, setting (home or aged care facility), total number of drugs prescribed, total 
number of chronic medical conditions, and the number of renally-cleared drugs prescribed from 
our list. Also included were dichotomous variables (presence or absence) for heart failure, 
diabetes and hypertension, which have previously been recognised as major contributing 
factors for renal impairment.10 34 The independent variables with probability values (P)≤0.1 in 
the univariate analysis were entered in to the multivariate logistic regression analysis using the 
Enter method. All variables were assessed for multicollinearity prior to inclusion in the logistic 
regression model. The probability for stepwise entry was set at 0.01 and removal at 0.1 
including constant in the model. A P-value of < 0.05 was considered as statistically significant. 
 
3.4 Results 
3.4.1 Patients’ characteristics 
The study sample included 4035 elderly patients, who had their renal function reported 
and were prescribed with at least one of the 31 renally-cleared drugs under review. 
Approximately 18% (n=720) of these patients were residents from aged care facilities (i.e. 
RMMR cases) and 82% (n=3315) were from the community setting (i.e. HMR cases). The 
mean (SD) age of the HMR patients was 78.3 (7.2) years and for RMMR patients was 86 (7.3) 
years. There was a female predominance in both settings: aged care (67.6%) and community 
(59.4%). A high level of polypharmacy was identified in the study sample. The mean (SD) 
number of drugs prescribed per patient was 12.9 (4.6) and 13.5 (4.8) in aged care and 
community settings, respectively (Table 3.1).  
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Characteristics HMR RMMR 
Number (%) Mean ±SD Number 
(%) 
Mean ±SD 
Setting 3315 (82.2)  720 
(17.8) 
 
Demographics 
Age 
Sex 
Male  
Female  
 
 
 
1346 (40.6) 
1969 (59.4) 
 
78.3±7.2 
 
 
 
 
 
 
233 (32.4) 
487 (67.6) 
 
86.0±7.3 
 
 
Health status 
Number of diagnoses per 
patient 
Number of medications 
per patient 
Number of renally-
cleared drugs from the 
drug list 
eCrCl  
Mean (SD) mL/min 
Median (range) mL/min 
CKD stagesa 
Stage 1 
Stage 2 
Stage 3 
Stage 4 
Stage 5 
Medical conditions 
Hypertension 
Diabetes 
Heart failure 
 
 
 
 
 
 
 
 
 
 
 
422 (12.7) 
1279 (38.6) 
1422 (42.9) 
176 (5.3) 
16 (0.5) 
 
2691 (81.2) 
1677 (50.5) 
381 (11.4) 
 
10.03±5.8 
 
13.5±4.8 
 
1.4±0.7 
 
 
62±23 
60 (4-165) 
 
 
 
 
 
 
 
 
 
 
 
 
56 (7.8) 
131 (18.2) 
396 (55) 
125 (17.3) 
12 (1.7) 
 
431 (59.8) 
307 (42.6) 
146 (20.2) 
 
8.5±3.7 
 
12.9±4.6 
 
1.2±0.5 
 
 
50±24 
46 (6-168) 
HMR- Home medicines review, RMMR- Residential medication management review, 
eCrCl- estimated creatinine clearance, CKD- Chronic kidney disease 
Table 3.1 Patient Characteristics 
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3.4.2 Prescribing pattern for renally-cleared drugs 
The majority of patients, 69.4% (n=2801 out of 4035), were prescribed only one 
renally-cleared drug from our list; 24.4% (n=986 out of 4035) patients were prescribed two 
drugs from the list. Only 6.1% (n=248 out of 4035) patients were prescribed three or more 
renally-cleared drugs from the list. Perindopril (n=762) and metformin (n=762) were the most 
commonly prescribed renally-cleared drugs among the patients who were on a single drug. 
Concomitant prescribing of perindopril with metformin (n=341), perindopril with 
bisphosphonates (n=185) and metformin with bisphosphonates (n=143) were most common in 
patients who were prescribed with two or more drugs. 
 
3.4.3 Extent of inappropriate prescribing  
Over one-quarter (n=1135 out of 4035; 28.1%) of patients in the study sample had 
evidence of inappropriate prescribing of at least one of the renally-cleared drugs and this 
included prescribing in excessive dose (80.6%; n=915 out of 1135), or when contraindicated 
(19.4%; 220 out of 1135). Overall, 71.8% patients (n=2900 out of 4035) in the study sample 
received appropriate doses based on their renal function. 
The incidence of inappropriate prescribing was higher in the RMMR patients; 25.9% 
of the HMR patients and 37.9% of RMMR patients received inappropriate prescribing for at 
least one of the renally-cleared drugs (P<0.001). The drugs/drug class most commonly 
prescribed inappropriately were perindopril, fenofibrate, glibenclamide, gliptins, metformin, 
olmesartan, bisphosphonates and strontium (Table 3.2). The extent of inappropriate prescribing 
for each drug, comparison of HMR and RMMR for inappropriate prescribing of individual 
drug and the top most inappropriately prescribed drugs across HMR and RMMR are shown in 
the Table 3.3, Table 3.4 and Table 4.5 respectively.
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Category Drugs Number of patients n (%) 
Total Not required Higher dose (n) Contraindicated 
Top five drugs prescribed 
most inappropriately with 
high dose 
Perindopril 1387 600 (43.2) 612 (44.1) - 
Fenofibrate 205 85 (41.4) 85 (41.5) 1 (0.4) 
Saxagliptin 15 11 (73.3) 4 (26.7) - 
Sitagliptin 183 127 (69.3) 41 (22.5) - 
Vildagliptin 51 36 (70.5) 11 (21.5) - 
Top five drugs prescribed 
most inappropriately when 
contraindicated 
Glibenclamide 29 20 (68.9) - 9 (31.0) 
Alendronate 543 454 (83.6) - 89 (16.3) 
Strontium 160 139 (86.8) - 21 (13.2) 
Risedronate 457 412 (90.2) - 45 (9.8) 
Olmesartan 71 66 (92.9) - 5 (7.0) 
Total inappropriate 
High dose + 
contraindicated 
Perindopril 1387 600 (43.2) 612 (44.1) - 
Fenofibrate 205 85 (41.4) 85 (41.5) 1 (0.4) 
Glibenclamide 29 20 (68.9) - 9 (31) 
Saxagliptin 15 11 (73.3) 4 (26.7) - 
Sitagliptin 183 127 (69.3) 41 (22.5) - 
Vildagliptin 51 36 (70.5) 11 (21.5) - 
Metformin 1514 203 (13.4) 272 (17.8) 54 (3.5) 
Table 3.2 Top most inappropriately prescribed drugs
44 
 
 
 
 
Drugs Number of Patients 
Total NR HD CI A 
Alendronate 543 454 (83.6) - 89 (16.3) - 
Clodronate 2 - - - 2 (100) 
Risedronate 457 412 (90.2) - 45 (9.8) - 
Zoledronic acid 130 124 (95.3) - 6 (4.6) - 
Ibandronic acid 1 - - - 1 (100) 
Strontium 160 139 (86.8) - 21 (13.2) - 
Teriparatide 4 4 (100) - - - 
Perindopril 1387 600 (43.2) 612 (44.1) - 175 (12.6) 
Olmesartan 71 66 (92.9) - 5 (7.0) - 
Valsartan 78 75 (96.1) 2 (2.6) - 1 (1.2) 
Fenofibrate 205 85 (41.4) 85 (41.5) 1 (0.4) 34 (16.5) 
Metformin 1514 203 (13.4) 272 (17.8) 54 (3.5) 985 (65.0) 
Glibenclamide 29 20 (68.9) - 9 (31) - 
Sitagliptin 183 127 (69.3) 41 (22.5) - 15 (8.2) 
Saxagliptin 15 11 (73.3) 4 (26.7) - - 
Vildagliptin 51 36 (70.5) 11 (21.5) - 4 (7.8) 
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Drugs Number of Patients 
Total NR HD CI A 
Rivaroxaban 1 1 (100) - - - 
Dabigatran 102 77 (75.4)  1 (0.9) 24 (23.5) 
Duloxetine 113 103 (91.1) 6 (5.3) - 4 (3.5) 
Pregabalin 139 56 (40.2) 5 (3.5) - 78 (56.1) 
Gabapentin 128 28 (21.8) 14 (10.9) - 86 (67.1) 
Levetiracetam 30 10 (33.3) 6 (20) - 14 (46.6) 
Memantine 13 11 (84.6) 2 (15.3) - - 
Paliperidone 3 1 (33.3) - - 2 (66.7) 
Pramipexole 99 68 (68.6) - - 31 (31.3) 
Varenicline 14 14 (100) - - - 
Solifenacin 84 81 (96.4) - - 3 (3.6) 
Tolterodine 6 6 (100) - - - 
NR: Dose adjustment not required based on renal function, HD: Inappropriately high dose, CI: Contraindicated, A:Appropriate dose, “-“:Not 
applicable 
Table 3.3 Extent of inappropriate prescribing for each drug
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Drugs Number of HMR Patients Number of RMMR Patients 
Total NR HD CI A Total NR HD CI A 
Alendronate 431 372 (86.3) - 59 (13.7) - 112 82 (73.2) - 30 (26.7) - 
Clodronate 1 - - - 1 (100)  - - - 1 (100) 
Risedronate 382 351 (91.9) - 31 (8.1) - 75 61 (81.3) - 14 (18.6) - 
Zoledronate 119 113 (94.9) - 6 (5) - 11 11 (100) - - - 
Ibandronate  1 - - - 1 (100) - - - - - 
Strontium 127 116 (91.3) - 11 (8.7) - 33 23 (69.6) - 10 (30.3) - 
Teriparatide 2 2 (100) - - - 2 2 (100) - - - 
Perindopril 1089 538 (49.4) 450 (41.3) - 101 (9.2) 298 62 (20.8) 162 (54.3) - 74 (24.8) 
Olmesartan 69 66 (95.6) - 3 (4.3) - 2 - - 2 (100) - 
Valsartan 76 73 (96) 2 (2.6) - 1 (1.3) 2 2 (100) - - - 
Fenofibrate 189 82 (43.3) 75 (39.7) 1 (0.52) 31 (16.4) 16 3 (18.7) 10 (62.5) - 3 (18.7) 
Metformin 1326 184 (13.8) 241 (18.1) 32 (2.4) 895(67.5) 188 19 (10.1) 31 (16.4) 22 (11.7) 117 (62.2) 
Glibenclamide 27 19 (70.3) - 8 (29.6) - 2 1 (50) - 1 (50) - 
Sitagliptin 168 126 (75) 32 (19) - 10 (6) 15 1 (6.6) 9 (60) - 5 (33.3) 
Saxagliptin 13 10 (76.9) 3 (23.1) - - 2 1 (50) 1 (50) - - 
Vildagliptin 48 34 (70.8) 10 (20.8) - 4 (8.3) 3 2 (66.6) 1 (33.3) - - 
Rivaroxaban 1 1 (100) - - - - - - - - 
Dabigatran 93 70 (75.3) - 1 (1.07) 22 (23.6) 9 7 (77.7) - - 2 (22.2) 
Duloxetine 87 82 (94.2) 4 (4.6) - 1 (1.1) 26 21 (80.7) 2 (7.6) - 3 (11.5) 
Pregabalin 125 50 (40) 5 (4) - 70 (56) 14 6 (42.8) - - 8 (57.1) 
Gabapentin 96 24 (25) 10 (10.4) - 62 (64.6) 32 4 (12.5) 4 (12.5) - 24 (75) 
Levetiracetam 22 6 (27.2) 5 (22.7) - 11 (50) 8 4 (50) 1 - 3 (37.5) 
Memantine 6 5 (83.3) 1 (16.6) - - 7 7 (100) - - - 
Paliperidone 1 - - - 1 (100) 2 1 (50) - - 1 (50) 
Pramipexole 73 54 (74) - - 19 (26) 6 14 (53.8) - - 12(46.1) 
Varenicline 13 13 (100) - - - 1 1 (100) - - - 
Solifenacin 77 74 (96.1) - - 3 (3.9) 7 7 (100) - - - 
Tolterodine 6 6 (100) - - - - - - - - 
Table 3.4 Extent of inappropriate prescribing: a comparison of HMR and RMMR 
NR: Dose adjustment not required, HD: Inappropriately high dose, CI: Contraindicated, A: Appropriate dose, “-“: Not applicable 
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Category HMR % RMMR % 
Top five drugs prescribed 
most inappropriately with 
high dose 
Perindopril (41.3) 
Fenofibrate (39.7) 
Saxagliptin (23.1) 
Vildagliptin (20.8) 
Sitagliptin (19) 
Fenofibrate (62.5) 
Sitagliptin (60) 
Perindopril (54.3) 
Saxagliptin (50) 
Vildagliptin (33.3) 
Top five drugs prescribed 
most inappropriately in a 
contraindicated condition 
Glibenclamide 
(29.6) 
Alendronate (13.7) 
Strontium (8.7) 
Risedronate (8.1) 
Zoledronic acid (5) 
Glibenclamide (50) 
Strontium (30.3) 
Alendronate (26.7) 
Risedronate (18.6) 
Metformin (11.7) 
Total inappropriateness 
High dose+ contraindicated 
 
 
 
 
Perindopril (41.3) 
Fenofibrate (40.2) 
Glibenclamide (29.6) 
Saxagliptin (23.1) 
Vildagliptin (20.8) 
Metformin (20.5) 
Sitagliptin (19) 
Fenofibrate (62.5) 
Sitagliptin (60) 
Perindopril (54.3) 
Saxagliptin (50) 
Glibenclamide (50) 
Vildagliptin (33.3) 
Strontium (30.3) 
Metformin (28.1) 
HMR- Home medicines review, RMMR- Residential medication management 
review 
Table 3.5 Top most inappropriately prescribed drugs: a comparison of HMR and RMMR 
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Of the variables tested against inappropriate prescribing in the univariate analysis, age, 
residential aged care setting, number of renally-cleared drugs prescribed, presence of 
hypertension, diabetes and heart failure were associated (at P≤0.1) whilst the number of 
diagnoses, number of medications, and sex were not. Table 3.6 presents the results of 
multivariate logistic regression analysis. The factors independently associated with patients 
being prescribed one or more renally-cleared drugs inappropriately were advancing age (odd 
ratio (OR)=1.06 per year increase, 95% confidence interval [CI] 1.05-1.07, P<0.001), the total 
number of renally-cleared drugs prescribed (OR=1.44 per unit increase, 95% CI 1.29-1.61, 
P<0.001), presence of diabetes (OR=1.51, 95% CI 1.30-1.76 P<0.001), presence of heart 
failure (OR=1.38, 95% CI 1.13-1.69, P<0.005) and living in aged care facilities (OR=1.28, 
95% CI 1.06-1.55, P<0.05). 
 
Variables p-
value 
Exp(B) 95% CI for Exp(B) 
Lower Upper 
Age in years <0.001a 1.06 1.05 1.07 
Number of renally-cleared drugs <0.001a 1.44 1.29 1.61 
Diabetes <0.001a 1.51 1.30 1.76 
Heart failure 0.001a 1.38 1.13 1.69 
Aged care setting  0.008a 1.28 1.06 1.55 
CI-Confidence interval, Exp(B)-Odds ratio 
Table 3.6 Correlates of inappropriate prescribing 
Note: a All p-values<0.05 statistically significant 
 
3.5 Discussion 
The presence of renal impairment in older people is often under-recognised, leading to 
incorrect dosing.156 Our findings suggest that both aged care residents and community-dwelling 
older people were often prescribed renally-cleared medicines, outside of the recommended 
guidelines. Overall, 28.1% of the elderly patients (n=1135 out of 4035) who were prescribed a 
drug under review received at least one drug inappropriately based on their renal function.  
Previous overseas studies have reported a rate of inappropriate dosing of renally-cleared 
drugs in elderly patients ranging from 12% to 43% in long-term care settings.9 10 12. About 43% 
of the elderly patients received at least one of 20 renally-cleared drugs inappropriately in a 
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cohort of 456 patients in four long-term care facilities in Canada.9 The drugs most frequently 
prescribed inappropriately were allopurinol, glyburide, ranitidine and metformin, and variables 
like age, weight, number of medications and the number of physicians prescribing in the facility 
were predictive for receiving an inappropriate prescription based on CrCl.9  About 12% of the 
patients had evidence of inappropriate prescribing of at least one of 21 renally-cleared drugs in 
a longitudinal study of 3804 elderly patients in 133 nursing homes in the USA and factors 
associated with potentially inappropriate prescribing were age older than 85 years, obesity and 
multiple comorbidities.10 In a cross sectional study by Rahimi et al, 50% of the patients were 
prescribed with renally-cleared drugs and 25% of them had at least one medication dosed 
incorrectly for renal function.12 A recent study in aged care residents in Australia has 
recognised metformin and perindopril as the top most inappropriately prescribed drugs in aged 
care settings.140 
The most inappropriately prescribed medications identified in our study were 
perindopril, fenofibrate, olmesartan, gliptins, metformin, bisphosphonates and strontium. The 
inappropriate prescribing of oral hypoglycaemics, angiotensin receptor blockers (ARBs), 
angiotensin-converting-enzyme-inhibitors (ACEIs) and drugs for the treatment of bone 
diseases for elderly patients with renal impairment has been noted in various studies.9 11 133 
ACEIs and ARBs are recommended as first line therapy in diabetic kidney disease and 
non-diabetic kidney diseases with proteinuria.157 In addition to lowering blood pressure, they 
have been found to reduce proteinuria and delay progression of CKD.158 Benazepril therapy 
was associated with a reduction of 23% in the rate of decline in renal function and a 52% 
reduction in the level of proteinuria.159 A lower dose of these agents is sufficient to treat 
hypertension in moderate to severe chronic renal impairment.160 161 but dose increment or use 
of maximum dose provides renoprotective benefits and slows CKD progression.162 However, 
it is worth noting that the very ACEIs used for its nephron-protective benefits may cause 
hyperkalemia, hypotension and acute decline in GFR of up to 15% from baseline.163 76. An 
acute decline in GFR is not necessarily a reason to discontinue these drugs if the benefits 
outweigh the risk (particularly for those with severe congestive cardiac failure).115 A recent 
observational study has reported that discontinuing ACEIs and/or ARB in patients with 
advanced CKD (stages 4 & 5) who are progressing to complete kidney failure/renal 
replacement therapy results in stabilization and improvement of kidney function and decreases 
or delays the need for dialysis.115 A randomised controlled trial called “STOP-ACEI trial” 
designed to confirm the association between stopping these drugs and stabilisation of kidney 
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function is ongoing.164 Till the further safety data emerge, it is ideal to withhold its use in 
general practice in patients with severe renal impairment. If used, patients should be monitored 
with extreme caution, as there is no sufficient evidence for safety. It is recommended that the 
renal function and electrolytes level be monitored while prescribing these drugs in patients with 
CKD as the decreased renal function affects the excretion of ACEIs and increases the risk of 
hyperkalaemia.38 157 The Kidney Health Australia and the Australian Medicine Handbook 
recommends stopping the usage of the ACEIs or ARBs, if the reduction in GFR exceeds 25% 
below the baseline value.38 43  
Bisphosphonates (alendronate and risedronate) are recommended as the first line 
therapy for prevention of osteoporotic fractures and are widely used for treatment of 
osteoporosis in post-menopausal women.165 Manufacturers suggest avoiding their use in severe 
renal impairment. However, patients who are at risk of fracture or have osteoporosis are mainly 
elderly or post-menopausal women and may have age-related decline in renal function or 
chronic kidney disease (CKD). This creates a significant challenge for prescribers in managing 
osteoporosis in these high-risk patients. The prescribing restrictions of bisphosphonates in 
CKD were based on the assumptions that chronic use of these drugs lead to further decline in 
renal function and retention of bisphosphonates in the skeleton increases, resulting in ‘‘switch-
off’’ of bone turnover.166 However, there are no robust data in terms of both alteration in 
pharmacokinetics and the impact on skeletal histology with bisphosphonate treatment in 
patients with CKD.166 A lack of strong scientific evidence and applicability of these 
recommendations in clinical settings have been recognised.167 168 On the one hand, there are 
reports describing adverse renal events, such as acute tubular necrosis and tubulointerstitial 
damage pertaining to bisphosphonates, while various studies have emphasised that 
bisphosphonates are safe even when there is a pronounced reduction in renal function.169 170 171-
173 The number of randomised controlled trials conducted to guide renal dosing of 
bisphosphonates in CKD is limited. Furthermore, small sample sizes, short durations of 
treatment and the retrospective nature of these studies restrict the generalisation of their 
findings.174 Larger, longer-term prospective studies on use of bisphosphonates in patients with 
CKD are warranted to ascertain the risks and benefits associated with these drugs in renal 
impairment.174 However, until the results of new studies confirm the safety of bisphosphonates 
in renal impairment and the new guidelines for using bisphosphonates in elderly with renal 
impairment are put into routine clinical practice, the current prescribing information for 
bisphosphonates as mentioned in the product information or the standard drug information 
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sources, should be followed. The current prescribing information suggests withholding 
bisphosphates in patients with severe renal impairment and using reduced dose in mild to 
moderate renal impairment. 
Another medication of particular interest was glibenclamide. It is well documented 
there is a high-risk of drug-induced hypoglycaemia associated with this drug if used in older 
people with renal impairment.175 176 The AMH recommends avoiding this drug in renal 
impairment and emphasises using glipizide or gliclazide.177 In contrast, the manufacturers’ 
product information recommends avoidance only in severe impairment and suggests using with 
caution in moderate impairment.178  
Our logistic regression analysis identified older age, presence of diabetes, heart failure, 
number of renally-cleared drugs (requiring dosage adjustment) prescribed and aged care setting 
to be associated with patients being prescribed one or more potentially inappropriate renally-
cleared drugs. The mean age of the patients in the RMMR group was greater than that of the 
HMR group, however this was not statistically significant. Both the variables ‘living in aged 
care facilities’ and ‘advancing age’ were independently associated with patients being 
prescribed one or more renally-cleared drugs inappropriately, as evident in the multivariate 
model. Studies have shown that inappropriate prescribing of renally-cleared drugs is more 
likely to occur in older people.9 10 There is an age-related decline in renal function in older 
patients that warrants dose reduction or avoidance of renally-cleared drugs. This natural decline 
in renal function markedly affects the clearance of drugs, even in the absence of CKD. 
Advanced age and presence of renal impairment have been found to be the major 
pathophysiological factors not accounted for in drug dosing.179 
It is well known that polypharmacy is one of the contributing factors for potentially 
inappropriate prescribing in patients over 65 years.130 In our analysis, we only looked at the 
occurrence of inappropriate prescribing (excessive dose or contraindicated with respect to 
CrCl) for drugs that are known to be problematic in older patients with declining renal function. 
We found that with more drugs (requiring dose adjustment) prescribed, the higher the 
likelihood of inappropriate dosing based on renal function. 
Diabetes is the one of the most common diseases in elderly that contributes to the 
development of CKD.180 181 It has been recognised that comorbidities like diabetes increases 
the likelihood of receiving potentially inappropriate prescription in older people.143 Patients 
with diabetes are at increased risk for receiving inappropriate dosing based on renal function. 
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Due to the fact that several drugs requiring dose adjustment are often prescribed in diabetes, 
and the disease itself is associated with renal impairment, patients with diabetes are at higher 
risk for inappropriate dosing based on renal function. CKD is associated with increased 
prevalence of heart failure, and, conversely, heart failure itself is a major contributor to CKD.182 
Thus, many medications require dose modification in patients with heart failure, due to the 
associated decline in renal function. Therefore, it would be best to monitor the renal function 
while prescribing newer drugs, nephrotoxic drugs or renally-cleared drugs in patients with 
diabetes or heart failure. 
A recent retrospective study in Australia examining RMMR reports from 911 aged care 
residents found that 48% of the residents had CKD and 16% of them received inappropriate 
prescription for renally-cleared medications.140 Similarly, we also observed that inappropriate 
prescribing of renally-cleared medications was common among residents of aged care facilities 
and our analysis demonstrated that aged care residents were more likely to receive 
inappropriate prescribing based on renal function. This could be attributable to the fact that 
there was a higher prevalence of CKD in the aged care patients as reported by their lower mean 
for CrCl.  
Designing an intervention program targeted toward improving the prescribing of these 
medications seems necessary. Computerised alerts at the time of electronic prescribing have 
been proven to be effective in improving dosing of primarily renally-cleared medications.183 
Other possible approaches for consideration would be conducting education/training programs 
for general practitioners and pharmacists geared towards recognising drugs that need caution 
in renal impairment as well as the patients at risk.  
A limitation of this study is that we could not determine clinical outcomes, such as 
adverse drug events associated with the inappropriate prescribing. Also, we could not 
determine the outcome of the HMR and RMMR reports because the data were not available to 
us. Further, the prescribers might have used a different information source than the AMH for 
renal drug dosing. The conflicting recommendations for the renal dosing of renally-cleared 
drugs among the commonly used drug information sources have been recognised.177 Also, CrCl 
could not be calculated on all patients due to lack of weight; thus, laboratory-based MDRD 
eGFR was used to identify inappropriate prescribing. Traditionally, the CrCl estimated from 
the Cockcroft Gault equation has been used for dosing purposes. However, the recent 
recommendations from the Kidney Health Australia, the National Kidney Disease Education 
Program (NKDEP), Food and Drug Administration (FDA) and the National Institute of 
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Diabetes and Digestive and Kidney Diseases (NIDDK) suggest that MDRD-based eGFR can 
be also be used for dosing of non-critical drugs in primary settings.87 103 184 185 
The eGFR reported in our study database were based on the MDRD formula. The 
medication review cases were collected prior to the adoption of the CKD-EPI formula by the 
Australian laboratories for reporting eGFR.106 However, some of the ranges for renal functions 
were quite narrow and this together with the use of eGFR as a substitute for CrCl for some 
patients may have led to significant confounding in the study.  
Our study was limited to drugs in the DVA list, so we excluded other renally important 
drugs used primarily in community settings such as antibiotics. This might have underestimated 
the extent of prevalence of inappropriate prescribing.  
 
3.6 Conclusions 
Potentially inappropriate prescribing of renally-cleared drugs is common in older 
Australians in community and aged care settings. Intervention studies to improve prescribing 
of renally-cleared drugs in the elderly appear warranted. 
 
3.7 Next step 
A key observation from the study above is that despite the existence of published 
guidelines for renal drug dosing, aged care residents and community dwelling older people are 
often prescribed renally-cleared medicines, outside of the recommended guidelines. Several 
explanations may be elucidated for this lack of dose adjustment. Prescribers’ poor knowledge 
of medications requiring dosage adjustment, the presence of renal impairment being 
overlooked by prescribers, lack of routine measure of renal function, inadequate data on the 
information sources to guide the prescribers on precautions and renal dosage adjustments and 
confusion surrounding the use of renal function estimating equations are proposed contributing 
factors to inappropriate prescribing. In the following chapters, we will explore these factors. 
The nature and types of renal dosing recommendations available in the standard drug 
information sources will be examined to determine if there is both adequate information and 
consistency across the sources. 
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Chapter 4 DOSE ADJUSTMENT GUIDELINES FOR MEDICATIONS IN PATIENTS WITH RENAL 
IMPAIRMENT: HOW CONSISTENT ARE DRUG INFORMATION SOURCES? 
4.1 Abstract 
Background 
It is known that patients with renal disease are often administered inappropriate dosages of 
drugs. A lack of quantitative data in the available drug information sources and inconsistency 
in dosing information may augment the problem of dosing error. 
Aims 
To determine the concordance among five drug information sources regarding the dosing 
recommendations provided for drugs considered problematic in patients with renal impairment 
and to determine the consistency among the sources regarding the definition of renal 
impairment and categorisation of chronic kidney disease. 
Methods 
Five standard drug information sources were reviewed for 61 drugs recommended to be used 
with caution in renal impairment. Information on recommendations for dosage adjustment in 
renal impairment was extracted and analysed. Further, the definition and classification of renal 
impairment were recorded. The recommendation for each drug was coded into six different 
categories and the inter-source reliability was calculated. 
Results 
Only slight agreement was observed among the sources (Fleiss Kappa: 0.3). Qualitative data 
were not well defined, and there was a lack of consistency in quantitative values. Some drugs 
marked as contraindicated in one source were not mentioned as such in others. Also, drugs 
considered as not requiring dosage adjustment in one source had explicit recommendations in 
other sources. The definition and classification of renal impairment differed among the five 
information sources. 
Conclusions 
There should be an evidence-based approach to drug dosage adjustment in order to bring 
uniformity to the recommendations. Regular updating of the content of the drug information 
sources is also important. 
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4.2 Introduction 
Chronic kidney disease (CKD) is a long-term health condition where a person has 
reduced renal function, with an estimated glomerular filtration rate (eGFR) of less than 60 
mL/min/1.73 m2, lasting for 3 months or more.2 The prevalence of CKD increases 
disproportionally in older people because of age-related physiological changes in renal 
function, alongside the increasing prevalence of other conditions such as diabetes and 
cardiovascular disease.146 186 Impaired renal function can have pronounced effects on the 
pharmacokinetics of many drugs as a result of alterations in glomerular filtration, tubular 
secretion, reabsorption or metabolism.82 Therefore, there is an increased risk of drug-related 
problems such as the use of contraindicated drugs and inappropriate doses, with potential 
adverse outcomes.187 188 It is essential to select the proper drug and individualise the dosage in 
order to avoid the occurrence of adverse events.149 Previous studies have reported that 20–67% 
of prescriptions for patients with impaired renal function contain errors.9 13 15 189 190The 
asymptomatic nature and opportunistic diagnosis of CKD are reasons for the higher prevalence 
of inappropriate prescribing.29 191Other contributing factors reported include prescribers’ poor 
knowledge of medications requiring dosage adjustment, the presence of renal impairment being 
overlooked by prescribers, underestimation of potential adverse events, and the lack of 
evidence-based data to guide prescribers on precautions and dosage adjustments.131 133 192 
Moreover, a lack of quantitative data in the available drug information sources, and 
contradiction and inconsistency in dosing information may augment the problem of dosing 
error.193 In Australia, the Australian Medicines Handbook (AMH)43 or the product information, 
provide recommendations for dosage adjustment in renal impairment. Other international 
resources commonly accessible include the British National Formulary (BNF)123 and the 
American Hospital Formulary System (AHFS).125 However, despite their availability, 
significant practice gaps have been reported in prescribing for patients with renal impairment. 
The purpose of this study was to compare systematically the recommendations for 
dosage adjustment in renal impairment among different drug information resources. We 
consulted the AMH (2012), Monthly Index of Medical Specialties (MIMS; 2012),124 BNF 
(2012), AHFS (2012), and a specialised text, Drug Prescribing in Renal Failure (DPRF; 
2007),81 for a range of drugs that are known to be problematic when used in patients with renal 
impairment. The specific objective was to determine the consistency among the sources in 
dosing recommendations provided for individual drugs and in the definition of renal 
impairment and categorisation of CKD. 
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4.3 Methods 
This systematic comparison included data extracted for 61 drugs recommended as to 
be used with caution in patients with renal impairment by the Department of Veterans’ Affairs, 
Australia108. Recommendations for dose modification in renal impairment for each of the 61 
drugs were extracted from the five sources. When a drug had more than one brand available in 
MIMS, only one brand was chosen randomly for analysis. Data extraction also included the 
definitions and categorisation of renal impairment in each of the five sources. One researcher 
(AK) extracted the data, which was reviewed independently by another researcher (RC). The 
definitions and categorisation of renal impairment reported in each of the five sources were 
compared to determine consistency. The recommendations for dose modification extracted 
from the five sources were allocated into six categories using an adaptation of the 
categorisation described by Vidal et al. as follows.193 
1 Contraindicated (CI): This category included drugs that were recommended to be avoided in 
renal impairment of any severity. For example, the AHFS recommended that ‘metformin alone 
or in fixed combination with other drugs is contraindicated in renal impairment’. 
2 Missing (M): This category included drugs that were not included in the information source. 
For example, AHFS contained no information on vildagliptin and strontium ranelate. 
3 Numerical recommendations (N): 
• Dose modification is recommended based on creatinine clearance (CrCl) calculated by 
Cockcroft-Gault (CG) formula or eGFR/serum creatinine (SCr) value. For example, AMH 
recommended a maximum daily dose of 50 mg for sitagliptin in patients with CrCl between 30 
and 50 mL/min and 25 mg for patients with CrCl of less than 30 mL/min. 
• Dose modification based on CrCl/eGFR/SCr is not mentioned, but there is a clear 
recommendation to avoid the drug below a certain range of CrCl/eGFR/SCr value. 
For example, AMH recommended teriparatide to be avoided in patients having a CrCl below 
30 mL/min. 
4 Non-numerical recommendations (NN): 
• Recommendations that were ambiguous. For example, the recommendation for 
metoclopramide in the BNF was to avoid or use small doses in severe renal impairment. 
• Did not mention the eGFR/CrCl value/severity of renal impairment for which the drug had 
to be avoided or reduced. For example, the recommendation for topiramate in AMH included 
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‘reduced maintenance dose and longer interval between dose adjustments may be needed in 
renal impairment as it takes longer to reach steady state concentrations’. Further, phrases like 
‘avoid in severe impairment’ in MIMS and AHFS were considered as non-numeric 
recommendations as these sources did not predefine ‘severe renal impairment’. However, if 
these sources mentioned the CrCl/eGFR range next to the severity of renal impairment, then 
such recommendations were considered to be numerical recommendations. 
• Use with caution. The drug information sources mentioned one of the following statements 
but failed to give the specific recommendation for dose adjustment based on the 
CrCl/eGFR/SCr value: ‘careful monitoring of dose is required’, ‘monitor the drug serum 
concentration’ and ‘monitor for side effects’. For example, AHFS recommended that 
‘particular attention to close monitoring of methotrexate is recommended for patients with 
renal impairment’. 
• Did not specify the required dose for the particular stage of renal impairment. For example, 
the recommendation for enoxaparin in BNF was ‘risk of bleeding increased, reduce dose if 
eGFR less than 30 mL/min/1.73 m2 – consult product literature for detail’. 
5 No advice mentioned (X): The drug monograph was present in the information source, but 
there was no information on its use in patients with renal impairment. For example, the 
monograph for vardenafil in AMH contained no information regarding dose adjustment in 
patients with renal impairment. 
6 Dosage adjustment not required (Y): The information source advised to give the normal drug 
dose in renal impairment. For example, the DPRF recommended that dose adjustment for 
bupropion is not required. For the purpose of analysis, the six categories of recommendations 
were coded numerically to assign computable values with CI = 1, M = 2, N = 3, NN = 4, X = 
5 and Y = 6 respectively. The concordance in dosing recommendation for all 61 drugs among 
the different sources was calculated using Fleiss Kappa (Κ).194-196 Kappa value ranges from -1 
to 1. Values ≤ 0 indicate poor agreement, 0.00–0.20 slight, 0.21–0.40 fair, 0.41– 0.60 moderate, 
0.61–0.80 substantial, and 0.81–1.00 indicates almost perfect agreement The concordance was 
determined in two approaches using REcal, an intercoder reliability web service.197 In the first 
approach, concordance was calculated for the 34 drugs that had information in all five sources, 
excluding drugs that were missing from one or more sources. In the second analytical approach, 
the DPRF book was excluded, as it was an older publication, and the concordance was 
determined for the 54 drugs included in all the remaining four information sources. 
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4.4 Results 
All the five information sources provided recommendations in quantitative terms for the 
majority of drugs examined in the study (Table 4.1). 
 
Category AMH MIMS BNF AHFS DPRF 
Contraindicated (CI) 3 1 1 2 0 
Missing (M) 0 0 1 6 27 
Numeric (N) 48 41 47 37 30 
Non-numeric (NN) 9 17 12 14 0 
No advice (X) 1 0 0 1 0 
Not required (Y) 0 2 0 1 4 
Total drugs 61 61 61 61 61 
Table 4.1 Category of renal dosing information  in drug information sources 
AHFS, American Hospital Formulary System; AMH, Australian Medicines Handbook; BNF, British National Formulary; 
DPRF, Drug Prescribing in Renal Failure; MIMS, Monthly Index of Medical Specialties. 
 
AMH provided precise recommendations (N and CI) for the highest number of drugs (n = 51), 
followed by BNF (n = 48). Monographs for 44% of the drugs (n = 27) were missing from 
DPRF. However, DPRF generally provided the clearest information for the other drugs. The 
first analysis showed only slight agreement (Κ: 0.3) among the five information sources. A 
moderate agreement (Κ: 0.4) was observed in the second analysis when the DPRF was 
excluded. When assessing the individual categories of drugs, the least agreement was found 
among the recommendations for gliptins (Κ: −0.19), followed by genitourinary drugs (Κ: 
−0.05), angiotensin-converting enzyme (ACE) inhibitors (Κ: −0.03), oral hypoglycaemics 
(metformin, glimepiride, glibenclamide) (Κ: 0.04), musculoskeletal drugs (Κ: 0.15), 
psychotropic drugs (Κ: 0.19) and neurological drugs (Κ: 0.19). There was marked variation 
among the information sources in how they presented the contraindicated drugs. In various 
instances, drugs marked as contraindicated in one source were not mentioned as such in others 
(Table 4.2).  
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Drugs AMH MIMS BNF AHFS DPRF 
Glibenclamide CI NN NN CI N 
Codeine CI NN NN NN N 
Metformin N N N CI N 
Vardenafil X Y N Y M 
Candesartan N N N NN Y 
Alprazolam NN NN NN NN Y 
Bupropion NN NN N NN Y 
Hydromorphone NN NN NN NN Y 
Teriparatide N Y N X M 
Table 4.2 Discrepancies among the information sources  
 
AHFS recommended avoiding metformin use even in mild renal impairment. However, the 
avoidance range for metformin according to AMH was CrCl < 30 mL/min; for MIMS, it was 
CrCl < 60 mL/min; for BNF, it was eGFR < 30 mL/min; and for DPRF, it was GFR <10 
mL/min. AMH and AHFS considered glibenclamide to be contraindicated in renal impairment, 
while DPRF recommended using normal dose in even severe renal impairment (GFR < 10 
mL/min). AMH considered codeine as contraindicated, whereas three information sources 
(MIMS, AHFS and BNF) did not specify this contraindication, and interestingly, DPRF 
recommended using half of the normal dose even if GFR < 10 mL/min. Similarly, drugs that 
required no adjustment according to one source had explicit quantitative recommendations in 
other sources. There were seven such instances for six different drugs. Three drugs 
(candesartan, alprazolam, hydromorphone) for which DPRF recommended no adjustment 
required were categorised by other sources as requiring it. For vardenafil, the BNF 
recommended reduced dosage in patients with renal impairment, whereas MIMS and AHFS 
recommended that no dosage adjustment was required. While MIMS recommended no 
adjustment for teriparatide, AMH and BNF provided quantitative recommendations. 
Monographs for both vardenafil and teriparatide were missing from DPRF. Apart from the 
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dissimilarity in the categories of recommendation, disparity was found among the information 
sources in relating to how they provided the quantitative recommendation. The dose reduction 
and dosing frequency advised for the particular drugs in the varying severities of renal 
impairment, contrasted among the sources (Table 4.3) 
On examining the individual information sources, it was found that some of the 
recommendations were contradictory. For instance, with regard to famotidine in AHFS, this 
information source suggested using one-half the normal dosage or prolonging the dosing 
interval to 36–48 h according to the patient’s clinical response in moderate renal impairment 
(CrCl < 50 mL/min) or severe impairment (CrCl < 10 mL/min). On the other hand, the same 
information source advised to use one-half the usual adult dosage in adults with CrCl of 30–60 
mL/min/ 1.48 m2 of body surface area and use one-fourth the usual adult dosage in patients 
with CrCl < 30 mL/min/1.48 m2. Other examples were: metoclopramide in BNF, ‘avoid or use 
small dose in severe renal impairment’; and bisoprolol in MIMS, ‘no dosage adjustment is 
required in patients with impairment of the kidney because of excretion equally by both liver 
and kidney. Nevertheless, caution is advised’ (Table 4.4).  
61 
Drugs/dose 
for normal 
renal function 
AMH MIMS BNF AHFS DRIRF 
CrCl 
(mL/min) 
Dose 
(Max/day 
CrCl 
(mL/min) 
Dose 
(Max/day) 
eGFR 
(mL/min/1.73 
m2) 
Dose 
(Max/day) 
CrCl  
(mL/min) 
Dose 
(Max/day) 
GFR 
(mL/min) 
Dose 
(Max/day) 
 
Metformin 
500-850 mg bd 
60-90 2 g <60 Avoid <45 Review 
the dose 
Avoid in RI >50 50 
30-60 1 g <30 Avoid 10-50 25% 
<30 Avoid <10 Avoid 
 
Glibenclamide 
1.25-20 mg  
q24h 
RI Avoid Severe 
RI 
Avoid Use with care in mild to 
moderate RI 
Avoid where possible in 
severe RI 
 
 
RI 
 
 
Avoid 
>50 No data 
10-50 No data 
<10 100% 
 
Sitagliptin 
100 mg OD 
30-50 50 mg <60 Avoid 30-50 50 mg 30-50 50 mg NA 
<30 25 mg <30 25 mg <30 25 mg 
 
Saxagliptin 
5 mg OD 
<50 2.5 mg >50 5 mg 2.5 mg in moderate to 
severe RI; use with caution 
in severe RI 
>50 NR NA 
30-50 Avoid ≤50 2.5 mg 
<30 Avoid <30 Avoid 
 
Teriparatide 
20 µg OD 
<30 Avoid Dosage adjustment 
not required 
Caution in moderate RI; 
avoid if severe 
No advice for dosage 
adjustment in RI 
NA 
 
Bupropion 
150-300 mg OD 
RI: 150 mg Use reduced dose 
and/or frequency 
RI: 150 mg Use with caution in RI No need for dosage 
adjustment 
 
Duloxetine 
30-60 mg OD 
<30 30 mg 
OD 
<30 30 mg <30 Avoid <30 Avoid NA 
Table 4.3 Some examples of discrepancies in quantitative recommendations among the information sources 
Note: RI: Renal impairment, ID: Initial Dose, MD: Maintenance Dose, ND: Normal Dose, NA: Not available, NR: Not required 
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Drugs  AMH MIMS BNF AHFS 
Analgesics Morphine: Use an 
alternative opioid (or reduce 
dose if CrCl <50 
mL/minute). 
Hydromorphone: Reduce 
dose in renal impairment and 
monitor for adverse effects. 
Tramadol: Avoid use or 
reduce dose. 
Codeine: Use with caution. 
Oxycodone: Dosage should 
be reduced and adjusted 
according to the clinical 
situation. 
Morphine: Avoid use or 
reduce dose. 
Codeine: Avoid use or 
reduce dose. 
Hydromorphone: Avoid 
use or reduce dose. 
Morphine: Use with caution. 
Codeine: Care should be 
exercised. 
Hydromorphone: Reduce 
initial dose. 
Oxycodone: Reduce dose and 
adjust according to the clinical 
situation. 
Neurological Baclofen: 5 mg initially; 
titrate dose cautiously 
according to response. 
Topiramate: Reduce 
maintenance dose. 
Levetiracetam: Reduce 
dose in renal impairment. 
Topiramate: Renal clearance 
is decreased in renal 
impairment. 
 
Topiramate: Use with 
caution if eGFR less than 60 
mL/minute/1.73 m2. 
Baclofen: May be necessary to 
reduce either oral or intrathecal 
dosage in renal impairment. 
Psychotropic Lithium: Use reduced dose 
and monitor carefully. 
Bupropion: Use low dose 
and monitor for adverse 
effects. 
Benzodiazepines: Use a 
lower initial dose in severe 
impairment. 
Lithium: Avoid in severe 
renal impairment. 
Lithium: Avoid if possible 
or reduce dose. 
Bupropion: Reduce dose to 
150 mg daily in renal 
impairment. 
Lithium: Should not be used in 
patients with severe renal 
disease. 
Bupropion: Use with caution 
in patients with renal 
impairment. 
*Venlafaxine: Reduce dose by 
25–50% in patients with mild-
to-moderate renal impairment 
and by 50% in HD. 
Blood 
disorders 
Enoxaparin: Use with 
caution in renal impairment 
reduce dose if CrCl <30 
mL/minute. 
 
_ 
Enoxaparin: Reduce dose 
consult product literature. 
                     
                   _ 
63 
 
Musculo- 
skeletal 
 
 
                      _ 
Methotrexate: Avoid in 
severe renal impairment. 
*Strontium ranelate: No 
dosage adjustment in patients 
with mild to moderate renal 
impairment. Avoid in severe 
impairment. 
 
 
                 _ 
Methotrexate: Particular 
attention to close monitoring is 
recommended. 
Cardio- 
vascular 
Sotalol: Increase dosing 
interval. Seek specialist 
advice for dose adjustment 
in severe impairment. 
Bisoprolol: No dose 
reduction required up to 10 
mg daily in renal 
impairment 
Digoxin: Use with caution in 
renal impairment. 
Captopril: Initial daily 
dosage should be reduced 
Bisoprolol: No dosage 
adjustment is normally 
required up to the max dose of 
10 mg. 
Digoxin: Reduce dose and 
monitor plasma-digoxin 
concentration. 
*Candesartan: 4 or 8 mg daily 
in severe impairment. 
Digoxin: Loading doses should 
be conservative. 
Spironolactone: Use with 
caution in renal impairment, 
contraindicated in rapidly 
deteriorating renal function, 
substantial impairment of renal 
excretory function. 
Endocrine  
                      _ 
 
                         _ 
Glimepiride: Should be 
used with care. 
Glibenclamide: Should be 
used with care. 
Glimepiride: Initial dosing 
should be conservative. 
Gastro- 
intestinal 
 
 
 
                    _ 
Metoclopramide: Initiate 
therapy at half of the dose in 
patients with clinically 
significant degrees of renal 
impairment. 
Ranitidine: Reduce dose on 
severe renal impairment. 
Metoclopramide: Avoid or 
use small dose in severe 
impairment. 
 
 
                      _ 
Table 4.4 Examples of ambiguous recommendations in information sources 
* Mild, moderate and severe impairment were not defined in the information sources.
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CrCl was the most common index to direct the dosage adjustment in the information sources. 
AMH and DPRF recommended dose adjustment based on CrCl calculated by the CG formula. 
However, BNF provided recommendations based on eGFR calculated by the modification of 
diet in renal disease (MDRD) formula.198 The renal function quantification methods varied 
among the drug monographs within AHFS and MIMS. For the majority of drugs, dosage 
adjustment was based on the CG formula, and for some drugs, the MDRD formula was used, 
especially when referring to manufacturers’ recommendations. The definition and 
classification of renal impairment differed in all five sources. The classification for renal 
impairment in BNF categorised the renal function into five different stages; this complies with 
the definitions by the British Renal Association.199 AMH had its own system of classification 
of renal impairment designed solely to aid the drug dosage adjustment; this differs from the 
Caring Australians with Renal Impairment guidelines.26 DPRF defined renal impairment based 
on absolute GFR and divided them into three categories; this does not correspond to any 
standard classification system. MIMS and AHFS did not provide clear definitions of categories 
of renal impairment, and terms like mild, moderate and severe impairment were used without 
definition. Furthermore, various terms were used for dosage recommendation in the 
information sources without proper definition; these included a clinically significant degree of 
renal impairment, rapidly deteriorating renal function and substantial impairment of renal 
excretory function. 
 
4.5 Discussion 
There was considerable variation between the information sources in recommendations for the 
use and dosing of drugs in patients with renal impairment. Vidal et al. similarly concluded that 
there was poor consistency among four information sources: BNF, Martindale, AHFS and 
DPRF for the renal dosing of 100 drugs used commonly in the hospital setting.193 However, 
their study had some limitations, particularly relating to the method of selecting the most 
commonly prescribed drugs within a hospital environment rather than focusing on high-risk 
drugs excreted primarily through the renal route.200 201 Therefore, we compared the drug 
information sources based on their dosing recommendations for the drugs that have most 
potential for inappropriate prescribing in kidney disease. The results of our study illustrate that 
there is a lack of quantitative recommendations in the various information sources to guide 
health professionals reliably on appropriate prescribing to minimise adverse outcomes in 
patients with renal impairment. It is recognised that it is unrealistic to quantify the appropriate 
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dose for some drugs with large pharmacodynamic variability– for instance, ACE inhibitors and 
β-blockers, whose dosage adjustment should not be based solely on pharmacokinetic 
parameters but clinical factors like blood pressure and heart rate as well. However, clear 
quantitative information in one source and unclear information in other information sources, 
such as ‘increase dosing interval’ or ‘seek specialist advice in severe impairment’, will 
complicate the prescribing decision. One of the reasons for the lack of robust dosing 
information could be the paucity of large population-based studies on dose adjustment in renal 
impairment. Another contributing factor could be the practice of the drug regulatory authorities 
that focuses mainly on clinical trials determining the maximum tolerated dosage in healthy, 
young individuals.201 Keeping aside the fact that few studies are available that determine the 
correct dose in renal impairment, the dissimilarity between standard information sources 
regarding the reported availability of clinical study data was remarkable; drugs for which one 
information source mentioned a lack of clinical study data on dose adjustment, other sources 
provided clear quantitative recommendations. It is well understood that contraindications and 
cautions are seldom absolute, but the differing recommendations create ambiguity and 
uncertainty, and can misdirect the users or prescribers. For particular drugs, such as oral 
hypoglycaemics, H2 receptor blockers, metoclopramide and many cardiovascular drugs, the 
information sources often did not provide explicit information for dosage adjustment, yet 
studies have shown that incorrect dosage adjustments are common with these categories of 
drugs.133 136 Guidelines for dose adjustment in renal impairment, even for drugs with a narrow 
therapeutic index (e.g. digoxin and lithium), were poorly mentioned in the information sources. 
Instead of a clear quantitative recommendation, qualitative and ambiguous terms like ‘reduce 
the dose’ and ‘loading dose should be conservative’ were often used. It was found that the 
information sources were relatively consistent in providing recommendations for newer drugs, 
such as levetiracetam, memantine, paliperidone, pramipexole and pregabalin. This improved 
consistency could be due to the manufacturers providing more robust data for clinical use and 
dosage adjustment, and regulatory authorities demanding more consistent information. Clearly, 
regular updating of the drug information sources is necessary, along with a need for all drugs 
that are to be used in patients with renal dysfunction to undergo at least one pharmacokinetic 
study in patients with varying degrees of renal impairment prior to marketing. An emphasis 
should be placed on conducting and disseminating research work focused on determining the 
correct drug dosage based on renal function. Uniformity in the categorisation of renal 
impairment would be desirable as prescribers tend to refer to more than one information source 
for advice on drug dose adjustment in renal impairment.202 Keeping in mind the new practice 
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of automatic eGFR reporting, drug dosage recommendations based only on CrCl could be 
inconvenient.203 204 Recently, it was suggested that the method of calculating eGFR should be 
changed to the CKD Epidemiology Collaboration (CKD-EPI) formula and that all laboratories 
should report eGFR values as a precise figure to at least 90 mL/min/1.73 m2.103 However, it 
has been recommended that the dosage adjustment for drugs with a narrow therapeutic index 
or excreted primarily by the kidney should be guided by CrCl calculated by the CG equation.205 
Further, in elderly or frail patients and in those with a low body mass index, CrCl is the 
preferred renal function quantification method.206 Therefore, recommendations for dose 
adjustment based on both CrCl and eGFR/CKD-EPI would be ideal. Editors of secondary 
sources accept the difficulties in finding and compiling the relevant information for patients 
with renal disease on which clear dosing guidelines can be formulated.201 207 208 Furthermore, 
the value of the product information will always be limited by the regulatory process (data 
requirements, economics and approval delays) and the generally conservative approach by 
manufacturers (fear of litigation). It will always be necessary to interpret the product 
information and make a risk-benefit decision for individual patients. Also, while adjusting the 
dose in clinical practice, the prescriber needs to be confident that the pharmacokinetic 
parameters of the patient they are treating do not vastly differ from the population in which the 
renal pharmacokinetic study was undertaken. Our study was limited to drugs used commonly 
in the community setting, and so excluded renally important drugs used primarily in hospital 
settings (e.g. aminoglycoside antibiotics). However, in light of the inconsistency in the 
recommendations for the 61 drugs in our study, we believe a similar result would be obtained 
if a greater number of renally problematic drugs were examined. Also, we acknowledge that 
there are other sources of drug dosing information in renal disease that might be used in 
practice, especially within specialist renal units. However, we have examined the information 
sources most commonly used by Australian general practitioners and pharmacists in the 
community setting. 
 
4.6 Conclusion 
There should be an evidence-based approach to drug dosage adjustment in renal disease 
to bring uniformity to the recommendations. Further, it would be beneficial to standardise the 
renal function quantification methods in the drug information sources. We believe that this 
would reduce the possibility of inappropriate dosing for patients with renal impairment. 
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4.7 Next step 
This chapter provided evidence that there is considerable variation amongst the 
information sources in recommendations for dosing of drugs in patients with renal impairment. 
The standard drug information sources are a compilation of the data from the drug clinical trials 
and the PI is the archive of the pharmacokinetics results provided by the manufacturers. In the 
next step, we aim to review the product information for drugs that are recommended to be 
either avoided or used with caution in renal impairment and investigate the extent to which 
information is available on dosing in renal impairment and the concordance in 
recommendations between manufacturers’ PI for the same generic drug. 
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Chapter 5 RENAL DRUG DOSING RECOMMENDATION: EVALUATION OF PRODUCT 
INFORMATION FOR BRANDS OF THE SAME DRUG 
5.1 Abstract 
We reviewed the official product information (PI) for brands of 28 drugs recommended 
to be either avoided or used with caution in patients with renal impairment, and investigated 
the extent to which information was available on dosing in renal impairment and the 
concordance between the dosing recommendations for the same generic drug. There was 
generally a lack of detailed information in the PI on the use of drugs in patients with renal 
impairment. The recommendations varied significantly among different brands of 
hydromorphone, morphine, oxycodone, tramadol, metformin and topiramate. 
 
5.2 Introduction  
Given the ageing of the population and the rising prevalence of chronic kidney disease 
(CKD), the quality of prescribing in patients with renal impairment is becoming increasingly 
important.85 209 Impaired renal function can be associated with alterations in drug absorption, 
protein binding, metabolism and excretion; therefore, it is essential to individualise the dosage 
of many drugs in order to avoid toxicity and the risk of therapeutic failure.82 149 The renal 
function of the patient should be considered when prescribing drugs that are eliminated 
unchanged by the kidneys, particularly those (i) with a narrow therapeutic index, (ii) with active 
metabolites that are primarily excreted by the kidney or (iii) that are nephrotoxic. The need for 
dosage adjustment can be determined by measurement of the kidney function of the patient, 
and the optimal dose can be determined by consulting standard drug information sources or the 
manufacturer’s product information (PI), which has been approved by the Australian 
Therapeutic Goods Administration (TGA).  
The Monthly Index of Medical Specialities (MIMS), a compendium of PI, is one of the 
most frequently consulted drug information sources in Australia.210 However, it has been 
criticised for having out-dated information and inaccuracies in the listed PI.211 A review of PI 
in MIMS revealed the presence of numerous errors and potentially hazardous information 
pertaining to the management of poisoning.212 Similarly, a comprehensive assessment of 
MIMS to examine the extent to which paediatric dosing information is available in PI showed 
that 81% contained inadequate information.213 In addition, marked discrepancies in paediatric 
dosing information between generic equivalent products were observed.  
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No formal studies in Australia have examined the renal dosing information in approved 
PI. Therefore, we aimed to review the PI for drugs that are recommended to be either avoided 
or used with caution in renal impairment,214 and investigate the extent to which information is 
available on dosing in renal impairment and the concordance in recommendations between 
manufacturers’ PI for the same generic drug. 
 
5.3 Methodology 
eMIMS215 was examined for commonly used generic drugs (n=28) recommended by 
the Australian Department of Veterans Affairs (DVA) to be either avoided or used with caution 
in patients with renal impairment.214 For each generic drug, all available brands, which were 
listed as having solid oral dosage forms were recorded. A total of 228 brands were obtained for 
the 28 drugs, corresponding to 30 manufacturers. One drug (digoxin) was excluded as the 
available brands were from the same manufacturer. In instances where a manufacturer had 
multiple brands for the same generics, only one brand was selected randomly. The final list of 
products included a total of 155 brands corresponding to 27 generic drugs. For each identified 
brand, the PI was consulted and data referring to renal impairment was collated from various 
sections: pharmacokinetics, contraindications, precautions, and dosage and administration. The 
renal dosing information within PI was assigned to one of four categories (Table 5.1). The 
dissimilarity between the PI from various manufacturers regarding the dosage 
recommendations was determined. Also, the use of CKD terminology and classification of 
renal impairment were recorded. 
 
5.4 Results 
There was generally a lack of detailed information in the PI on the use of drugs in 
patients with renal impairment. The majority of PI documents (88 of 155 PI; 57%) provided 
quantitative recommendations (Table 5.2) regarding dosage adjustments for renal impairment, 
but this was often not detailed enough to help users to make an informed decision. For instance, 
statements such as “avoid in severe renal impairment (creatinine clearance, CrCl<15 mL/min) 
but reduce dose and monitor side effects in moderate and mild impairment” were considered 
quantitative, but the recommendations are probably inadequate to perform dosage adjustment 
in patient care settings. For 37 PI documents (24%), an altered dosage regimen was proposed 
without a quantifiable measure of renal function reported in the dose recommendation. The 
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results of pharmacokinetic studies in patients with renal impairment were not presented in 59 
PI (38%). Twenty brands did not have full PI and advice like “contact the manufacturer” was 
mentioned. Four of the PI mentioned the lack of data regarding use in patients with renal 
impairment and thus recommended avoiding the drug in these patients. The PI for relatively 
new drugs, such as levetiracetam, gabapentin and pramipexole, had more detailed renal dosing 
information than for older drugs. 
 
Table 5.1 Types of renal dosing recommendations 
 
 
1. Quantitative  
 Dose modification was recommended based on renal function value. 
 Clear recommendation to avoid the drug below a certain range of renal function. 
2. Qualitative  
 Ambiguous or imprecise recommendation. 
 Recommended altering the dosage regimen but did not provide any quantifiable 
dose based on renal function. 
3. Contact manufacturer 
 No PI provided in MIMS for the brands. 
 Advice such as “contact manufacturer for full prescribing information” was given. 
4. Lack of data: 
 PI implied that safety and effectiveness of product in renal impairment had not 
been established; therefore, avoid using the drug in severe renal impairment. 
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Drug class Generics Number of PI 
examined 
 Nature of dosing information in PI 
Contact manufacturer Qualitative Quantitative Lack of data 
Analgesics Hydromorphone 2 - 2 - - 
Morphine 3 - 3 - - 
Oxycodone* 2 - 1 1 - 
Tramadol 10 2 3 5 - 
Endocrine 
 
Glibenclamide 2 - 2 - - 
Glimepiride 7 1 1 5 - 
Metformin 10 1 1 8 - 
Neurological Baclofen 4 - 4 - - 
Gabapentin 9 - - 9 - 
Galantamine 4 - - 4 - 
Levetiracetam 10 3 - 7 - 
Memantine 3 - - 3 - 
Pramipexole 2 1 - 1 - 
Topiramate 8 1 - 7 - 
Psychotropic Amisulpride 4 - - 4 - 
Alprazolam 6 - 6 - - 
Bupropion 2 - - - 2 
Lithium 2 - - - 2 
Venlafaxine 8 2 - 6 - 
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Table 5.2 Nature of dosing information in product information from various manufacturers for the same generic drugs 
*Available brands were in different formulation (conventional and modified release tablets), **excluded as both brands were from same manufacturer. 
 
Cardiovascular Enalapril 9 2 - 7 - 
Atenolol 10 2 - 8 - 
Bisoprolol 9 1 8 - - 
Digoxin** - - - - - 
Spironolactone 2 - - 2 - 
Gastrointestinal Ranitidine 11 3 8 - - 
Musculoskeletal Allopurinol 4 - 4 - - 
Alendronate 10 1 - 9 - 
Colchicine 2 - - 2 - 
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Sometimes, contradictory information was presented within the same PI. For instance, with 
Memanxa (memantine), in the “contraindication section” of the PI, it is mentioned that the drug 
should not be used in patients with CrCl less than or equal to 50 mL/min. However, in the 
“dosage and administration section”, it is stated that in patients with moderate renal impairment 
(CrCl 30 - 49 mL/min) or severe renal impairment (CrCl 5 - 29 mL/min), the dose should be 
10 mg per day.  
The renal function severity terms used and the associated quantitative values were not 
consistent among the PI. The most common renal function measure reported in the PI was CrCl 
(77 of 155 PI). Few PI used explicit terms to define the severity of impairment but these were 
not consistent with the contemporary standard definitions of CKD. The recommendations for 
dosage adjustment in renal impairment varied among the PI for the different brands of six 
generic drugs out of 27 drugs examined. These drugs were hydromorphone, morphine, 
oxycodone, tramadol, metformin and topiramate (Table 5.3). The renal function severity at 
which the drug should be avoided varied among the PI. For instance, with tramadol, the 
avoidance range for the brand Tramedo was CrCl<10 mL/min whereas for the brand Duotram 
it was CrCl<30 mL/min. For the same drug, some brand’s PI provided ambiguous 
recommendations while other PI documents provided clear quantitative recommendations. For 
example, the brand APO-Topiramate recommended use with caution in patients with renal 
disease whereas the brand Topamax suggested using half of the usual starting and maintenance 
dose in moderate and severe renal impairment. Similarly, the renal function quantification 
method used in recommendations varied among the PI. For metformin, the brand Glucophage 
gave a dosage recommendation based on CrCl, whereas the brand Genepharm gave it with 
serum creatinine (SrCr).  
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Drugs Brands/ Date of TGA 
approved information 
Recommendation in PI 
CrCl 
mL/min 
Dose 
Max/day 
Hydromorphone Dilaudid 
22/02/2010 
Should be used with caution and the initial dose should be reduced in those with RI. 
Jurnista 
12/03/2013 
Reduce dose in moderate renal insufficiency. In severe renal insufficiency reduce both dose 
and dosing interval and monitor for ADE. 
Morphine Anamorph 
7/05/2003 
CI in severe renal disease. 
Apotex 
15/06/2011 
CI in severe RI or use one-half the usual dose in significantly decreased renal function. 
Oxycodone Endone 
2/07/2009 
In RI reduce dose and adjust according to clinical situation. 
 
Oxycontin 
3/11/2011 
<60  one half of usual dose in RI 
Tramadol Tramal 
5/04/2013 
Not recommended in severe renal insufficiency. 
APO-tramadol SR (south 
cross) 
9/11/2010 
<10 CI 
Dutrotram XR  <30 CI 
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1/05/2008 
GA tramadol SR 
28/05/2010 
<30 Reduce dose 
<10 Not recommended 
Lodam SR Contact manufacturer 
Tramedo SR 
8/02/2008 
<30 Increase dosage interval to 12 hours 
<10 CI 
Metformin Glucophage 
23/03/2012 
<60 CI 
Formet 
16/06/2005 
Should not be used in diminished renal function. 
Metformin 
(Genepharm) 15/12/2005 
CI in SrCr level> 135 micromols/L in males and > 110 micromols/L in females. 
Metformin Pfizer Contact manufacturer. 
Topiramate Topamax  
14/08/2012 
Use half of the usual starting and maintenance dose in moderate and severe renal impairment. 
Topiramate Generic health Contact manufacturer. 
APO- Topiramate  
29/08/2012 
Use caution in renal disease. 
Table 5.3 Discrepancies among the various brand's product information on how they present the renal dosing information 
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5.5 Discussion  
We found a lack of detailed information in the PI on the use of drugs in patients with renal 
impairment. The renal function severity terms used and the associated quantitative values were 
not consistent among the PI. The findings of our study are in concordance with the results of 
several overseas studies that concluded that there were inadequate dosage recommendations 
and marked discrepancies among the PI regarding the method to quantify renal function.216 217 
We examined the eMIMS for drugs which have the most potential for adverse outcomes if 
prescribed inappropriately in renal impairment.11 Therefore, we anticipated specific dosing 
recommendations based on the degree of renal impairment, as the dose information is of utmost 
importance in using these drugs safely and effectively in patients with renal impairment. 
However, we found that 38% of PI lacked data on pharmacokinetic studies in renal impairment 
and 24% suggested an altered dosage regimen without a quantifiable measure of renal function. 
Perhaps the provision of more complete pharmacokinetic data in special groups, such as those 
with renal impairment, should be compulsory for the registration of new drugs. In an attempt 
to improve the quality of renal dosing information, the United States Food and Drug 
Administration in 1998 published a “Guidance for industry: pharmacokinetics in patients with 
impaired renal function”.218 The positive impact of this guidance on the consistency, clarity 
and quality of recommendations has been studied.216 In Europe, the European Medicines 
Evaluation Agency published its “Note for guidance on evaluation of pharmacokinetics of 
medicinal products in patients with impaired renal function”.219 This guidance was adopted by 
the TGA in Australia in 2004 to ensure that manufacturers give appropriate and specific dosage 
recommendations in patients with reduced renal function.220 Although the majority of PI 
examined here (85%) were recorded as having been approved by TGA in the post-guidance 
era, the consistency and quality of renal dosing recommendations were still questionable. The 
renal function severity values were also not uniformly consistent with the definition and range 
of renal function as recommended in the guidance.220  
Dosage adjustment recommendations based on serum creatinine in the PI can be 
problematic as the serum creatinine is not a reliable marker of CKD.221 Furthermore, the lack 
of prescribing information for some brands in eMIMS and impractical recommendations, such 
as contacting the manufacturer, might deter prescribers from dose adjustment or even using the 
information source. Also, the inconsistencies in renal dosing information between the PI from 
various manufacturers for the same generic drug is of concern and may have clinical 
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ramifications in patients with renal impairment, especially when the discrepancy is as marked 
as that mentioned above for tramadol.  
The PI for older medicines often provided inadequate and out-dated recommendation 
for dose adjustment. Yet, a search of the literature revealed clear dose recommendations based 
on renal function for many of these drugs, including baclofen, ranitidine, oxycodone and 
topiramate.165 222-225 Clearly, regular updating of the PI seems necessary. Perhaps, an expiry 
date should be assigned for PIs in order to enforce upgrading the information with time. 
Otherwise, in clinical practice prescribers perhaps know that the PIs are often out of date and 
tend to ignore them - either using therapeutic drug monitoring, if available, or clinically 
monitoring the patients. 
A recent study found conflicting recommendations for the renal dosing of medications 
among PI and four other commonly used drug information sources. 177 The limited updating of 
PI in MIMS has been highlighted previously. A detailed critique of PI for thyroid medications 
from four different manufactures pointed out erroneous therapeutic recommendations, 
inappropriate dosage adjustment and exclusion of well recognised indications and side 
effects.211 It was observed that 11 of 16 errors remained uncorrected two years after the 
publication of this review.226 On examining the PI after six years, it was found that the errors 
still remained uncorrected.227 
5.6 Conclusion 
There were inconsistent or missing renal drug dosing recommendations across brands 
for the same generic drug. Regularly updating of PI seems necessary. The measure of renal 
function also requires standardisation to ensure optimal drug dosing.
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5.7 Next step 
This chapter demonstrates that inconsistent or missing renal drug dosing 
recommendations across brands for the same generic drug remains a significant problem. Lack 
of information to guide the prescribers on precautions and dosage adjustments contributes to 
inappropriate prescribing leading to adverse outcomes in patients with renal impairment. The 
inconsistency in renal function severity terms used and the associated quantitative values 
among the PI create ambiguity and uncertainty, and can misdirect the users or prescribers. This 
adversely affects the quality of prescribing and should be considered as a factor contributing 
to inappropriate prescribing. By regularly updating the PI and bringing standardisation in the 
measure of renal function, better outcomes may be achieved for improving usage of medicine 
and quality of care for CKD patients as whole. 
In the next step, we are examining another important factor that contributes to 
inappropriate prescribing in patients with renal impairment. An essential part of the safe drug 
prescribing in patients with CKD is the accurate estimation of renal function as CKD staging 
influences all aspects of pharmacological and non-pharmacological therapy, especially in 
identifying the drugs that need to be avoided or require dose modification.  
The agreement among the renal function estimating equations in dosing of renally-
cleared drugs commonly prescribed in primary care settings, is an important issue to be 
addressed in improving usage of medicine in CKD patients. 
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Chapter 6 COMPARISON OF EQUATIONS FOR DOSING OF MEDICATIONS IN RENAL 
IMPAIRMENT  
6.1 Abstract  
Aim: To determine the concordance among the Cockcroft-Gault, the Modification of Diet in 
Renal Disease (MDRD) and the CKD-Epidemiology Collaboration (CKD-EPI) equations in 
hypothetical dosing of renally-cleared medications. 
Methods: A total of 2163 patients prescribed at least one of the 31 renally-cleared drugs under 
review were included in the study. Kidney function was estimated using the three equations. 
We compared actual prescribed dosages of the same drug to recommended dosages based on 
the kidney function as calculated by each of the equations and applying dosing 
recommendations in the Australian Medicines Handbook.  
Results: There was a significant difference in the kidney function values estimated from the 
three equations (P<0.001). Despite the good overall agreement in renal drug dosing, we found 
selected but potentially important discrepancies among the doses rendered from the equations. 
The CKD-EPI equation non-normalised for body surface area had a greater rate of concordance 
with the Cockcroft-Gault equation than the MDRD equation for renal drug dosing. 
Conclusions: There is need for a long-term multi-centre study in a diverse population to define 
the clinical effects of the discrepancies among the equations for drug dosing. Given the greater 
concordance of the non-normalised CKD-EPI equation with the Cockcroft-Gault equation for 
dosing, the recommendation by Kidney Health Australia and the United States National Kidney 
Disease Education Program that “dosing based on either eCrCl or an eGFR with body surface 
area normalisation removed are acceptable” seems suitable and practicable for the purpose of 
dosing of non-critical drugs in the primary care setting. 
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6.2 Introduction 
Chronic kidney disease (CKD) is a significant and growing public health problem that 
is associated with premature mortality.27 Renal impairment alters the effects of many drugs, 
sometimes decreasing their effects but more often increasing their effects and potentially 
toxicity.107 Many of these changes are predictable and can be prevented by adjusting drug 
doses.76 Traditionally, the creatinine clearance (CrCl) estimated by the Cockcroft-Gault 
equation93 has been the most commonly used method to estimate renal function for drug dosing 
purposes, as evidenced by its widespread use in both drug developmental arenas and 
recommendations that appear in pharmaceutical product information.93 In recent years, several 
new equations have been proposed to estimate kidney function in patients with CKD; the 
Modification of Diet in Renal Disease (MDRD) and Chronic Kidney Disease – Epidemiology 
Collaboration (CKD-EPI) equations.97 102 These latter equations, normalised for the patient’s 
body surface area (BSA) and expressed in mL/min/1.73 m2, are routinely used in Australian 
laboratories and health centres to automatically report eGFR with every request for serum 
creatinine determination.203 204 There is abundant evidence that these two new equations 
provide more accurate estimation of the GFR.98 However, there has also been discussion on 
whether these new equations could be used for renal drug dosing.228-231 Studies have questioned 
the use of the Cockcroft-Gault equation for renal dosing and recommended using MDRD for 
conducting renal pharmacokinetic studies and adjusting doses in the clinical settings.87 185 The 
Cockcroft-Gault formula is prone to high variability due to inconsistent use of ideal, actual or 
adjusted body weight, and indicates the need for dosage adjustment more often due to a more 
conservative estimation of kidney function.232 233 
The United States National Kidney Disease Education Program stated that either the 
Cockcroft-Gault or MDRD equation can be used as the estimate of kidney function for drug 
dosing.234 Similarly, in 2007 the Australasian Creatinine Consensus suggested that using the 
eGFR calculated with the MDRD formula was acceptable to assist with drug dosing decisions 
in general practice for non-critical-dose drugs.103 This has led to considerable debate on the 
topic231 235 with some studies suggesting that Cockcroft-Gault should remain the equation of 
choice for drug dosing as the differences in the doses rendered were too significant to replace 
Cockcroft-Gault with MDRD for dosing.217 231 236-239 
The CKD-EPI equation has been recommended to be used in clinical laboratories to 
routinely provide eGFR values with each request for serum creatinine.106 There is, however, 
limited information on the clinical application of this equation for the purpose of dose 
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adjustment. Further, unlike MDRD, there has been no formal recommendation on use of this 
equation for drug dosing. However, it is worth noting that clinicians often use the eGFR 
provided by the laboratories for drug dosing purposes in the clinical setting.240 
Given this background, we were interested to evaluate the agreement among the three 
formulae if hypothetically used in dosing of renally-cleared drugs commonly prescribed in 
primary care settings. The two objectives of the study were (1) compare kidney function 
estimates based on the CKD-EPI, Cockcroft-Gault and MDRD equations, and 2) determine the 
concordance among the Cockcroft-Gault equation, MDRD (with and without BSA 
normalisation) and the CKD-EPI equation (with and without BSA normalisation) for 
hypothetical dosing of renally-cleared medications. 
 
6.3 Methods 
We examined a sample of de-identified medication review cases extracted from the 
database of Medscope, an IT company providing decision support solutions for accredited 
pharmacists performing medication reviews. The Home Medicines Review and Residential 
Medication Management Review services were conducted by accredited pharmacists in 
collaboration with GPs between January 2010 and June 2012. Methods for data extraction for 
this study have been explained previously.241 Ethical approval was granted by the Tasmanian 
Health and Medical Human Research Ethics Committee (H0012386). 
All individuals (n=2163) who had their weight, height and serum creatinine reported 
and were prescribed one or more of the drugs under review, were included in the study. We 
used a list of 31 renally-cleared drugs that are commonly prescribed in the community and 
recommended, by the Australian Department of Veterans’ Affairs, to be avoided or used with 
dose adjustment in patients with renal impairment (Appendix 1).242  
Kidney function was estimated using the MDRD, CKD-EPI and Cockcroft-Gault 
equations. The CrCl was estimated using actual body weight, as we aimed to compare the 
Cockcroft-Gault equation; based on actual body weight with the MDRD and CKD-EPI 
equations both with and without normalisation for body surface area. The estimated kidney 
functions were analysed for any significant discrepancies (Table 6.1).To further elucidate the 
impact of the observed discrepancies on drug dosing, for each patient we compared actual 
prescribed dosages of the same drug to recommended dosages based on the level of kidney 
function as calculated by each of the estimating equations and applying explicit 
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recommendations for renal drug dosing in the Australian Medicines Handbook (AMH).43 For 
each drug, the prescribed doses were marked as ‘appropriate (A)’, ‘inappropriate (IA)’’, ‘dose 
modification not required (NR)’ based on the conformity with the adjustment specified in the 
AMH using the kidney function estimated from each equation. Both inappropriately high dose 
and contraindicated prescription were treated as inappropriate prescription. Fleiss Kappa 
values along with pairwise percentage agreement were calculated to determine the concordance 
among the three equations.  
 
CKD-EPI equation 
 
For females with SCr ≤ 62μmol/L= 144 × (SCr in μmol/L 
×0.0113/0.7)-0.329 × (0.993) age in years 
For females with SCr > 62 μmol/L= 144 × (SCr in μmol/L × 
0.0113/0.7)-1.209 × (0.993) age in years 
For males with SCr ≤80 μmol/L= 141 × (SCr in μmol/L × 0.0113/0.9)-
0.411 × (0.993) age in years 
For males with SCr >80 μmol/L= 141 × (SCr in μmol/L × 0.0113/0.9)-
1.209 × (0.993) age in years 
MDRD equation eGFR-MDRD (mL/min/1.73m2) = 175 × (SrCr × 0.0113)-1.154 × age-
0.203 (× 0.742 if female) 
Cockcroft-Gault CrCl (mL/min) = [(140 – Age) × wt] / (0.813 × SrCr) (× 0.85 if 
female) 
Table 6.1 List of GFR estimating equations 
Units for all formulae. Serum creatinine concentration (SrCr)in μmol/L; Weight (Wt) in kg; Age in years 
Abbreviations: CKD-EPI, Chronic Kidney Disease Epidemiology collaboration; MDRD Study, Modification of Diet in Renal 
Disease Study 
 
The Cockcroft-Gault equation is reported unadjusted for body surface area in units of mL/min, 
whereas MDRD and CKD-EPI equations are adjusted for body surface area. The recommended 
unit for drug dosing recommended by the Kidney Health Australia is mL/min. Also, the 
Therapeutic Goods Administration (TGA) approved product information provides dosing 
information by mL/min. Therefore, for the purpose of comparison, the GFR estimated using 
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MDRD and CKD-EPI were converted to this unit, by multiplying each patient’s BSA and 
dividing by 1.73 m2 and the analyses were repeated. 
All statistical analyses were conducted using IBM SPSS Statistics for Windows, 
Version 20.0. Armonk, NY: IBM Corp., Excel 2010 (Microsoft Corporation, Redmond, USA) 
and ReCal online web service.197 The analysis of variance (ANOVA) repeated measure test 
was used to determine the significance of differences in the kidney function estimates 
determined from the three equations (Cockcroft-Gault, MDRD and CKD-EPI). A P-value of 
less than 0.05 was considered as significant. The concordance in dosing recommendation for 
each drug based on the kidney function estimates from these equations was determined using 
Fleiss Kappa (К). Fleiss kappa is a statistical measure that calculates the reliability of 
agreement between more than two raters. It is a measure of the degree of agreement that can 
be expected above chance.196  
 
6.4 Results 
The clinical characteristics of the study participants are summarised in Table 6.2. The 
mean age of the patients was 72.2 years and 59.5% were female. The ANOVA repeated 
measure test demonstrated a statistically significant difference in the kidney function values 
rendered from the three equations (P<0.001). All pairwise comparisons between the values for 
eGFR and eCrCl were significantly different from each other (P<0.001). 
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Characteristics Mean (SD) or % 
Age, years 72.2 (11) Range, 26:99 
≥65 84.3 
Female 59.5 
Weight (kg) 80.7 (20.9) 
Height (cm) 163.6 (10.2) 
SrCr (µmol/L) 91.2 (40.3) 
BMI, kg/m2 30 (7) 
>30 kg/m2 45.1 
BSA, m2 1.9 (0.27) 
Cockcroft-Gault (mL/min) 73.5 (38.9) 
MDRD eGFR (mL/min/1.73 m2) 71.8 (25.4) 
CKD-EPI eGFR (mL/min/1.73 m2) 66.2 (21.2) 
Table 6.2 Patient Characteristics 
Note: values expressed as mean (standard deviation) Abbreviations: BSA- body surface area, BMI-body mass index CG, 
Cockcroft-gault equation using actual body weight; MDRD, Modification of Diet in Renal Disease Study equation; CKD-EPI 
Chronic Kidney Disease – Epidemiology Collaboration 
 
Table 6.3 shows the concordance among the three equations in dosing of the renally-cleared 
drugs. The level of agreement ranged from moderate to very good. Concordance among the 
equations was lower for drugs that have fewer kidney function categories for dose adjustment. 
When the analyses were repeated for the CKD-EPI and MDRD study equations with the 
removal of BSA normalisation (expressed in units of mL/min), a higher concordance was 
observed among the three equations (Table 6.3). Both the CKD-EPI and MDRD with the 
removal of BSA normalisation showed greater concordance to the Cockcroft-Gault equation 
than the normalised equations.  
Table 6.4 shows the pair-wise comparison of the MDRD and the CKD-EPI equations with the 
standard Cockcroft-Gault. In comparison to the MDRD equation, the CKD-EPI equation had 
a greater concordance with the Cockcroft-Gault equation for renal drug dosing. This pattern 
was consistent with all the drugs tested. 
At an individual level the discordance in the doses rendered from the equations was 
considerable. For each drug, the number of patients who required dosage adjustment or were 
prescribed doses higher than the recommended dose differed depending upon the equation used 
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to estimate renal function (Table 6.5). For instance, 39.5% and 38.8% of the patients receiving 
metformin would require dose adjustment if Cockcroft-Gault and CKD-EPI equations were 
used, respectively, to estimate the kidney function. However, 52.4% of the patients would 
require dosage adjustment based on the MDRD equation.
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Drug/Dosing 
Level 
N 
received 
this 
dose 
Cockcroft-
Gault 
(mL/min) 
MDRD 
(mL/min/1.73 
m2) 
MDRD* 
(mL/min) 
 
CKD-EPI 
(mL/min/1.73 
m2) 
CKD-EPI* 
(mL/min) 
Overall agreement 
(Fleiss Kappa) 
CG vs 
MDRD vs 
CKD-EPI 
CG vs 
MDRD* vs 
CKD-EPI* 
NR IA A NR IA A NR IA A NR IA A NR IA A 
Dosing Level (1)  
Alendronate 253 219 34 - 244 9 - 242 11 - 238 15 - 236 17 - 0.51 0.60 
Risedronate 201 186 15 - 199 2 - 195 6 - 194 7 - 192 9 - 0.33 0.62 
Strontium 69 61 8 - 67 2 - 66 3 - 67 2 - 66 3 - 0.46 0.61 
Duloxetine 74 68 4 2 71 2 1 72 2 - 70 3 1 70 3 1 0.75 0.62 
Dosing Level (2)  
Sitagliptin 126 94 22 10 103 14 9 105 12 9 100 16 10 102 14 10 0.71 0.82 
Dabigatran 48 35 - 13 40 1 7 42 - 6 38 1 9 40 1 7 0.51 0.57 
Dosing level (3)  
Perindopril 620 296 240 84 376 185 59 411 157 52 331 218 71 374 179 67 0.69 0.73 
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Fenofibrate 150 96 33 21 85 43 22 101 31 18 78 49 23 96 33 21 0.74 0.77 
Metformin 956 377 133 446 232 173 551 402 113 441 335 198 423 371 128 457 0.58 0.68 
Pregabalin 68 31 4 33 36 2 30 45 1 22 33 3 32 41 1 26 0.21 0.64 
Dosing Level (4) 
Gabapentin 63 18 7 38 15 4 44 26 2 35 14 2 47 22 5 36 0.54 0.57 
Table 6.3 Concordance in renal drug dosing among the renal function estimating equations 
Abbreviation:A-appropriate dose, IA- inappropriate dose that is defined as inappropriately high dose and contraindicated prescriptions, NR-dose modification not required 
*not normalised to body surface area  
#Dosing level refers to the number of kidney function categories for dose adjustment as specified in AMH. 
The last column shows the Fleiss Kappa value which indicates the level of concordance among the three equations CG, MDRD, CKD-EPI (both normalised for BSA and non-normalised for BSA) 
in dosing of the renally-cleared drugs. 
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Drug Kappa value 
Average Pairwise Percent Agreement (%) 
 MDRD* (mL/min) CKD-EPI* (mL/min) 
Alendronate 0.46 
90.1 
0.60 
92.0 
Risedronate 0.52 
95.0 
0.61 
95.5 
Sitagliptin 0.73 
90.4 
0.81 
92.8 
Dabigatran 0.50 
83.3 
0.55 
85.4 
Perindopril 0.63 
79.1 
0.71 
83.8 
Fenofibrate 0.69 
84.6 
0.90 
95.3 
Metformin 0.57 
73.9 
0.70 
84.6 
Pregabalin 0.55 
75.0 
0.85 
92.6 
Gabapentin 0.63 
79.6 
0.70 
85.9 
Table 6.4 Concordance in dosing recommendations using the Cockcroft-Gault versus MDRD and CKD-EPI equations 
Abbreviation: MDRD, Modification of Diet in Renal Disease Study equation; CKD-EPI Chronic Kidney Disease – Epidemiology Collaboration 
*not normalised to body surface area 
 
 
 
89 
 
S.N. Patient characteristics Estimated renal function Prescribed dose Recommended dose based 
on renal function 
Gender Age  
(yrs) 
Weight
(kg) 
SrCr 
(µmol/L) 
CG MDRD CKD-
EPI 
Description Dose/day 
(mg) 
CG MDRD CKD-EPI 
1 F 83 104 100 61.7 48.8 45.1 Clodronate 
800mg Tab,  
2 nocte 
1600 A IA IA 
3 M 86 59 123 31.9 51.4 45.6 Dabigatran 
110mg Cap, 
 1 bd 
220 IA NR IA 
4 F 80 65 140 29.0 33.4 30.6 Duloxetine 60mg 
Cap,  
1 m 
60 IA NR NR 
5 F 85 58 71 46.7 72.1 67.2 Fenofibrate 
145mg Tab, 1 
midday 
145 IA NR NR 
6 F 83 76 150 30.0 30.6 27.6 Gabapentin 
300mg Cap, 1 tds 
900 A A IA 
7 M 85 70.2 120 39.6 53.1 47.3 Glibenclamide 
5mg Tab, 2 bd 
20 CI NR CI 
8 F 81 64 65 60.4 80.7 76.9 Levetiracetam 
1000g Tab, 1 bd 
2000 A NR IA 
9 M 82 58.8 144 29.1 43.3 38.7 Memantine 20mg 
Tab, 1m 
20 IA NR NR 
10 F 93 51.6 110 22.9 42.7 37.4 Metformin 850mg 
Tab, 1bd 
1700 CI NR IA 
11 F 78 69 85 52.3 59.6 56.8 Pregabalin 150 
mg Cap, 1 d 
150 IA A IA 
12 F 87 50.5 126 22.1 37.0 33.1 Risedronate 35mg 
Tab, 1 weekly 
5 CI NR NR 
13 M 58 88 125 71.0 54.7 54.4 Saxagliptin 5mg 
Tab, 1d 
5 A NR NR 
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Table 6.5 Examples of discrepancies among the equations 
A-appropriate dose, NR-dose adjustment not required based on renal function, CI-contraindicated, SrCr-serum creatinine
14 M 78 75 127 45.0 50.6 46.4 Sitagliptin 100mg 
Tab, 1 mane 
100 IA NR IA 
15 M 69 96.6 205 41.2 29.8 27.7 Solifenacin 5mg 
Tab, 1 d 
5 NR NR A 
16 F 80 105 144 46.0 60.6 58.0 Strontium 2000 
mg, 1 nocte 
2000 NR NR CI 
17 F 78 87 104 53.9 47.3 44.5 Vildaglitpin 50mg 
Tab, 1 bd 
100 NR IA  IA 
18 M 92 65 150 25.6 40.4 34.4 Zoledronic acid 5 
mg, mdu 
5 IA NR IA 
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6.5 Discussion 
We found a statistically significant difference in the kidney function estimations rendered from 
the three equations in the same group of patients. The overall differences in the mean eGFR 
values were quite small; however, at an individual level they gave estimates that differed 
substantially. We cannot determine which equation best approximated the true kidney function 
in our study due to lack of actual measures of kidney function. Further, the validation of the 
equations was not the purpose of this study.  
We found a good agreement between the eGFR and eCrCl for dosing of non-critical 
drugs. Our results suggest that the equations have moderate-substantial agreement in dosing of 
non-critical drugs in primary care settings. This finding is consistent with the study by Steven 
et al, which concluded that there was little difference in the drug dose that would be 
administered using eCrCl and eGFR.243 The normalisation of eGFR had an impact on drug 
dosing decisions; there was a higher level of agreement among the equations when the 
normalisation to BSA was removed from the eGFR values. This aligns with the United States 
National Kidney Disease Education Program’s (NKDEP) suggested approach that either an 
eCrCl or an eGFR with BSA normalisation removed, are acceptable for drug dosing 
estimations.244 
We found that the CKD-EPI equation, not adjusted for BSA, had the highest 
concordance with the Cockcroft-Gault equation for both estimating renal function and the 
dosing of the renally-cleared drugs. This finding is consistent with the previous literature which 
demonstrated that the CKD-EPI equation non-normalised to the BSA correlated more closely 
with the Cockcroft-Gault equation than did other formulae.203 Similarly, in another study, the 
non-normalised CKD-EPI equation (mL/min) was found superior to the normalised CKD-EPI 
equation in estimating GFR (mL/min/1.73 m2) for drug dosing.245  Using the GFR (mL/min) 
as the reference for dosing, the CKD-EPI with the removal of BSA normalisation (mL/min) 
was associated with greater dosing concordance of carboplatin.245 
The non-normalised CKD-EPI (mL/min) provided results, which were less biased and 
comparable at predicting GFR (mL/min) at higher levels of GFR and body mass index.246 247 
A possible explanation for these findings would be that in this and the previously mentioned 
studies, the mean BSA for the sample was about 2 meter square.247 The BSA of 1.73 m2 is the 
average normal mean value for young adults. The main purpose of reporting eGFR normalised 
to BSA was to allow harmonisation of results in individuals of various body size.248 The 
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normalisation or removal of this will have little effect for patients whose BSA is close to 1.73 
m2. However, for elderly people, or in patients whose body size is very different than average, 
the BSA should be considered.  
The Cockcroft-Gault equation has been used as the preferred method to assess kidney 
function for drug dosing in the past. With the introduction of new classification of CKD, the 
new MDRD equation was used for diagnosing and staging CKD. This equation was later 
suggested for drug dosing. However, more recently, it has been suggested that the CKD-EPI is 
the most accurate method for estimating GFR.102 157 Compared with the MDRD study equation, 
it provides less negative bias at values higher than 60 mL/min/1.73m2 and more accurate 
estimation of eGFR in diverse populations.102 Use of a single kidney function estimate for 
detection, drug dosing and management of CKD would facilitate better health care delivery in 
the primary care setting.249 With laboratories automatically reporting CKD-EPI eGFR 
estimates, this equation, if validated for drug dosing, would be a useful tool for health 
professionals and potentially address the confusion associated with the existing practice of 
using different formulae for different purposes. 
The performance of renal estimating equations in renal dosing has been evaluated in 
various instances and discrepancies have been reported. However, very little is known 
regarding the clinical outcomes of the observed discrepancies.250 The differences in dosing 
based on different estimates of creatinine clearance may, in many cases, be clinically 
unimportant, or can be further refined based on clinical response. There is a need for a long-
term multi-centre study in diverse populations to define the clinical effects of such 
discrepancies. In the interim, for individuals in whom the three equations provide substantially 
different estimates of kidney function or when prescribing drugs with narrow therapeutic 
indices or dose-dependent toxicities, assessing kidney function using alternative methods such 
as measured CrCl or measured GFR using exogenous filtration markers, should be considered. 
It is also recommended that prescribers use the available estimates along with their best 
judgement and clinical response to determine renal dosing for individual patients.251 252  
It should be noted that most of the discrepancies in drug dosing between equations 
might occur near the boundary between levels of renal function. These cut-offs could be 
arbitrary and not very precise with regards to drug clearance. In some cases, doses can double 
depending on which side of the boundary the renal function estimation falls. Moreover, it is 
accepted that clinical decisions may often over-ride the renal dose recommendations. 
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Laboratories provide serum creatinine measurements based on the creatinine assays that 
are aligned to the reference isotope-dilution mass spectrometry (IDMS) in Australia.103 The 
MDRD Study equation has been re-expressed for standardised serum creatinine.101 The CKD-
EPI equation was developed using creatinine assays that are IDMS-aligned. However, the 
Cockcroft-Gault equation has not been re-expressed for use with standardised serum 
creatinine.253 This might have contributed to the observed discrepancies among the equations. 
The MDRD equation has been found to have a negative bias at values higher than 60 
mL/min/1.73m2.254  This equation tends to overestimate eGFR values in patients above 60 
mL/min/1.73 m2, indicating need for dose adjustment less frequently.255 Some of the drugs 
examined in the study, such as metformin, gabapentin and pregabalin, have dose adjustments 
recommended near or above 60 mL/min. We did not evaluate the various corrections or 
modifications of the Cockcroft-Gault equation that have been proposed, such as using lean or 
ideal body weight. We only did the analysis for CrCl estimated based on actual body weight. 
 
6.6 Conclusions  
There is need for a long-term multi-centre study in a diverse population to define the 
clinical effects of the discrepancies among the equations for drug dosing. Given the greater 
concordance of the non-normalised CKD-EPI equation with the Cockcroft-Gault equation for 
dosing, the recommendation by Kidney Health Australia and the United States National Kidney 
Disease Education Program that ‘dosing based on either eCrCl or an eGFR with body surface 
area normalisation removed are acceptable’, seems suitable and practicable for the purpose of 
dosing of non-critical drugs in the primary care setting. 
 
6.7 Next step 
The aforementioned studies examined the factors contributing to the problem of dosing 
error in patients with CKD. These included a lack of quantitative data in the available drug 
information sources, and contradiction and inconsistency in dosing information among the PI, 
in addition to confusion surrounding the use of renal function estimating equations for drug 
dosing purposes. 
In the next chapter, we present the findings of a survey we undertook to understand the 
factors associated with inappropriate prescribing of medications in patients with CKD from the 
94 
 
 
prescriber’s perspective. We also aim to understand the GPs’ views on applicability, utility and 
the potential barriers to using the available guidelines and information sources for drug dosing 
purposes in primary care settings. Ultimately, we will identify the areas that need intervention 
to improve dosing in patients with CKD. This will assist in the design of interventional 
programs aimed at improving the quality of care in patients with CKD. 
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Chapter 7 POTENTIAL BARRIERS TO THE USE OF AVAILABLE GUIDELINES AND 
INFORMATION SOURCES FOR RENAL DRUG DOSING PURPOSES: A SURVEY OF GENERAL 
PRACTITIONERS 
7.1 Abstract 
Introduction. General Practitioners (GPs) are the frontline caregivers for patients with chronic 
kidney disease (CKD) and are provided with access to evidence-based guidelines to support 
them in optimal medication management. Nonetheless, studies have documented suboptimal 
prescribing in patients with CKD in Australian primary care settings. This study examines the 
potential barriers to optimal management of medications in CKD from the prescriber’s 
perspective. 
Method. A web-based survey of Australian GPs was conducted. The survey was divided into 
three sections, covering demographic and professional practising information, approach to drug 
dosing in CKD, and barriers to using the current guidelines and how these could be overcome. 
Results. One hundred and fifty-eight GPs completed the survey. The majority of the GPs were 
males (64.6%) and the median duration of clinical practice was 20 years. In general, there was 
low familiarity with CKD management guidelines and a lack of confidence in identifying and 
dosing renally-cleared drugs. Limited time or more urgent patient issues and fear of being 
perceived as ‘over-servicing’ for pathology testing, were prominent factors felt to limit 
ordering a kidney function test. GPs have embraced electronic resources to a greater extent 
than paper-based information sources. The MIMS was the most widely used information 
source. There was a general scepticism expressed concerning the usefulness, reliability and 
applicability of the information sources for renal dosing. The major barriers to using guidelines 
were lack of easy access during consultations and inadequate or ambiguous recommendations 
on renal dosing. The factors responsible for inappropriate prescribing from the GPs’ 
perspective were a lack of awareness on the availability of information sources and lack of 
routine renal function testing.  Clinical decision support systems and online training and 
education were the most preferred interventions, as ranked by the GPs. 
Conclusion. Updating the information sources to present the key elements in an unambiguous 
format, in conjunction with efforts to build consensus among the standard information sources, 
seems necessary. As of a result of this, GPs can incorporate the recommendations into practice. 
Improved dissemination of existing guidelines, online education to increase awareness on drug 
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dosing, available guidelines and how to use them, and decision support system to aid GPs in 
identifying renally-cleared drugs, also appear warranted. 
 
7.2 Introduction 
Chronic kidney disease (CKD) is a major health problem in Australia, and globally, due 
to its increasing prevalence and close association with morbidity and mortality.256 It has been 
estimated that 10% of all adults presenting to a general practice in Australia have CKD and 
80% have at least one risk factor for CKD.38 Every day, more than five Australians commence 
dialysis or transplantation.257 Data from Kidney Health Australia indicates that the number of 
patients with end-stage kidney disease (ESKD) tripled between 1991 and 2009, and is projected 
to continue to rise during the next decade; increasing by nearly 80% between 2009 and 2020.258 
Early diagnosis, timely referral to nephrologists and optimal medication management, 
play significant roles in delaying the progression of CKD or preventing the occurrence of 
ESKD.259 However, due to the asymptomatic nature of the disease, kidney damage typically 
goes unnoticed until the stage where the therapeutic interventions are often ineffective.70 
Therefore, CKD must be actively sought to be recognised and managed. CKD screening is 
recommended by several nephrology professional bodies, with the intent of limiting or 
preventing CKD progression, inappropriate drug dosing and nephrotoxic injury.260  
Impaired renal function has pronounced effects on the pharmacokinetic and 
pharmacodynamics properties of many drugs; therefore, optimal drug selection and dose 
modification are imperative to optimise patient outcomes and minimise drug-related 
problems.82 186 It is important to review renally excreted medications and avoid nephrotoxic 
medications in people with CKD.109 Dosage reduction or cessation of renally excreted 
medications is generally required once the GFR falls below 60 mL/min/1.73 m2.382 
General practices are the best place to screen for and manage CKD, with 80% of 
Australians visiting their local General Practitioners (GPs) for care at least once a year.261 GPs 
are the frontline caregivers for patients with CKD. Typically, CKD identification is best 
performed in primary care and can be managed without referral to a specialist. GPs are the 
primary decision-makers when it comes to prescribing medications, and are provided with 
                                                          
2 About half of the drugs included in our drug list (appendix 1) required dosage adjustment based on renal 
function only at CrCl≤30 mL/min  
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various electronic tools with access to evidence-based guidelines and standard drug 
information sources to support them in optimal medication management in CKD. However, 
analysis of prescription records from tertiary care hospitals and aged care facilities within 
Australia suggests a high proportion of suboptimal prescribing for patients with CKD.128 140 
These findings are consistent with results from overseas studies, which indicate low adherence 
to renal dosing guidelines, leading to inappropriate prescribing for patients with CKD in 
community settings.9-15 While the problem of suboptimal prescribing for community-based 
patients with CKD has been well identified and studied in Australia, the reasons have not been 
researched. A proper understanding of this is needed to design interventions aimed at 
improving the quality of prescribing for patients with CKD.  
Studies conducted in the USA have shown that renal dosing guidelines are often 
overlooked and this is a major contributor to overall inappropriate prescribing and drug-related 
problems in aged care facilities.9 12 GPs have expressed difficulty in deciding whether there is 
a need for renal function assessment and have acknowledged the complexity of medication 
regimens in patients with CKD.20 21 262 GPs were reluctant to diagnose CKD on the basis of a 
glomerular filtration rate, and felt that labelling older people as having CKD was 
problematising aging.20 Some studies indicated difficulty faced by GPs in explaining the 
disease to patients, where they feared alarming people by diagnosing them, especially in early-
stage CKD.20 262 
While the literature is replete with reports on GPs’ awareness about CKD management 
guidelines and nephrologist referral practices among primary care physicians,17 21 263 there is 
limited information available on the potential barriers to optimal management of medications 
in CKD from the prescriber’s perspective.  Little is known about information sources that GPs 
use when deciding on drug doses for patients with CKD. To date there has not been any studies 
conducted to identify GPs’ perspectives regarding the applicability and utility of these 
guidelines in patients with CKD.  
We were interested in undertaking a survey to understand the options available to GPs 
to assist in managing medications in patients with CKD and to assess GPs’ views on 
applicability, utility and potential barriers in using the available guidelines and information 
sources for drug dosing purposes in primary care settings.  
We were interested to find out whether the GPs know about currently published CKD 
guidelines, whether they have used them, and whether they considered their practice had 
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changed since the provision of laboratory-provided eGFR. We also wanted to know how GPs 
would respond to a set of statements generated from debates in the current literature regarding 
the use of particular drugs in CKD. We wanted to know the level of confidence they have in 
dosing of renally-cleared drugs. Finally, we were interested to determine what sort of strategies 
to improve medication use in renal disease were most likely to have acceptance and use by 
GPs. 
 
7.3 Methods 
7.3.1 Ethics approval 
Ethical approval for the study protocol was granted by the Tasmanian Health and 
Medical Human Research Ethics Committee Tasmania, Australia (H0015068). 
 
7.3.2 Design, Participants and setting 
A web-based, cross-sectional survey of Australian GPs was conducted for 12 weeks 
between 1st December 2015 to 1st March 2016. The survey were designed using LimeSurvey 
open source PHP web application software (http://www.limesurvey.org) and was hosted online 
at the University of Tasmania. A sample of 4000 GPs identified from the National Health 
Services Directory were sent an invitation via email to take part in the online survey.264 
 
7.3.3 Questionnaire design and content 
Questionnaire items and the theoretical basis for the questionnaires were identified from 
the literature review.17 18 20 21 24 265 The survey was divided into three sections covering: 
demographic and professional practising information, approach to drug dosing in CKD, 
preferred drug information source for renal drug dosing and barriers to using them, and how 
they can be overcome (Appendix 2). The questions were a mixture of multiple choice, open 
ended, rank-order and Likert-type questions.  
Questions were designed to assess how frequently GPs encountered problems with 
deciding dosages for patients with CKD and, to identify the factors that prompt the GPs to 
perform renal function measurement or drug dosing. The participants were asked about the 
guidelines or information sources they use for drugs dosing purposes and if they observe any 
obstacles in using them. GPs could select multiple barriers, including information sources, 
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patient factors, lack of time etc. Because studies indicate that drugs like bisphosphonates, ACE- 
inhibitors and metformin are more likely to be prescribed inappropriately in patients with CKD, 
and given the added ambiguous, conflicting information about their use in literature, we 
focused some questionnaire items on recognising GPs’ opinions on using these drugs in 
patients with CKD. A four-point Likert scale was used to rate the feasibility, reliability and 
utility of the guidelines.  The survey questionnaires also explored whether the GPs recognise 
the need for intervention to optimise drug dosing for patients with CKD.  
A draft questionnaire was prepared and pre-tested among the investigators and minor 
changes in word selection and instructions were made to the questionnaire. 
 
7.3.4 Survey implementation 
A personally addressed email that included a brief description of the study, the 
investigators’ affiliation, and a link to the survey were sent to the GPs. A click on the link 
redirected them to the survey page. Emails contained statements ensuring confidentiality, and 
the respondents were offered an opportunity to anonymously participate in a draw for a prize 
(e.g. Apple iPad) to encourage participation (Appendix 3, sample of invitation email). 
 
7.3.5 Statistical analysis 
All statistical analyses were conducted using IBM SPSS Statistics for Windows, 
Version 20.0. Armonk, NY: IBM Corp. and Excel 2010 (Microsoft Corporation, Redmond, 
USA). Data were summarised using descriptive statistics, including means (± standard 
deviation) for continuous variables and proportions/percentages for categorical variables. 
Pearson Chi-squared and Kruskal-Wallis test were used to determine the association between 
variables. Spearman’s rank correlation coefficients were calculated for measuring correlations. 
For the open-ended questionnaires, comments were entered in a word processing program and 
organised by question number. Investigators determined the themes and categorised the 
comments. 
 
7.4 Results 
Of the random 4000 email addresses identified from the National Health Services 
Directory, 45% of the addresses were non-operational and 10% responded with automatically 
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generated emails indicating the GPs were out of the office. A total of 189 GPs clicked on the 
survey link and were directed to our survey page. Of these, 158 filled out the survey, equating 
to a response rate of 7.2%. This included 125 respondents who completed all the questionnaires 
and 33 respondents who partially completed the survey, answering between 25 to 29 questions 
each (Figure 7.1). 
 
Figure 7.1 Survey implementation and responses 
 
7.4.1.1 Participant Characteristics 
GPs practising in New South Wales (45, 28.5%), Victoria (39, 24.7%), South Australia 
(27, 17.1%), Queensland (14, 8.9%), Tasmania (23, 14.6%), Western Australia (9, 5.7%) and 
the Northern Territory (1, 0.6%), filled out the survey. Respondents’ characteristics are 
summarised in Table 8.1 The majority of respondents were male (64.6%) and the median for 
clinical practice was 20 years, with a range of one to fifty-five years. The median number of 
CKD patients seen by the GPs per week was 6, with a range of 1 to 90 patients. There was a 
fairly even distribution of GPs across practice locations. The GPs generally used electronic 
prescribing software in their practice (97.5%). Medical Director and Best Practice were the 
most widely used prescribing softwares (Table 7.2). 
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Variables N (%) Mean (SD) 
Gender 
Female 
Male 
 
56 (35.4) 
102 (64.6) 
 
Years in profession  
≤5 
5-10 
10-25 
25-30 
30-35 
>35 
 
35 (22.2) 
23 (14.6) 
37 (23.4) 
17 (10.8) 
25 (15.8) 
21 (13.3) 
20 (15) 
State 
New South Wales 
Victoria 
South Australia 
Queensland 
Tasmania 
Western Australia 
Northern Territory 
 
45 (28.5) 
39 (24.7) 
27 (17.1) 
14 (8.9) 
23 (14.6) 
9 (5.7) 
1 (0.6) 
 
Practice location 
Urban 
Suburban 
Rural 
other 
 
56 (35.4) 
55 (34.8) 
46 (29.1) 
1 (0.6) 
 
No. of patients with CKD seen per week  9.6 (11.8) 
Mode of prescribing 
Electronic prescription 
Paper-based prescription 
 
154 (97.5) 
4 (2.5) 
 
Table 7.1 Respondent characteristics  
Continuous variables are presented as means with standard deviations. Categorical variables are expressed as percentages and 
N. 
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Software Frequency Percent 
None* 4 2.5 
Medical Director 64 40.5 
Best Practice 68 43 
ZedMed 5 3.2 
Genie 7 4.4 
MedTech32 2 1.3 
Practix and Profile 2 1.3 
Others 
Monet 
Communicare 
Medinet 
6 
1 
3 
2 
3.8 
Total 158 100.0 
Table 7.2 Common prescribing software among the GPs 
*used paper-based prescription 
 
7.4.1.2 Preferred renal function measure for drug dosing 
More than half of the participants reported that they use laboratory eGFR for the 
purpose of drug dosing. 20.8% (n=33) claimed that they use serum creatinine for drug dosing 
and 18.3% (n=29) reported that they use CrCl for drug dosing (Figure 7.2). There was no 
significant association between preferred renal function measure of choice and GPs’ 
demographics (gender, location, setting, years of practice and number of patients with CKD 
seen in a week). 
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Figure 7.2 Renal function measure of choice  
(N=158) 
 
For the prescription of drugs in elderly patients, 60.1% (n=95) claimed to take the 
laboratory provided eGFR into account, 24.7% (n=39) considered serum creatinine, 13.3% 
(n=21) took account of estimated creatinine clearance and 1.9% (n=3) of GPs were unsure 
about which renal function measure should be considered. (Figure 7.3) 
 
 
Figure 7.3 Renal function measure taken into account in elderly 
N=158 
Before prescribing medication to an elderly patient, 46.8% (n=74) of the GPs evaluated 
renal function only for certain drugs, 36.1% (n=57) evaluated regularly, even for a repeat 
prescription, and 24.1% (n=38) evaluated for all the new drugs. (Figure 7.4) 
20.9
59.5
18.3
1.3
Preferred measure of renal function for dosing purpose among the 
GPs
Serum creatinine Laboratory eGFR Estimated CrCl using Cockcroft-Gault (CG) formula Others
13.3
24.7
60.1
1.9
Which measure of renal function the GPs take into account while prescribing in 
elderly
Estimated creatinine clearance
Serum creatinine level
Laboratory eGFR
Unsure
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Figure 7.4 Evaluation of renal function in elderly 
Percentages do not sum to 100 as multiple responses were possible. N=158 
 
7.4.1.3 Barriers to ordering a renal function tests  
The majority of the GPs (56.9%, n=90), reported that it is fairly practical or feasible to 
assess renal function before prescribing renally-cleared drugs; 29.7% (n=47) reported that it is 
very practical or feasible, 10.1% (n=16) GPs reported that it is not practical or feasible and 
3.2% (n=5) of the GPs were unsure.  
GPs were asked if they recognise any of the seven given factors as obstacles to ordering 
a renal function test. Limited time or more urgent patient issues, patient’s non-adherence and 
fear of being perceived as ‘over-servicing’ were the top three factors believed to generally limit 
ordering a kidney function test (Figure 7.5). The questionnaire also had an open-ended option 
to capture other obstacles not listed.
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Figure 7.5 Obstacles to ordering a kidney function test 
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Other obstacles listed by the GPs were; confusion surrounding the current best accepted 
measure of renal function test, lack of access to pathology, timeframe of results, practitioner’s 
inertia, logistics of getting some people to get a test before they need a drug, patient’s 
preference to avoid blood tests, lack of patient’s understanding about the importance of renal 
function, difficulty for patients and the cost to the community (Table 7.3). 
 
Patient’s factors 
-Difficulty for patients 
-Lack of understanding on the importance of 
renal function monitoring 
-Cost to community 
-Patient time constraints esp. if elderly; 
patient mobility  
-Patient’s preference to avoid blood tests 
External factors 
-Lack of acceptable recent renal function 
tests 
-Pathology access and result timeframe  
Prescriber’s factors 
-Logistics of getting some people to get test 
before they need drug 
-Practitioner inertia 
 
Do not feel any restriction apply 
-Everyone gets it when ordering bloods tests 
yearly 
-I don't recognise any 
restrictions/concerns/barriers 
-Most patients with chronic health issues 
will have regular blood test. Hence, I have 
no issues with getting the kidney function 
test.” 
Table 7.3 Verbatim responses on barriers to ordering a kidney function test 
 
7.4.1.4 GPs’ use of automated laboratory eGFR  
GPs had an overall positive attitude towards the automated eGFR monitoring. When 
asked about whether their overall approach to CKD diagnosis had changed since automated 
eGFR reporting, almost half of the GP 47.5% (n=75) said it had. However, 32.3% (n=51) said 
it had not and a minority [20.3% (n=32)] of respondents were unsure. (Figure 7.6) 
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Figure 7.6 Responses to automated eGFR and change in practice 
 
When asked if the laboratory eGFR has changed their overall approach to renal drug dosing, 
40.5% (n=64) of the GPs believed it had changed their approach to drug dosing. However, 
33.5% (n=53) believed it had not and 25.9% (n=41) respondents were unsure.  
When asked if the eGFR had changed the practice of referral to nephrologists, 34.8% 
(n=55) of the GPs believed it had, 51.9% (n=82) believed it had not and 13.3% (n=21) 
respondents were unsure. The approach to referral to a nephrologist had not changed as much 
their approach to diagnosis and drug dosing. 
Verbatim responses to how the automated eGFR has changed the way they diagnose 
CKD and perform drug dosing in CKD were organised into eight and ten themes, respectively 
(see Table 7.4 and Table 7.5). Based on the GPs’ written feedback, the automated eGFR has 
increased awareness and enhanced detection of CKD making the diagnosis easier and efficient 
as indicated by the following quotes;  
“It is a clearer way to pick up early CKD. I have a better stratification of risk based on using 
an eGFR.” 
“Previously if the creatinine was normal I did not really consider renal function when 
prescribing a lot of drugs in the elderly. The eGFR makes me stop to consider the drugs I am 
prescribing and any effect on renal function.” 
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GPs indicated that consultation time was decreased; the eGFR streamlined their work and 
removed the need for calculating it themselves, and they often used it for dosage adjustment. 
“Much easier than CrCl so I do it more often.” 
“Do not use SrCr anymore.” 
One GP expressed using eGFR as an additional tool to measure renal function that assists in 
renal dosing and used this for drug dosing selectively. 
“For general purposes, in patients in the normal weight range, then I am happy to use the lab 
eGFR. However, for very thin or very overweight patients, on really dose critical drugs, then I 
would go looking for alternative measures to inform my dosing, but this always takes time, 
hence I don't do it for simple/straightforward drug dosing.” 
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Index of main themes Verbatim responses 
(A) Enhanced detection of CKD  Easier to diagnose/identify (5) 
 Easier to see reduced renal function, particularly trends 
 I see it as easier to take note of 
 It is a clearer way to pick up early CKD. I have a better 
stratification of risk based on using an eGFR 
(B) Increased awareness 
 
 Become aware of the whole issue, was scarily naive before 
 I notice it more! It has raised more awareness of CKD (10) 
 It helps to alert me to the possibility of CKD in a patient, which 
can lead me to investigate further. 
 Made me more aware as adds weight to creatinine level 
 More aware of renal impairment even when creatinine is almost 
normal in older patients 
 I am more conscious of CKD with the eGFR in front of me 
 More aware of deterioration & need to change treatment 
 More aware because of easy availability 
 More aware of renal impairment when prescribing medications 
 More sensitive and aware 
 More vigilant; also use urine ACR in conjunction with eGFR 
 Think of it more often. I calculate CrCl using Cockcroft 
equation if I am worried about a particular patient or drug 
(C) Enable CKD staging   Easier to classify 
 Give a percentage function of the kidney 
 Gives a more easily compared unified number for serial 
monitoring across labs and longitudinally - can easily categorize 
as stage 3-5 
 I can grade the CKD more easily and discuss risk factors more 
easily with the patient 
(D) Increased prevalence/recognition 
of CKD 
 Has allowed increased screening of patients for CKD 
 CKD is more frequently diagnosed CKD 
 Unrecognised CKD is not a problem anymore 
 I do not overlook eGFR anymore 
 More recognisable than creatinine; makes me take notice of 
deteriorating function 
(E) Increased accuracy and 
simplicity in diagnosis of CKD 
 It has generally simplified the process 
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 It provides a reasonably accurate prompt to investigate patients 
at risk of CKD. 
 More information makes diagnosis simpler 
 Simpler monitoring for progression, change over time. 
 Simpler to sort out what is happening 
(F) Increased confidence  It has increased my confidence in deciding whether to prescribe 
a medication 
 Offered reassurance when eGFR is normal 
(G) Improved productivity and time 
efficiency 
 Able to calculate CKD quicker 
 Likely to just look at that, rather than to do a calculation 
 Prompts to work out creatinine clearance 
 Readily availability 
 It is now quicker and easier to diagnose 
(H) Reliance on eGFR as primary 
measure of renal function  
 Don't use Cockcroft-Gault formula any more 
 Don’t really solely on serum creatinine 
 It's just easier than getting Creatinine clearance, so I use this test 
 No longer relying on the serum creatinine 
 Use eGFR a primary measure 
 Using eGFR rather than serum creatinine alone, as a guide 
 Calculated GFR is close to that from the lab so I now rely more 
on the lab result 
(I) More concordance with the 
guidelines 
 Guidelines use eGFR 
(J) Better treatment decisions  I can provide the correct dosing for the condition without 
affecting the kidneys 
 Offers a guideline to prescribing 
 Reduce or  stop medications  known to adversely affect eGFR 
(K) An additional tool/information   As reference review  
 I use it as a rough guide to creatinine clearance. 
 It adds a parameter that I can take into account along with 
creatinine and CrCl 
 I take it into account as a relatively "objective" measure 
Table 7.4 Automated eGFR and changes in CKD diagnosis 
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Index of main themes Verbatim responses 
(A) More alert to need of dose 
adjustment 
 More likely to flag it as an issue and review 
 Alert to changes 3 
 Awareness of iatrogenic ARF 
 More frequently identified 
 More aware of reduced kidney function and its implications 2 
 Extra red-flag to renal impairment 
 Extra market for highlighting renal function rather than creatinine alone 
 More aware 
 Makes me stop to consider the drugs I am prescribing and any effect on 
renal function 
 Reminds me to check and alter doses 
 Ready availability, increased awareness 
 Easier to diagnosis 
 More likely to take notice of dose changes required in renal failure. 
 Same as previous answer 
 Try to adjust drug dosage to stage of renal failure 
(B) More likely to adjust dose 
 
 
 
 I tend to adjust drugs more often 
 Makes me check PI to determine dose adjustments more often 
 Tend to change prescribing and reduce or delete medications which have 
an adverse effect on renal function, and more likely to adjust as a result of 
abnormal eGFR 
 I do dose adjustment more often as much easier than calculating CrCl 
(C) Easier and quicker to adjust 
dose 
 Easier to adjust 
 Easier and faster to estimate dose 
 It’s quicker to calculate dose adjustment. 
 Simpler, clearer and quicker dose adjustments 
 Simpler to use 
 
(D) Dose adjustment is more 
rigorous  
 Spend more times with the patient 
 Useful and available measure 
 Using worsening eGFR to dictate treatment protocols 
 
(E) Appropriateness of medication 
and dosing improved  
 More careful dose adjustment 
 More informed 
 Dosage changes are based on eGFR 
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 Certainly for anyone with eGFR less than 50 I double check items I am 
prescribing for them 
 Medications that are nephrotoxic, or medications that are cleared primarily 
through the kidneys, will be dose adjusted or be changed to alternative 
medications. 
(F) More aligned to guidelines  Doses are adjusted according to eGFR on prescribing guidelines 
 Drug dosing guidelines appear to refer more commonly to eGFR than 
creatinine levels. 
 I look up the PI when eGFR is below normal 
 It provides an accessible figure used by drug companies to tailor dose 
adjustment according to the measure. 
 I tend to rely on this as a gauge of the presence and severity of renal 
failure when considering medication that is renally excreted 
 I will decrease the dose if the clearance is less or not prescribe the drug if 
it is excreted by the kidney 
 Use eGFR and recommended dosage regimes 
(G) Follow a clear and consistent 
guidance protocol for renal dosing  
 For general purposes, in patients in the normal weight range, then I am 
happy to use the lab eGFR. However, for very thin or very overweight 
patients, on really dose critical drugs, then I would go looking for 
alternative measures to inform my dosing, but this always takes time, 
hence I don't do it for simple/straightforward drug dosing. 
 I look up renal dose for the medication in question and act accordingly. 
 When the latest renal function result is available, I do either formally or 
informally, review the patient’s medication regimen, and consider the 
dosage to see if an adjustment is indicated. 
 I will ring a renal physician if I'm particularly worried or don't know. It's 
always something that sits in the background of so many of our patients. 
 When I do note abnormal eGFR -  I tend to check up if any of the patient's 
current medications make the renal function worse.  
(H) More confident It has made me more sure of dosing - and dose titration 
(I) Do not use CrCl and Srcr 
anymore 
 Much easier than CrCl so I use it more often 
 Use eGFR and recommended dosage regimes 
 Do not use CrCl anymore 
 Do not rely on SrCr anymore 
Table 7.5 Automated eGFR and associated changes in drug dosing 
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7.4.1.5 Preference for drug dosing-CrCl or eGFR 
When asked if the GPs used Cockcroft-Gault equation for estimating CrCl for drug 
dosing purposes, 45 respondents said yes. Of these, 22 used actual body weight and 19 were 
unsure given they used online calculators. 105 respondents said they used laboratory eGFR for 
drug dosing purposes, exactly as provided by the laboratory (Table 7.6). 
 
 Number of respondents 
Creatinine Clearance 
Actual body weight 
Ideal body weight 
Adjusted body weight 
Unsure as I use online calculators 
Use ideal or actual body depending upon body habitus 
 
45 
22 
1 
2 
19 
1 
Laboratory eGFR 
eGFR exactly as provided by the laboratory 
Use eGFR normalised for the patient’s body surface area  
Use normalised eGFR only for patients with extremes of body weight 
Unsure 
Others 
105 
80 
5 
14 
3 
3 
 N=150 
Table 7.6 GPs’ preference for drug dosing: creatinine clearance or eGFR 
 
7.4.1.6  Usage of controversial drugs in CKD 
Respondents were asked about their agreement or disagreement to the set of statements 
generated from debates in the current literature regarding the use of drugs with some 
controversies in CKD. A total of 142 GPs responded to this question. 
When asked if Angiotensin-converting (ACE) inhibitors and angiotensin II receptors 
(ARBs) can be safely prescribed at all stages of CKD and whether they should not be 
deliberately avoided just because GFR is reduced, 7.7% (n=11) of GPs strongly disagreed, 
39.4% (n=56) mildly disagreed, 14.7% (n=21) neither agreed nor disagreed, 33% (n=47) 
agreed and 4.9% (n=7) strongly agreed. When asked if bisphosphonates can be used in all 
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stages of CKD with correct dosage adjustment, 10.5% (n=15), 26% (n=37), 35.2% (n=50), 
27.4% (n=39) and 0.7% (n=1) of the GPs strongly disagreed, mildly disagreed, neither agreed 
nor disagreed, agreed and strongly agreed, respectively (Figure 7.7). 
 
 
Figure 7.7 Usage of controversial drugs in CKD 
N=142 
7.4.1.7 Confidence in dosing of renally-cleared drugs 
44.7% of GPs reported feeling confident in identifying and dosing of nephrotoxic drugs. 
41.3% of GPs reported feeling confident in determining doses for ACE-inhibitors, 24.2% of 
the GPs were confident in determining the doses for bisphosphonates and 55.2% of the GPs 
were confident in determining the dose for metformin in patients with CKD (Figure 7.8). 
 
Figure 7.8 Confidence in renal drug dosing  
N=145 
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A Spearman’s rank-order correlation was run to determine the relationship between GPs’ 
confidence and the demographic characteristics. There was a strong, positive correlation 
between GPs’ confidence in identifying nephrotoxic drugs and length of professional practice, 
which was statistically significant (P=0.04). There was no correlation between gender or the 
number of patients with CKD (seen per week) with the confidence.  
 
7.4.1.8 Information sources for renal drug dosing  
The majority of the GPs 60.2% (n=77) experienced difficulties in deciding on drug 
dosage for patients with CKD (Figure 7.9).  
 
Figure 7.9 Difficulty in deciding drug dosage in patients with CKD 
N=128 
GPs were asked about their most preferred information source for deciding the dose in patients 
with CKD. A total of 128 GPs responded to this question. The MIMs, Therapeutic Guidelines 
and the AMH were the most widely used information sources among the GPs. Fifty percent of 
the GPs (n= 64) preferred MIMs/Product information, 19.5% (n=25) preferred Therapeutic 
Guidelines and, 11.7% (n=15) preferred the AMH, 3.9% (n=5) preferred the renal drug 
reference guide, 2.3% (n=3) preferred the British National Formulary (BNF), 3.1% (n=4) 
preferred contacting pharmacist and 9.4% (n=12) chose the option others. (Figure 7.10). 
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Figure 7.10 Preferred drug information sources 
(N=128) 
 
The majority of the GPs (81.6%, n=129 out of 158) responded that they access the drug 
information sources electronically and, 18.3% (n=29 out of 158) of the GPs reported that they 
access them as paper-based (print) drug information sources to extract information on renal 
dosing of the drug. 
 
7.4.1.9 Guidelines’ accessibility, reliability and applicability  
Out of the 29 GPs who used paper-based information sources to gain information on 
renal dosing, 51.8% (n=15) responded that the information sources were easily accessible, 
2.6% (n=6) said the guidelines were not easily accessible and 27.6% (n=8) were unsure. (Figure 
7.11) 
Out of the 129 GPs who accessed information sources electronically, 70.5% (n=91) 
responded that the guidelines were easily accessible; 24% (n=31) believed that they were not 
easily accessible and they take too much time navigating and 5.5% (n=7) of the GPs were 
unsure. (Figure 7.12) 
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Figure 7.11 Accessibility of paper based guidelines 
(N=29) 
 
 
Figure 7.12 Accessibility of electronic guidelines 
(N=129) 
31.3% (n=40) GPs found CKD guidelines useful, 61.7% (n=79) found them to be fairly useful, 
3.1% (n=4) found them to be unuseful and 3.9% (n=5) were unsure. 
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Figure 7.13 Usefulness of guidelines 
(N=128) 
 
69.5% (n=89) of the GPs found the guidelines to be very applicable, 10.2% of the GPs (n=13) 
found them to be not applicable and 20.3% (n=26) were unsure. 
 
Figure 7.14 Applicability of guidelines 
(N=128) 
 
31.2% of the GPs (n=40) found CKD guidelines to be very reliable, 51.6% of the GPs 
(n=66) found them to be fairly reliable, 3.1% of the GPs (n=4) found them to be unreliable and 
14% (n=18) were unsure. 
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Figure 7.15 Reliability of guidelines 
(N=128) 
 
Familiarity with Kidney Health Australia guideline 
41.8% (n=66) of the GPs believed that Kidney Health Australia’s CKD management in 
general practice guidelines had been helpful in managing their patients with CKD. 35.5% 
(n=56) were not familiar with the guidelines and 13.2% (n=21) said they did not find the 
guidelines useful and 9.5% (n=15) were unsure (Figure 7.16). 
 
 
Figure 7.16 Familiarity with CKD guidelines  
(N=158) 
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7.4.1.10 Factors limiting the access the guidelines 
Commonly endorsed barriers to accessing the information sources to perform drug 
dosing are shown in Figure 7.17. 
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Figure 7.17 Barriers to accessing guidelines for renal dosing 
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7.4.1.11 Factors responsible for inappropriate prescribing  
Factors responsible for inappropriate prescribing as suggested by the GPs are presented 
on Figure 7.18. GPs not making use of information available on drug dosing, insufficient access 
to dosing information during consultation, lack of awareness of availability of information 
sources, GPs not making used of information about individual patients and, the lack of routine 
renal function assessment were factors cited as contributing to inappropriate prescribing in 
CKD. 
 
Figure 7.18 Contributors to inappropriate prescribing 
 
7.4.1.12 Interventions to enhance optimal dosing in CKD  
GPs were asked to rank the interventions that would most appeal to them to help 
optimise the medication for patients with CKD. Respondents’ ratings for pre-specified 
interventions, based on means from the Likert scales, are presented on Table 7.7. The three 
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most desired interventions ranked by the GPs were clinical decision support system, face to 
face and online learning modules, and academic detailing visits by a nephrologist. 
 
S.N. Types of intervention Mean (SD) 
rank 
Rank of 
intervention types 
 
1 Clinical decision support systems that assist 
with drug dosing decisions 
2.4 (1.7) 1 
2 Academic detailing visits by a nephrologist 3.3 (1.7) 3 
3 Pharmacist-conducted medication reviews 3.9 (1.5) 5 
4 Online training and education 3.8 (1.5) 4 
5 Continuing medical education lectures 4 (1.5) 6 
6 Face to face and online learning modules 3.3 (1.5) 2 
Table 7.7 Interventions to optimise dosing in CKD 
N=125, Ranked by Mean Rank Order, Rank score ranges from 1 to 6, (1: most important, 5: least important) 
 
7.5 Discussion 
The results of our study highlight the barriers to GPs ordering routine kidney function 
tests and using the guidelines and information sources for optimal dosing in patients with CKD. 
This study informs the areas where interventions need to occur to address these barriers and 
help identify the choice of interventions likely to be most effective. Previous overseas studies 
have demonstrated a knowledge gap and subsequent suboptimal CKD management practices 
among the GPs in the primary care settings.16-19 Lack of awareness of CKD guidelines, less 
accurate diagnostic procedures, low confidence of GPs, limited educational and administrative 
resources for CKD management, desire for more CKD practice guidance, and a lack of 
awareness of eGFR and its correct usage, were some of the observations noted from these 
studies.18 20-22 23 24  
The GPs included in our study expressed similar comments. Our findings elaborate 
more upon the results of these studies by examining factors beyond those of GPs’ knowledge 
and understanding, to identify system-level, practice-level confounding factors that serve as 
barriers to implementing available evidence-based guidelines for prescribing in patients with 
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CKD. In contrast, the GPs in our study demonstrated more awareness towards the use of eGFR 
as an indicator of kidney disease and often stated using it for drug dosing purposes. 
Overall, our results support those of other studies that indicate continued low awareness 
of CKD management guidelines, uncertainty around acceptable renal function tests, confusion 
surrounding the most correct test for renal dosing and a desire for intervention programs to 
improve CKD care. Additionally, the GPs expressed concerns over the inadequate and 
ambiguous renal dosing recommendations included in the drug information sources. 
Furthermore, time constraints, fears of over-servicing, risk of over diagnosis associated with 
automated eGFR, practitioner’s inertia and the logistics of getting a test before prescribing, 
were some of the challenges to ordering a kidney function test. 
In an online survey of GPs, George et al reported lack of confidence as one of the main 
barriers to the management of CKD in primary care. 18 Similarly, GPs in our study reported 
low confidence in identifying nephrotoxic and renally-cleared drugs while prescribing for 
patients with CKD. GPs also demonstrated varying opinions on the usage or avoidance of drugs 
such as bisphosphonates, ACE-inhibitors and metformin in renal impairment. Contributing 
factors could be the inconsistent and inadequate recommendation regarding their dosing across 
the standard information sources and the contradictory information pertaining to their use or 
avoidance in CKD in the literature.241 Educational interventions have been found to be effective 
in improving the level of confidence of GPs in CKD management. 266 
The AusHeart study has concluded that CKD is common, significantly under‐
recognised and under‐treated in primary care.267 In rural general practice in Australia, there are 
significant shortfalls in the recording of kidney function.268 The national survey of Australian 
GPs has shown that 50% of patients attending general practice have undergone a kidney 
function test in the previous 12 months.269 The most frequent barriers to ordering a kidney 
function test, recognised by the GPs in our study were- limited time or more urgent patient 
issues, fear of over-servicing and the associated cost. The recent decision by the Federal 
Department of Health and Ageing to include the measure of kidney function as a part of the 
GP Practice Incentive Payment could potentially resolve some of the barriers. GPs expressed 
discomfort in discussing early CKD and the need for dosage adjustment with patients due to 
the potential risk of provoking concern in patients by labelling their declined renal function as 
kidney disease. This discomfort could be resolved by including CKD care in discussion of 
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diabetes or hypertensive care and sharing the responsibility of reassuring patients with other 
practice staff .262  
We found that the GPs had favourable views towards the automated eGFR reporting 
and this was consistent with results from other studies.270 271 GPs demonstrated more awareness 
of eGFR as an indicator of CKD, often listing it as a preferred tool for renal dosing purposes. 
This aligns with the recent recommendation from the Australasian Creatinine Consensus in 
using the eGFR calculated with the MDRD formula for drug dosing decisions in general 
practice for non-critical-dose drugs.106 Easy availability, enhanced detection and better 
accuracy has made automated eGFR a preferred choice for renal dosing in general practice.272  
However, caution is required while using eGFR for drug dosing. Dosage adjustment in specific 
patients, such as the elderly or those in extremes of body weight, need consideration for body 
surface area.273 Interventions aimed at providing more information in regards to usage and 
interpretation of eGFR values would seem appropriate.  
There was less familiarity with the Kidney Health Australia guideline among the GPs 
and some of the GPs expressed that it was not very helpful in the primary care setting. Studies 
overseas have documented GPs lack of awareness of CKD management guidelines.18 19  
Deficiencies in knowledge regarding the CKD management guidelines was identified as one 
of the important barriers to CKD care and was the reason for suboptimal management of 
CKD.16 GPs who are less aware to the guidelines are less likely to recognise CKD and monitor 
its progression.16  
Limited awareness to CKD guidelines might be due to the reason that these guidelines 
are relatively newer and are lesser publicised than hypertension or diabetes guidelines.21 Some 
CKD management guidelines, such as KDOQI guidelines, are cumbersome to read and 
competing demands create difficulty for GPs to access practical elements during patient 
consultation.274 Due to lack of awareness about existing CKD guidelines, GPs largely rely upon 
evidence-based diabetes and hypertension guidelines to manage the CKD.23 Continuing 
medical education has been suggested to overcome the knowledge gap of GPs in the 
identification and medication management in CKD. 17  
GPs have embraced the electronic resources to a greater extent than paper-based 
resources. The time taken to navigate was the main barrier to accessing the electronic sources. 
Information source preferences were consistent between rural and non-rural GPs. These 
findings are in concordance with previous studies.275 276 There was a general scepticism 
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expressed concerning the usefulness, reliability, and applicability of the information sources. 
MIMS/Product information was the most commonly used information source for renal dosing. 
Despite being the one of the most frequently consulted drug information sources in Australia, 
MIMS has been found to suggest an altered dosage regimen without a quantifiable measure of 
renal function for renally-cleared drugs.178 
The majority of the GPs said they have difficulty in adjusting dose in CKD patients. 
Lack of easy access to guidelines, lack of time, ambiguous information, and evidence not 
related to the context of primary care, limited their use of the guidelines. In our study, 21% of 
GPs still believed in renal dosing based of serum creatinine level. A similar result was found 
in general practices overseas.17 Although used in daily practice, it is inappropriate to use serum 
creatinine level in isolation for screening renal function, particularly in the elderly.87 This 
reliance on serum creatinine level leads to underestimation of renal impairment and 
subsequently contributes to incorrect prescribing. 
The challenges implied by the results of our study require an innovative approach to 
optimise dosing in patients with CKD. Addressing the barriers to using the guidelines with 
concrete interventions at the levels at which they occur would help to improve the dosing in 
patients with CKD. Insufficient and ambiguous information in drug information sources to 
guide the dosing has been pointed out at various times.177 193 There is a need for the drug 
information providers to present the renal dosing information in an unambiguous format so that 
the GPs can easily incorporate them into their daily practice. Guidelines with clear non-
controversial and evidence recommendations are more likely to be employed than guidelines 
with recommendations that are unclear, controversial or based on opinion.277  
Lack of awareness about available information sources and skills to access them can be 
improved by systematic educational intervention. A series of brief, individualised training 
sessions on available sources and updated information on renal dosing could help develop 
accessing information skills. The significant time to seek information coupled with a need to 
consult multiple sources, each with a varying design and interface, is a potential barrier to drug 
dosing which could be addressed through the use of a tool, integrating multiple sources into a 
single interface. This would allow access to multiple sources without the need to extensively 
search and could provide information from each individual source. Continued online medical 
education focusing on updated information can potentially address the confusion associated 
with the existing practice of using different formulae for different purposes.  
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A decision support system incorporated within the prescribing software that could alert 
the provider to order a serum creatinine test maybe beneficial. The alert could also provide 
references to guidelines and studies that informed these guidelines. Studies are needed to 
understand if such interventions could improve dosing without substantial economic impacts 
or disrupting the general practice workflow. 
 
7.6 Conclusion 
Addressing the barriers to using the guidelines with concrete interventions at the level 
at which they occur to ultimately improve the dosing in patients with CKD, is warranted. 
Updating the information sources to present the key elements in an unambiguous format in 
conjunction with efforts to build consensus among the standard information sources seems 
necessary. As a result, GPs can incorporate the recommendations into practice. Improved 
dissemination of existing guidelines, online education to increase awareness on drug dosing, 
available guidelines and how to use them, and decision support systems to aid GPs in 
identifying renally-cleared drugs, appear warranted. 
 
7.7 Next step 
Inappropriate prescribing increases the risk of adverse drug events and can lead to 
morbidity, increased hospitalisation along with an excessive healthcare utilisation and 
substantial economic burden.126 154 The majority of these adverse drug events occur as a result 
of medication dosing error and are predictable and often preventable. Preventable adverse drug 
events often occur as a result of medication dosing errors.192 Prescribing errors can occur 
because the prescribers do not have immediate access to the updated information related to the 
drugs.278 The problem of dose inappropriateness can be addressed to some extent by general 
education and by raised awareness of medications requiring dosage adjustment and, the need 
for routine assessment of renal function.12 Clinical pharmacist dosing services, reinforced by 
an immediate concurrent feedback strategy implemented by the clinical pharmacist, improved 
the dosing of renally-cleared drugs, lowered the rate of adverse drug events, reduced the cost 
and improved the overall delivery of healthcare.129 279 280 
Computerised dosing programmes have increased the proportion of doses of renally 
eliminated drugs adjusted to renal functions, decreased drug costs and, have the potential to 
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prevent adverse drug events.278 Pharmacist-conducted medication reviews have been found to 
be effective in reducing the use of potentially inappropriate medicine for elderly people in 
Australian community settings.139 It seems that pharmacist involvement in medication 
management and online education and training programs in the community settings is 
warranted to avoid the unwanted effects of drugs. This ensures optimal patient outcomes and 
improve the quality of healthcare delivered to patients. Based on this background, in the next 
phase, we conducted a systematic review on studies that examined the interventions provided 
by pharmacists in patients with CKD and determined the outcomes.  
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Chapter 8 TYPES AND NATURE OF PHARMACIST MEDIATED INTERVENTIONS AND THE 
OUTCOMES IN CKD-A SYSTEMATIC REVIEW 
8.1 Chapter Introduction 
This chapter presents a systematic review to examine the published literature to 
recognise and appraise the outcomes that can be influenced by pharmacists’ interventions in 
the management of patients with CKD. 
The scope of the review was broadened by the inclusion of studies on patients with 
ESRD in addition to studies performed on patients with mild and moderate CKD. This is 
because the NKF-KDOQI guideline explicitly highlights the need for routine pharmaceutical 
care at all stages of CKD. This includes conducting regular medication reviews, dose 
monitoring, therapeutic drug monitoring, and detection of adverse drug reactions. There are 
five stages of CKD based on GFR values: at risk (>90 mL/min/1.73 m2), mild (60-89 
mL/min/1.73 m2), moderate (30-59 mL/min/1.73 m2), severe (15-29 mL/min/1.73 m2), and 
renal failure or ESRD (GFR <15 mL/min/1.73 m2). Pharmaceutical care is equally warranted 
at all these stages of CKD to optimise pharmacotherapy and patient care. 
An additional reason for broadening the scope of the review to include ESRD patients 
was that drug regimens of ESRD patients are prone to frequent change and are more susceptible 
to drug-related problems (e.g. dosing problems and medical record discrepancies). Therefore, 
intensified care and additional monitoring is warranted for these patients. For example, patients 
with ESRD undergoing dialysis are prescribed an average of 12 medications and present around 
six comorbidities. Patients who have undergone a renal transplant are also required to take a 
multitude of drugs and adherence to these medications is essential to avoid graft rejection and 
medical costs. Given the complexity of dosing and changes in drug pharmacodynamics and 
pharmacokinetics, pharmacist provided intervention is imperative for these patients. 
The broadening of the scope of the review aligns with the overall aim of the thesis: to 
determine how to improve the use of high-risk medications in patients with CKD. Initially, we 
quantified the extent of inappropriate prescribing in CKD patients at all stages of severity, 
through examination of HMR and RMMR cases. Later, through the online survey, we 
established pharmacist intervention as one of the preferred methods for GPs to ensure correct 
dosing and optimal management of CKD. The management of CKD is multifaceted and 
includes the management of comorbidities, drug dose monitoring, and patient education. As 
pharmacotherapy experts, pharmacists are indispensable for these tasks. Given the aim of this 
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chapter is to determine the type of interventions conducted by pharmacists in terms of the 
management of CKD, it is additionally necessary to include ESRD patients. This is particularly 
the case because the management of CKD is a continuous process starting from the early stages 
and continues for ESRD patients both with and without dialysis and transplant. 
 
8.2 Introduction 
With the growing prevalence of chronic renal impairment worldwide, the number of 
patients developing end stage renal disease (ESRD) and undergoing dialysis or receiving renal 
replacement therapy is increasing every year.281 Opportunity exists for involvement by 
pharmacists in all stages of chronic kidney disease (CKD), from diagnosis to ESRD. In general, 
CKD is associated with various comorbidities and complications that require multiple 
medications.282 283 A dialysis patient on average receives 10 prescription drugs and 2 non-
prescriptions drugs.242 Drug-related problems (DRPs) are frequent in patients with CKD and 
special attention should be given towards their identification, prevention and resolution.187 The 
higher prevalence of DRPs, frequent occurrence of adverse drug events190 284 and patients’ non-
adherence285 requires the active involvement of pharmacists in renal disease management, as 
the task of drug use monitoring and controlling cannot be performed by a single health 
professional and requires a multidisciplinary approach. Pharmaceutical care programs 
involving multidisciplinary health care teams have proven to be very effective in the 
management of chronic illnesses like hypertension286, asthma287, diabetes288 and 
hyperlipidaemia289. Significant gaps in regards to optimal pharmacotherapy, adherence, 
referral to nephrologist and management of comorbidities in patients with CKD have been 
reported in various studies, and these may be subject to interventions by pharmacists.180 290 
This systematic review aims to examine the published literature to recognise and 
appraise the outcomes that can be influenced by pharmacists’ interventions in the management 
of patients with CKD in various settings. Two specific questions directed the review: 
 What are the types of interventions provided by pharmacists in patients with renal 
disease? 
 What is the effect of these interventions in patients with renal disease? 
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In this review the term ‘intervention’ refers to any action undertaken by the pharmacist 
with the aim to improve the therapeutic outcomes in the patients. 
8.3 Methodology  
8.3.1 Design and study selection 
A literature search was conducted according to the Preferred Reporting Items for 
Systematic reviews and Meta Analyses (PRISMA) to review the available literature on the 
effect of pharmaceutical care in patients with chronic kidney disease.291 Five databases 
(PubMed, International Pharmaceutical Abstracts, Embase, CINAHL and Cochrane) were 
searched for relevant articles in January 2015 without time limits. 
Inclusion criteria for this systematic review were studies addressing:  
 Interventions provided by pharmacists or pharmacists as a part of a team. 
 Interventions provided through a pharmacy-based decision support system. 
 All type of studies including controlled (randomised and non-randomised) and 
uncontrolled trials (observational studies). 
 Results published in abstract form (e.g. congress abstract) were included if they 
provide information on interventions and outcomes. 
 Studies done in all range of settings (hospital ward, ambulatory, transplant clinics).  
 
Exclusion criteria for the review were: 
 Studies in a language other than English. 
 Review articles or case reports. 
 Studies that did not report the nature of the intervention(s). 
 Studies that did not report the outcomes of the intervention(s). 
Search strategy: The following queries were used in the databases to identify the relevant 
articles. 
PubMed (“Pharmacists” [Mesh] OR "Pharmaceutical Services"[Mesh] OR "Community 
Pharmacy Services"[Mesh] OR "Pharmacy Service, Hospital"[Mesh] OR “Pharmaceutical 
Services, online” [Mesh]) AND ("Kidney Failure, Chronic"[Mesh] OR "Renal Insufficiency, 
Chronic"[Mesh] OR "Renal Dialysis"[Mesh] OR "Renal Replacement Therapy"[Mesh])  
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International Pharmaceutical Abstracts ("Clinical pharmacy" OR "pharmaceutical care" OR 
"Pharmacist" OR “Hospital Pharmacy") AND ("chronic renal disease" OR "renal 
insufficiency" OR "dialysis" OR" renal transplant" OR "renal replacement therapy")  
CINAHL ("Clinical pharmacy" OR "pharmaceutical care" OR "Pharmacist" OR “Hospital 
Pharmacy") AND ("chronic renal disease" OR "renal insufficiency" OR "dialysis" OR" renal 
transplant" OR "renal replacement therapy")  
Embase 'Clinical pharmacy'/exp OR 'pharmaceutical care'/exp OR 'pharmacist'/exp OR 
'hospital pharmacy'/exp AND ('renal insufficiency'/exp OR 'kidney'/exp OR 'renal replacement 
therapy'/exp)  
Cochrane Pharmacist AND Kidney/Renal  
Additionally, the reference sections of the publications were screened manually for other 
relevant articles.   
 
8.3.2 Data extraction 
Data in relation to predefined parameters including study design, year of publication, 
country, duration, setting, aim, characteristics of patients, type of interventions and outcomes, 
were extracted. 
 
8.4 Results 
A total of 1093 records were obtained from the various databases. After removing the 
duplicates, 994 articles were retrieved for further evaluation. Among the retrieved articles, a 
total of 802 articles were excluded by title screening. The full texts of the remaining 192 articles 
were assessed for eligibility and 122 studies were excluded. The predominant reasons for 
exclusion were a) articles not mentioning any intervention performed by pharmacists in 
patients with CKD and b) articles without a method or result section. Finally, 74 articles were 
included in the review after adding four articles identified from reference lists. A total of 15 
studies were available as abstracts.292-306 The diagrammatic representation of the search process 
is shown in figure 9.1. 
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Figure 8.1 Search strategy 
 
8.4.1 Study Characteristics 
The majority of the studies were conducted in the hospital outpatient (ambulatory) 
setting (n=39), followed by 25 in inpatients, 5 in the community, 1 in both ambulatory and 
inpatients, 3 in renal transplant clinics, and 1 in a dialysis centre. Most of the studies had an 
uncontrolled design. There were 8 prospective non-randomised controlled, 40 prospective 
uncontrolled, 2 retrospective controlled, 7 retrospective uncontrolled, 13 prospective 
randomised controlled and 4 historical controlled. The studies were carried out in the USA 
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(n=44), Canada=1, Europe (n=13) and Asia (n=16). In terms of participants, 26 studies were 
conducted in haemodialysis patients (HD), 32 in CKD, 10 in transplant patients, 6 in dialysis 
(HD and peritoneal dialysis; PD) patients. 
The mean sample size varied greatly from a minimum of 23 participants to maximum 
of 2002 participants (excluding the studies that used the decision support system as a means of 
intervention). The sample size for the studies involving decision support ranged from 17,828 
to 51,877 participants. Eight studies did not report the sample size.292 295 297 299 301 303 307 308 
Pharmaceutical care activities in patients with CKD indicated an increasing trend with the year. 
(Pearson correlation=0.6, P<0.01) Figure 8.2. 
 
 
Figure 8.2 Studies focusing on pharmaceutical intervention in patients with CKD per year 
 
The interventions performed by pharmacists in the included studies could be categorised into: 
Pharmaceutical care services with primary focus on (Figure 8.3) 
1. Management of co-morbidities and complications (n=27, 37.8%)  
2. Optimisation of drug therapy (n=39, 51.3%)  
3. Educational activities (n=8, 10.8%). 
The types of outcomes observed and key measurements of such outcomes used in the studies 
were grouped as follows. 
135 
 
 
 Clinical/physiological outcomes: This included the change in the physiological, 
biochemical and disease-related parameters in the patients as a result of intervention. 
The key measurements of such outcomes were levels of haemoglobin, glycosylated 
haemoglobin, triglycerides, cholesterol, parathyroid hormone, serum creatinine, 
systolic blood pressure, diastolic blood pressure, blood glucose, length of hospital stay, 
hospitalisation rate and occurrence of adverse events etc. 
 Humanistic outcomes: This included change in behavioural parameters as a result of 
intervention. The key measurement parameters of such outcomes were:  
-Patient (knowledge, awareness, quality of life, adherence)  
-Physician (acceptance of recommendation) 
 Drug-related outcomes: drug therapy appropriateness, dosing error. 
 Economic outcomes: Cost saving 
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  
Figure 8.3 Nature and type of pharmaceutical interventions in patients with CKD 
 
 
Management of 
comorbidities
Optimisation of drug therapy
Education
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hyperparathyroidism-managing protocols
-Protocol driven administration of erythropoietin
-Conversion of erythropoietin administration
fromIV to SC route
-Providing medical and therapeutic information
-EPO and iron therapy monitoring
-Ascertain ESA indication and dose
-Promotion of adherence
-Education and training regarding the disease
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individually labelled syringe for each patient on
a daily basis.
-Promote use of renin-angiotensin system
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Optimisation of drug therapy
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-Therapeutic recommendation
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-Start or discontinue a drug
-Identify nephrotoxic drugs
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-Making therapeutic recommendations
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-Identifying and correcting drug record
discrepancies
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management
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-Providing medication/disease education 
to patients
-Improving adherence
-conferences on patient care and 
written/oral consultations
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8.4.2 Types and the nature of pharmacist’s interventions 
Pharmacist intervention-optimal management of co-morbidities and complications  
The most common co-morbidities and complications of CKD managed by pharmacists 
were anaemia,214 225 292 295 299 303 304 307 309-314 hyperlipidaemia,294 315 diabetes,301 316 
hypertension,317 318 hyperphosphatemia319 and hypocalcaemia.319 Pharmacists were primarily 
responsible for implementing disease management protocols, drug dosing protocols and 
providing therapeutic information to physicians. Pharmacists were also involved in developing 
and implementing a phosphate management protocol210, managing infections320 and ulcers in 
patients with CKD218. Comprehensive comorbidity management programs in some studies 
included managing independent dosing and dose modification of erythropoietin and iron 
therapy.214 295 299 303-305 307 311 321 322 Pharmacists were primarily involved in counselling the 
patients regarding disease/drug/dietary therapy and implementation of adherence-enhancing 
activities such as training regarding device use and erythropoietin administration methods. 
Pharmacists performed medication reviews and provided therapeutic recommendations to 
physicians. Few studies gave special attention towards monitoring and adjusting the dose of 
darbopoietin.225 304 Apart from this, the pharmacists were involved in providing information to 
physicians in renal anaemia.310
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Table 8.1 Intervention focused on the optimal management of comorbidities in CKD  
Reference 
Year 
Author 
Patient 
characteristic
s 
N(C/T) 
Age (Years) 
Mean (SD) 
Study 
design/ 
Setting 
 
Aim Duration 
(months) 
Intervention Key  
measurements 
Outcomes of 
intervention/Result 
Allenet 
 (2007)  
France 
14 Dialysis 
11 TP 
52.3 (15.4) 
Prospective 
uncontrolled 
Ambulatory  
Assessment of a 
pharmacist run anaemia 
education program for 
patients with CKD. 
3 -Education and training  
(medical and 
therapeutic 
information)  
-Hb Level 
-Adherence 
-High level of patient 
adherence achieved with an 
optimal haemoglobin level 
within two months. 
Kimura 
(2004)  
Japan 
45 HD 
NM 
Prospective 
uncontrolled 
Ambulatory  
Evaluation of the impact 
of pharmacist run 
anaemia management 
program for the ESRD 
patients.  
9 -Education and training  
(drug information to 
physician on renal 
anaemia) 
-Dose monitoring and 
adjustment 
-DUE and therapeutic 
recommendations 
-HCT level -Increased trend of mean HCT 
and number of patients with 
HCT >30%. 
Millitello 
(2010)  
USA 
NM HD Prospective 
uncontrolled 
Ambulatory 
A pharmacist-driven 
team approach to 
anaemia management in 
NM -Dose monitoring and 
adjustment  
-No. of patients 
with target Hb 
level 
-Increase in number of 
patients within the Hb target 
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an outpatient dialysis 
unit. 
(EPO and iron therapy 
monitoring) 
range (10-12 g/dl) from 50% 
to 70%.  
To LL 
(2001)  
USA 
49 HD 
60(12) 
Retrospectiv
e 
uncontrolled 
Ambulatory 
Comparison of a 
pharmacist run anaemia 
management program 
with physician based 
anaemia management 
program in a Veterans 
dialysis centre. 
6 -Dose monitoring and 
adjustment  
(EPO, iron therapy 
monitoring) 
-HCT level 
-Tsat 
-Iron dose 
-No significant changes after 
intervention in 
 HCT[mean(SD) 
35.36(3.33) vs 
36.21(3.46)]  
 Tsat [mean(SD) 29.82 
(14.92) vs 30.78(13.17)] 
-Reduction in dose of 
elemental iron.  
Walton  
(2005)  
USA 
278 HD 
46.2(13.4) 
Prospective 
uncontrolled 
Ambulatory 
Assessment of 
pharmacist managed 
anaemia program in a 
HD clinic. 
6 -Dose monitoring and 
adjustment (epoetin 
and iron therapy 
monitoring) 
-Hb level 
-Ferritn 
-Tsat 
-Significant elevation after 
intervention in  
 Hb level (9.5 vs11.8 g/dl) 
 Ferritn [mean(SD) 280.9 
(326.4) vs 431(22.1)] 
 Tsat [mean(SD) 21(7.9) 
vs 33(8)]  
-Increase in number of 
patients with  Hb>11 g/dl. 
Bucaloiu 
(2007)  
USA 
134 CKD 
(62/74) 
NM 
Prospective 
controlled 
Ambulatory 
Assessment of the effect 
of a pharmacist driven 
anaemia management in 
patients with CKD 
32 -Dose monitoring and 
adjustment (protocol 
driven administration 
of erythropoietin) 
-Hb level 
- Tsat 
-Pharmacist managed group 
maintained higher percentage 
of Hb and Tsat value and 
achieved the goal Hb level 
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compared with the 
physician managed 
group. 
 faster than physician managed 
group 
 Hb (mean 69.8 vs 43.9%)  
 Tsat (mean 64.8 vs 
40.4%) 
 Time (47.5 vs 62.5 days) 
Quercia 
(2001)  
USA 
NM HD 
NM 
Prospective 
uncontrolled 
Ambulatory 
Evaluation of cost 
avoidance and clinical 
benefits derived from a 
pharmacy managed 
anaemia program. 
1995, 1998 -Dose monitoring and 
adjustment (EPO and 
iron dose monitoring) 
-Formulation of 
anaemia management 
protocol 
-Level of HCT 
-Cost avoidance 
-Significant cost avoidance in 
EPO from 1995-1998 
(estimated $1018638). 
-Decrease in number of 
patients with HCT< 31% 
(32% in 1994 to 14% in 1998). 
Joy 
(2007)  
USA  
166 CKD 
NM 
Prospective 
uncontrolled 
Ambulatory 
Assessment of the effect 
of a clinical pharmacist 
managed anaemia 
programs.  
28 -Dose monitoring and 
adjustment 
(darbopoietin) 
-No. of patients 
achieving target 
Hb 
-Increase in no. of patients 
with Hb target range (41% vs 
78%). 
Brown 
(2007) 
USA 
190 (73/117) 
CKD 
Retrospectiv
e 
controlled 
Ambulatory 
To determine clinical 
significance and cost 
effectiveness of 
pharmacist-run EPO 
Clinic. 
  -Dose monitoring and 
adjustment 
(darbopoietin and 
epoetin) 
-No of patients 
achieving goal Hb 
level 
-Cost of therapy 
-92% of patients in EPO clinic 
and 69% of patients in control 
group achieved goal 
haemoglobin level. 
-Cost saving in EPO clinic 
patients. 
Buenviaje 
(2000) 
HD Prospective Comparison of 
pharmacist managed 
3 month -Medication review 
-Dose  adjustment 
-HCT level 
-EPO dose 
-No significant difference 
between the protocol group 
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USA uncontrolled 
Ambulatory 
anaemia program to 
physician based anaemia 
management. 
-Total iron dose 
-Mean Tsat 
and the physician managed 
group in  
 Mean HCT level (36.2% 
versus 35.4%) 
 Total EPO dose (7.7 
million units versus 8.5 
million units) 
 Oral iron dose (95,550 mg 
versus 85,605 mg, 
P=0.638)  
 Mean TSAT (30.78% 
versus 29.82%, P=0.66).  
-Higher use of IV Fe in 
physician managed group. 
Qin 
(1998) 
USA 
NM Prospective  
uncontrolled 
Ambulatory 
To determine the impact 
of pharmacy services in 
decreasing EPO usage 
while avoiding anaemia 
of ESRD. 
NM -EPO dose  monitoring -HCT level 
-Cost reduction 
-Significant improvement in 
HCT 
-Reduction in EPO dose per 
treatment 
-Cost avoidance of $184,000 
annually. 
 
Ueoka 
(2000) 
USA 
HD Prospective 
uncontrolled 
Ambulatory 
To improve patient 
outcomes while reducing 
the total weekly dose of 
24 
 
-Dose monitoring and 
adjustment 
-Dose reduction 
-HCT level 
-Average weekly 
erythropoietin dose reduced 
by 31%.  
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erythropoietin through 
establishing the clinical 
pharmacist role in 
providing consistent 
assessment and dose 
adjustment.  
-Conversion of 
erythropoietin 
administration from the 
IV to the SC route. 
 
-Mean HCT maintained in the 
range of 32 to 36%. 
Anonymous 
(1998)  
USA 
160 HD (1996) 
175 HD (1997) 
NM 
Prospective 
uncontrolled 
Inpatients 
Assessment of 
pharmacist management 
of hypocalcaemia and 
hyperphosphatemia. 
12 -Dose monitoring and 
adjustment 
(preparation of IV 
calcitriol by pharmacist 
for each patient on a 
daily basis) 
-No. of patients 
with the disease 
conditions 
-Significant decrease in no. of 
patients with moderate to 
severe hyperparathyroidism  
 [mean (SD) 12 (7) vs 23 (14)).  
Yokum 
(2008)  
UK 
34 (17/17) HD 
51.1(12.7) 
47.6(14.4) 
Randomised 
controlled 
Ambulatory 
Evaluation of a 
phosphate management 
protocol designed to 
achieve optimum serum 
phosphate levels in HD 
patients. 
4 -Patient education and 
training (medication 
and disease)  
-Serum phosphate 
management protocol 
-Serum phosphate 
level 
-Reduction in serum 
phosphate level [mean (SD) 
1.81 (0.54) Vs 2.07 (0.25) 
mmol/L. 
-No change in parathyroid 
hormone level. 
Chisholm 
(2002)  
USA 
 
23 (10/13) TP 
47(12.7) 
51(16.8) 
 
Randomized 
controlled  
Transplant 
clinic 
Assessment of difference 
in BP control between 
the renal transplant 
patients with or without 
pharmaceutical care. 
12 -Medication Review  
(Identifying, 
preventing and 
resolving DRPs) 
-Education and training  
-SBP and DBP 
level 
-Reduction in mean SBP and 
DBP in intervention group at 
the second, third and fourth 
quarter of the study. 
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-Therapeutic 
recommendations 
-Promotion of 
adherence 
Chisholm 
(1999) 
 USA 
33 (15/18) TP 
NM 
Randomized 
controlled 
Transplant 
clinic 
Evaluation of effect of 
pharmaceutical care 
services on renal 
transplant patients' blood 
glucose levels. 
12 
 
-Medication review 
(Identifying, 
preventing and 
resolving DRPs) 
-Therapeutic 
recommendations 
-FBG level -Reduction in the FBG level in 
the intervention group. 
Shaffer 
(2003) 
USA 
285 dialysis 
NM 
Prospective 
uncontrolled 
Dialysis 
centre 
To develop a dialysis 
unit protocol to improve 
dyslipidaemia control 
and to increase provider 
awareness 
2  -Ordering and 
assessment of lipid 
level. 
 -Therapeutic 
recommendations to 
providers 
-Total cholesterol 
-LDL-C 
-Reductions in total 
cholesterol and LDL 
-Increase in the rate of lipid 
panel labs and statins order.  
-Increase in provider 
awareness. 
Viola 
(2002)  
USA 
26 HD 
55.7 (11) 
Prospective 
uncontrolled  
Ambulatory 
Assessment of the 
effectiveness of a 
multidisciplinary lipid 
management program. 
6 -Dose monitoring and 
adjustment 
-Laboratory test order 
-Patient education and 
training  
(medication 
counselling) 
 
-LDL-C 
-HDL-C 
-Total cholesterol 
 
-Significant reduction after 
intervention in 
 LDL [mean (SD) 80 
(3) vs 96 (5) mg/dL 
 Cholesterol [mean 
(SD) 151 (4) vs 170 
(7) mg/dL 
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 -Increase in no. of patients 
reaching target LDL (88 
versus 58%) 
Leal  
(2008)  
USA 
601 CKD 
 57.7 (13.5) 
Prospective 
uncontrolled  
Community 
To evaluate a pharmacist 
based disease state 
management service  
NM -Dose monitoring and 
adjustment 
-Education and training 
(disease and 
medications) 
-HbA1C level 
-BP 
-Cholesterol 
-Increase in number of 
patients at target goals for BP, 
HbA1C and cholesterol 
receiving aspirin and 
angiotensin converting 
enzyme inhibitor. 
Abrahams 
2005  
USA 
140 HD 
NM 
Retrospectiv
e 
uncontrolled 
Ambulatory 
To evaluate the effect of 
pharmacy managed 
collaborative program to 
optimally manage 
anaemia and secondary 
hyperparathyroidism  
10 years -Drug use evaluation 
-Dose monitoring 
-Erythropoietin and 
calcitriol prepared in 
individually labelled 
syringe. 
-Cost saving 
-No. of patients 
achieving target 
Hb 
-Cost avoidance of over 
$250,000 annually 
-Increase in the number of 
patients within the target 
haematocrit range of 31 % to 
36%. 
Aspinall 
(2012) 
USA 
91/314 CKD 
78.4 (8.8) 
73.9 (10.9) 
Historical 
control 
Ambulatory 
Impact of pharmacist-
managed ESA clinics for 
patients with non-
dialysis-dependent CKD 
6 -Dose monitoring and 
adjustment (ascertain 
ESA indication and 
dose) 
-No. of patients 
achieving target 
Hb level 
 
 
-More number of patients 
achieved target Hb range in 
pharmacist-managed ESA 
clinics (71.1% vs 56.9% for 
usual-care sites (P < 0.001). 
 
Santschi 
(2011) 
Canada 
89 (41/48) 
CKD 
73.3 (7.7) 
Randomised 
controlled  
Community 
-Evaluate the impact of 
ProFiL, (collaborative 
and multidisciplinary 
6 -Medication review 
(identify DRPs) 
 -ProFiL patients had a larger 
reduction in systolic BP than 
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71.9 (10.4) care programme) on 
management of 
hypertension treatment 
in patients with CKD 
-Therapeutic 
recommendations to 
physician 
 
the usual care group. (-4.7 
mmHg vs-0.4 mmHg.  
Nasution 
(2013) 
Indonesia 
143 (80/63) 
CKD 
47.06 (13.80) 
49.44 (13.08)  
Prospective 
controlled 
Inpatient 
To evaluate the clinical 
and economic impacts of 
clinical pharmacy 
education (CPE) on 
infection management 
among patients with 
CKD 
6 -Education and training 
Health providers were 
given clinical 
pharmacy education 
(CPE) on dose 
adjustment according 
to the level of kidney, 
identifying drug-
related problems.  
 
-Number of lives 
saved/100 
patients treated. 
-Cost-
effectiveness 
ratios for patients 
with CPE and 
without CPE  
-Treatment of CKD was   more 
effective with CPE (CKD 
stage 4, 88.89; CKD stage 5, 
65.45) than without CPE 
(CKD stage 4- 78.57; CKD 
stage 5-57.58). 
-Treatment of CKD was more 
cost-effective with CPE  
compared with treatment of 
without CPE 
Mousavi 
(2013) 
Iran 
Pre-
intervention: 
375 
Post-
intervention-
236 CKD 
51.2 (18.3) 
50.2(18.8) 
Prospective 
uncontrolled 
Inpatient 
To assess the role of 
clinical pharmacists to 
decrease inappropriate 
stress ulcer prophylaxis 
(SUP) prescribing and 
related costs for 
these patients. 
6 -Develop SUP 
prescribing protocol  
-Educational classes 
for medical doctors on 
appropriate SUP 
prescribing. 
-Provide 
recommendation 
-Number of 
patients who 
received SUP 
appropriately 
-Significant relative reduction 
in inappropriate SUP 
prescribing and related cost in 
patients with renal 
insufficiency by about 44% 
and 67% respectively. 
Leung 
(2005) 
160 (80/80) 
CKD 
Prospective 
uncontrolled 
To evaluate the effect of 
disease management 
24 -Periodic laboratory 
assessments (BP, 
-Onset of the first 
event of ESRD 
-Structured care patients had 
slower rate of renal decline (P 
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Hong Kong 61.1 (8.8) Ambulatory program for patients with 
diabetic nephropathy on 
the time to onset of 
ESDR or all-cause death 
compared with usual 
care. 
plasma glucose, 
HbA1c, renal function, 
Hb, serum 
Lipids) 
- Risk factors control 
-Reinforce patient 
adherence 
-Suggesting use of 
renin-angiotensin 
system inhibitors. 
-Hb, LDL, 
cholesterol level 
< 0.032), increased use of 
renin-angiotensin system 
inhibitor, reductions in BP, 
LDL cholesterol  
-ESDR developed in 24 and 40 
patients in the structured care 
and usual care groups 
respectively. 
 
Debenito 
(2014) 
USA 
101 (70/31) 
CKD 
72.0 (13.3) 
 65.6 (14.1) 
Retrospectiv
e controlled 
Ambulatory 
To evaluate the impact of 
a clinical pharmacy 
anaemia management 
service on adherence to 
monitoring guidelines, 
clinical outcomes, and 
medication utilization in 
patients with CKD 
36 -Manage drug therapy 
for a given indication 
-Initiation or 
discontinuation of 
specified medications, 
-Dose adjustment and 
ordering appropriate 
laboratory 
tests 
-Proportions of  
patients achieving 
target Hb level 
and number of 
days required to 
achieve target 
-Average weekly 
dose of ESA 
therapy and its 
associated cost  
Pharmacist-managed patients 
in comparison to usual care 
patients had improvement in 
-Adherence to guidelines for  
Hb monitoring (32.3% vs. 
14.3%, P=0.049),  
-Iron monitoring (61.3% vs. 
30.0%, P = 0.005)  
-Time to achieve Hb target (28 
days vs 41 days, P = 0.135) 
-Proportion of patients 
achieving target Hb (96.8% vs 
95.7%, P = 0.654).  
-Lesser epoetin alfa during the 
6-month period, leading to an 
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annualized savings of $1,288 
per patient in drug 
expenditures. 
Dashti 
 (2012) 
Iran 
86 HD 
Median 
(range) 56 
(22–84) 
Prospective 
uncontrolled 
Inpatients 
Evaluation of the impact 
of clinical pharmacy 
services in the 
management of 
complications in HD 
patients. 
39 -Dose adjustment and 
monitoring 
 
 
-Hb level 
-Total cholesterol 
-LDL-C 
-Serum Ca and  
iPTH level 
-Optimal range of serum Ca 
and iPTH level achieved in 
patients who initially were on 
suboptimal and supra optimal 
range. 
-Hb level increased in anaemic 
patients. 
-Serum ferritin reached target 
values in all patients. 
-Total cholesterol and LDL 
decreased to near-optimal 
values in dyslipidaemia 
patients. 
Dashti 
(2013) 
USA 
 
92 (47/45) HD 
53.6 ± 15.0 
Randomised 
controlled 
Inpatient 
To assess the impact of 
pharmaceutical care on 
HRQoL of 
haemodialysis patients 
6 -Medication review 
(identify DRPS) 
-Drug therapy 
monitoring and dose 
adjustment 
-Interview patient and 
care-provider  
to evaluate patient’s 
medication adherence  
-Education and 
training (disease, 
drugs, correct 
administration) 
Improvement in 
patient’s quality 
of life 
-HRQoL improved 
significantly from median 
56.9 at the initiation of the 
study to 72.2 at the end of the 
study in the case group (P = 
0.001). 
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-Counselling on 
lifestyle modification 
and nutrition  
-Information booklets 
  
Hb: Haemoglobin, CKD: Chronic kidney disease, HD: Haemodialysis, TP: Transplant patients, ESRD: End stage renal disease, HCT: Haematocrit, NM: Not 
mentioned, BP: Blood pressure, SBP: Systolic blood pressure, DBP: Diastolic blood pressure, DUE: Drug use evaluation, Tsat: Transferrin saturation, FBG: 
Fasting blood glucose, HbA1C: Glycosylated haemoglobin, LDL-C: low-density lipoprotein cholesterol,  HDL-C: high-density lipoprotein cholesterol, TP: 
Transplant, EPO: Erythropoietin, DRPs: Drug-related problems, iPTH: Serum intact parathyroid hormone, EPS: Erythropoiesis-stimulating agents, HRQoL: 
Health-related quality of life, GFR: Glomerular filtration rate 
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Implementation of anaemia management program 
Twelve studies reported the impact of the clinical pharmacists interventions in the 
management of anaemia in patients with CKD.214 225 292 295 299 303 304 307 309-311 Two groups of 
studies were identified. In the first three trials, the tested hypothesis was whether the 
pharmacist-driven anaemia management program, compared with a physician-managed 
program was associated with improved outcomes. In a non-randomised controlled trial, 
Bucaloiu et al312 found that the protocol-driven administration of erythropoietin managed by 
pharmacists, as opposed to physicians, resulted in a higher percentage of haemoglobin and 
transferrin saturation value and faster achievement of target haemoglobin level (11-12.9 mg/dl) 
with use of lesser dose of erythropoietin. In contrast to these findings,  Buenviaje et al303 
reported that there was no significant difference between the protocol managed group and 
physician managed group in mean haematocrit level (36.2% versus 35.4%), total EPO dose 
(7.7 million units versus 8.5 million units) and mean transferrin saturation level (30.78% versus 
29.82%, p=0.66). The only difference was a higher use of intravenous iron in the physician 
managed group. Similarly, To et al311 reported the pharmacist-managed protocol to be equally 
effective as the physician managed protocol and there was no significant difference in mean 
haematocrit level, total erythropoietin dose and total elemental iron dose. The haematocrit level 
was slightly higher than the desired range of 33-36% in the pharmacist-managed group. The 
authors attributed this to the requirement of the minimum two-week interval for erythropoietin 
dosage modification; i.e. the dosage adjustments were incremental in order to prevent wide 
fluctuations in haematocrit level. 
In nine other studies, the hypothesis that a pharmacist-conducted anaemia management 
program improves outcomes in patients with CKD was tested without the use of any control 
group. The pharmacists were primarily involved in counselling the patient regarding 
disease/drug/dietary therapy and implementation of adherence-enhancing activities such as 
training regarding device use and, erythropoietin administration methods.309 310 Pharmacists 
performed medication reviews and provided therapeutic recommendations to physicians.310  
 
Implementation of hyperparathyroidism management program  
Two studies described the implementation and effect of pharmacist-based management 
of hyperparathyroidism/hypophosphatemia/hyperkalaemia in patients with CKD. Ay et al319 
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used a before and after design to examine the effect of pharmacist monitoring and adjusting 
the dose of calcitriol on serum phosphate and parathyroid hormone in patients with CKD. 
Pharmacists’ interventions, consisting of preparing intravenous calcitriol for each patient on a 
daily basis, led to a significant decrease in the number of patients with moderate to severe 
hyperparathyroidism [(mean (SD) 12(7) vs. 23(14)]. 
In a randomised controlled trial, Yokum et al210 designed a phosphate management 
protocol and evaluated its effect in achieving optimum serum phosphate level in 34 
haemodialysis patients. They utilised an intensive patient education program reinforced by the 
serum phosphate management protocol. This resulted in a reduction in serum phosphate, with 
mean (SD) 1.81(0.54) in control vs 2.07(0.25) mmol/L in the intervention group. However, 
there was no change in parathyroid hormone level. 
 
Implementation of hypertension management program in patients with CKD 
Pharmacist intervention produced a significant decrease in systolic and diastolic blood 
pressure, along with an increase in the number of patients reaching the target level for blood 
pressure.317 318 Chisholm et al317 prospectively randomized renal transplant patients into an 
intervention group and a control group to determine if patients who received direct patient care 
from a clinical pharmacist had better blood pressure control compared to those who did not 
engage with clinical pharmacy services. The clinical pharmacy services included a clinical 
pharmacist performing medication reviews, with emphasis on preventing or resolving 
medication-related problems and providing medication recommendations. Mean systolic blood 
pressure and diastolic blood pressure decreased significantly in the test group.  
 
Implementation of blood glucose management program in patients with CKD  
Pharmaceutical care service in a renal transplant clinic demonstrated a positive impact 
on patients' blood glucose control, along with the increase in number of patients at target goals 
for blood pressure, glycosylated haemoglobin and cholesterol level. Chisholm et al301 
demonstrated beneficial and a statistically significant difference in fasting blood glucose level 
between a pharmacist (mean change of 0 mg/dl, \-/21 mg/dl, \-/40 mg/dl, and \-/44 mg/dl) and 
a usual care group (+7 mg/dl, +13 mg/dl, +13 mg/dl, and +20 mg/dl) for the first, second, third, 
and fourth quarters of the study. The pharmacist care group received pharmaceutical care 
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services, which included an ongoing medication review and providing appropriate 
pharmacotherapy recommendations.  
 
Implementation of hyperlipidaemia management program in patients with CKD  
Two studies addressed the effect of an implementation of a dyslipidaemia control 
program by a pharmacist in dialysis patients.294 315 The dyslipidaemia control program involved 
the clinical pharmacists conducting medication reviews, ordering/assessment of lab tests, dose 
optimisation and providing recommendations to the physician. This resulted in reduction in the 
total cholesterol level [mean (SD) 80(3) vs 96(5) mg/dl] and an increase in the number patients 
reaching target level for low density lipoprotein. 
 
Overall management of multiple complications and comorbidity 
Three studies investigated, tested and measured the impact of clinical pharmacy 
services on the management of multiple complications in haemodialysis patients - 
hyperlipidaemia, anaemia, and hypercalcemia/hyperparathyroidism.305 321 322 There was 
achievement of optimal serum calcium, parathyroid hormone, haemoglobin and cholesterol 
level etc. The cost avoidance after the implementation of program was significant. 
 
Pharmacist intervention-optimisation of drug therapy  
There were 39 studies that aimed to optimise the drug therapy in patients with CKD. 
There were two approaches to optimise the drug therapy a) pharmacist conducting medication 
reviews, drug therapy monitoring and adjustment and b) use of a decision support system.  
Pharmacists were primarily involved in identification, prevention and resolution of DRPs and 
drug therapy monitoring and adjustment.151 152 220 227 306 323 Other significant pharmaceutical 
activities conducted by the pharmacist included- participation in ward rounds324, oral and 
written consultations with physicians324, preparing erythropoietin unit dosage from multi dose 
vial in pharmacy297, assessing the need for adjuvant iron therapy293 298 324, patient education and 
counselling302 324, routine laboratory assessment298 316, patient adherence promotion316, and 
dose modifications for iron preparations.325  
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Five studies described the use of a computerised decision support system (CDSS) for 
optimising drug dose in patients with impaired renal function.135 308 326-328 This system assisted 
the drug dosing relative to the kidney function of patients. Chertow et al135 found an increase 
in rates of appropriate dose by 13% and appropriate drug frequency by 24%, and a decrease in 
the length of stay as result of merging CDSS with a computer order entry system and the 
patient’s electronic record. Three studies investigated the use of a decision support that alerts 
prescribers to the need of dose adjustment in patients with CKD.308 326 328 These studies 
demonstrated significant reductions in rate of excessive administration of drugs and fewer 
medications error in test groups compared to the usual care group (33% vs. 49%) after the use 
of the decision support system.
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Reference 
Author 
Year 
Country 
Patient 
characteristics 
N(C/T) 
Age (Years) 
 Mean (SD) 
Study 
design/ 
  Settings 
 
Aim Duration 
(months) 
Intervention Key 
measurement 
Result/Effect of intervention 
Castelino 
(2011)  
India 
 
308 (HD&PD) 
NM 
Prospective 
uncontrolled 
Ambulatory 
and  
Inpatients 
Evaluation of DRPs and 
determining the role of 
clinical pharmacists in 
preventing DRPs in renally 
compromised patients 
 
9 
-Medication review 
(DRPs identification and 
prevention) 
-Therapeutic 
recommendations 
-PhR 
acceptance  
-PhR accepted in 97% of cases 
which resulted in change in 
therapy in 83% of the cases. 
Hassan  
(2009)  
Malaysia 
163 /154 CKD   
55.56 (14.15) 
55.30 (14.37) 
Prospective  
HC 
Ambulatory 
 
Assessment of the impact of 
dose adjustment service by 
pharmacist in patients with 
CKD 
8 -Dose monitoring and 
adjustment 
 
-Physician 
adherence 
-No. of ADRs 
-Cost savings 
-PhR 
acceptance rate 
 
-Reduction in 
 Physician’s 
nonadherence with 
dosing guidelines by 
27.5%  
 Number of ADRs (73 
events reduced to 49 
events) 
-Cost savings of $2250 US 
-54.6% PhR accepted  
 
Kaplan  
(1994)  
USA 
30 HD 
40.5 
Prospective 
uncontrolled 
Ambulatory  
Evaluation of the impact of a 
medication review program 
in patients with ESRD on HD 
2 -Dose monitoring and 
adjustment  
-PhR 
acceptance  
-76% PhR accepted 
-70% of PhR implemented 
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(DRPs reported to 
prescribers) 
Pai   
(2009)  
USA 
 
104 HD (57/47) 
56.3 (15)/ 
60.5 (14.7) 
Randomised 
controlled/ 
Ambulatory 
 
Evaluation of effect of 
pharmacist intervention on 
drug use, drug cost, 
hospitalization rates and 
DRPS 
24 
 
 
-Dose 
monitoring/adjustment 
Rate of 
hospitalisation  
-Reduction in hospitalisation 
[mean(SD) 1.8 (2.4) in test Vs 
3.1(3.0)  control] 
Chisholm 
(2007)  
USA 
36 TP 
52.78(13.37) 
Prospective 
uncontrolled  
Ambulatory 
Evaluation of effects of a 
medication assistance 
program with medication 
therapy management on the 
clinical outcomes and 
HRQOL of renal transplants 
recipients 
24 -Medication review 
(DRPs identification and 
prevention) 
-Therapeutic 
recommendations 
 
- FBG 
-HbA1C 
-Triglycerides 
-BP 
-HRQOL 
-Number of 
graft rejections 
-Reduction in FBG, HbA1C, 
LDL, cholesterol, 
triglycerides, BP and no. of 
graft rejections 
-Increase in no. of patients 
reaching target serum 
cyclosporine levels. 
-Increase in  HQOL 
Castro  
(2010)  
USA 
60 (58HD,2PD) 
NM 
Prospective 
uncontrolled 
Ambulatory 
Assessment of outcomes of 
implementing a medication 
therapy management service 
for dialysis patients 
6 -Medication review 
(MTM program) 
-SBP 
-HB 
-P 
-Ca-P 
 
-MTM group had 
improvement in level of   
 SBP from 150±22 to 
144±18/ mm Hg 
 HbA1c from 9.2±1.6 
to 9.0±2 
 P from 6.2 to 5.6 
mg/dl 
155 
 
 
 Ca-P from 56±19 to 
50±16 
-Non-MTM group had no 
improvement in all the above 
clinical parameters 
Chisholm 
 (1998)  
USA 
NM TP Prospective 
uncontrolled 
Transplant 
clinic 
Evaluation of pharmaceutical 
activities provided by a 
clinical pharmacist in a renal 
transplant clinical settings 
8 -Therapeutic 
recommendations 
PhR acceptance 
rate 
-95.6% PhR accepted  
-67.9% of PhR had a 
significant and 29.3% had a 
very significant (29.3%) 
impact on patient care. 
Chisholm  
(2000)  
USA 
201 TP 
NM 
Prospective 
uncontrolled 
Ambulatory 
Evaluation of impact of the 
pharmacist's interventions on 
patient care and physicians' 
prescribing decisions 
18 -Medication review 
(DRPs identification and 
prevention) 
-Therapeutic 
recommendations 
-PhR 
acceptance rate 
-Out of 844 PhR made for 201 
patients, 96% were accepted. 
Chisholm  
(2000)  
USA 
61 TP 
NM 
Prospective 
uncontrolled 
Ambulatory 
To assess drug cost savings 
resulting from a clinical 
pharmacist-managed 
medication assistance 
program for renal transplant 
patients designed to assists 
patients to procure 
immunosuppressant from 
12 -Patients who were 
unable to purchase their 
immunosuppressant were 
enrolled in 
manufacturer’s 
medication assistance 
programs. 
 -For each dollar spent in 
pharmacist's time, a minimum 
of $4 was returned to the 
institution. 
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pharmaceutical 
manufacturers. 
Gonyeau 
(2005)  
USA 
292 CKD 
79 (NM) 
Prospective  
uncontrolled 
Inpatients 
Assessment of impact and 
acceptance of pharmacy 
interventions on appropriate 
dosing 
6 week -Dose monitoring and 
adjustment 
-Dosing 
appropriateness 
-PhR 
acceptance rate 
-Prevention of 
ADR and errors 
-Cost savings 
-15% increase in appropriate 
renal drug dosing (66.5% to 
81.2% P<0.0001), 
-38% of interventions 
accepted. 
-5 ADR and 3 medication 
errors prevented 
-Cost savings of $29,166 
Moretti  
(2006)  
USA 
242 CKD 
NM 
 
Randomised 
controlled 
Ambulatory 
Determination of the impact 
of ambulatory clinic 
pharmacist on EPO treatment 
goals  
2 -Recommendations on 
 Obtaining more 
recent labs tests 
 Need for iron 
supplementation 
-Dose monitoring and 
adjustment (EPO) 
-PhR 
acceptance rate 
-75% of PhR were accepted. 
 
Nichols  
(2001)  
USA 
NM dialysis 
NM 
Prospective 
uncontrolled 
Inpatients 
Assessment of pharmacy 
based EPO dose management 
protocol for a dialysis unit  
8 -Dose monitoring and 
adjustment  
 EPO dose 
determined by 
monthly HCT 
level 
-HCT level 
-Cost savings 
-Improved HCT level after 
intervention (24% of patients 
had HCT<30 in baseline VS. 
5% of patients had HCT<30 in 
endline) 
-Drug cost savings of $374,000 
annually (Drug cost reduced 
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 Syringes 
prepared in 
pharmacy from 
multi-dose vials 
from $50 per patient per 
treatment to $30) 
 
Pardo 
(2002)  
Spain 
215 CKD 
NM 
Prospective 
uncontrolled 
Inpatients 
Assessment of impact of 
pharmaceutical interventions 
on elderly patients with a low 
creatinine clearance 
3 -Dose monitoring and 
adjustment 
-Cost saving -Saving of $384.53 over a 
three-month period. 
Tanprayoo
n 
(2009)  
USA 
 
80/80 CKD 
 
66.7 (13.4) 
65.4 (15.6 ) 
Prospective 
historical 
control 
Inpatients 
Evaluation of the impact of a 
pharmacist-driven EPO 
monitoring program 
 -Dose monitoring and 
adjustment 
(appropriateness of EPO 
dose regimen  
-Need for adjuvant iron 
therapy assessed 
-Correct 
indication 
-Correct dosage 
regimen 
-Intervention group compared 
to control had more 
appropriateness in 
 Indications (64 vs. 70 
patients)  
 Dosing regimen in 
intervention than 
control group (65 vs. 
70 patients) 
 Iron replacement and 
laboratory studies (61 
vs. 76 patients) 
-35 out of the 60 interventions 
were accepted. 
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Grabe 
(1997)  
USA 
45 HD 
52(16) 
Retrospective 
uncontrolled 
Ambulatory 
Evaluation of DRPs and 
impact of clinical pharmacist 
interventions in HD patients 
1 -Medication review 
-Drug monitoring and 
adjustment 
-Therapeutic 
recommendations 
-PhR 
acceptance rate 
-81% PhR accepted. 
-6.9% PhR had no significance  
-78% PhR were significant 
-4.9% PhR were very 
significant 
-1% were extremely 
significant 
Ohnishi 
(2011)  
Japan 
84 HD 
NM 
Retrospective 
uncontrolled 
Ambulatory 
Assessment of pharmacist-
implemented management 
program to ensure 
appropriate use of 
erythropoietin-stimulating 
agents 
12 -Drug monitoring and 
adjustment 
-Therapeutic 
recommendations  
( changes in the dose of 
erythropoietin and 
administration of iron 
preparations) 
-Hb level -Optimal Hb levels achieved in 
patients with low Hb level 
(<10 g/dl).  
-Reduction in Hb level in 
patients with higher Hb 
level(>12 g/dl) 
Tang  
(1993)  
USA 
50 HD 
NM 
Retrospective 
uncontrolled 
Ambulatory 
Assessment of role of a 
clinical pharmacist in care of 
patients receiving chronic 
HD 
6 week -Therapeutic 
recommendation on 
drug selection, drug 
discontinuation, dose 
selection, therapeutic 
monitoring 
-Positive 
outcomes 
-90.5% intervention resulted in 
positive patient outcome 
-7.9% intervention 
resulted in no observable 
change or had no effect on 
outcome 
-1.5% interventions showed 
negative outcomes 
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Pai  
(2009)  
USA 
107 HD (46/61) 
55.8 (15.1) 
60 (15) 
Randomized 
controlled 
Ambulatory 
Evaluation of the effect of 
pharmaceutical care on 
HRQOL in HD patients. 
2 Medication review 
 
-RQLP 
questionnaire 
 HRQOL did not worsen in 
pharmacist intervention group 
and it was maintained as such 
for an additional year. 
Soler  
(1996)  
Spain 
22 HD (BL) 
29 HD (1991) 
38 HD (1994) 
40 HD (1995) 
NM 
Prospective  
Uncontrolled 
Ambulatory 
Evaluation of clinical and 
economic benefits of 
collaboration between 
hospital pharmacy services 
and dialysis centre to control 
the use of epoetin 
48 Implementation of a 
standard protocol for 
dispensing and utilisation 
of epoetin 
-HCT level 
-Hb level 
-Elevation in HCT, Hb and 
ferritin level 
-Reduction in levels of iron and 
transferrin saturation. 
Alvarez 
(2009)  
Spain 
185 (88/97) 
CKD, drugs 
with renal risk 
Prospective 
uncontrolled 
Inpatients 
Comparison of adherence of  
prescriptions according to the 
dosage guide before and after 
applying pharmacist 
intervention programme 
2 -Drug monitoring and 
adjustment 
-Adherence  
-Cost saving 
-Reduction in non-adherence 
after intervention (18.7% vs 
2.1%) 
-Significant cost saving due to 
intervention 
Golightly 
(1993)  
USA 
627 CKD 
NR 
Retrospective 
Uncontrolled 
Inpatients 
Assessment of effectiveness 
of a program for monitoring 
drug prescriptions in renal 
patients 
 -Medication reviews 
-Drug monitoring and 
adjustment 
-Assessment of creatinine 
function 
-Recommendation to 
physician 
-Change in drug 
therapy 
-233 changes in drug therapy 
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Patel 
(2005) 
USA 
119 CKD Prospective 
uncontrolled 
Ambulatory 
Evaluate opportunities for 
pharmacists to work 
collaboratively with 
physicians to improve 
medication use and CKD 
patient outcomes. 
NM -Review of medical 
records, 
-evaluations of DRPs, 
-therapeutic 
recommendations 
-PhR 
acceptance
  
-40.9% of the 
recommendations were 
accepted. 
Possidente 
(1999) 
USA  
 
  
31 HD, 6 PD Retrospective 
uncontrolled 
Inpatients 
To evaluate the continuity of 
drug therapy and the 
incidence of drug-related 
problems (DRPs) in long-
term dialysis patients who 
required hospitalization  
14 weeks -Medication review 
-DRPs identified 
-Recommendation to 
physician 
-PhR 
acceptance  
-Physicians accepted 154 of 
the 161 recommendations.  
-Clinical significance of the 
accepted recommendations 
was: somewhat significant, 
24.7%; significant, 58.4%; 
very significant, 16.9%. 
Chertow 
(2001) 
USA 
17,828 CKD 
(7887/9941) 
52.5 (18.4) 
52.5 (18.3) 
Prospective 
randomised 
controlled 
Inpatients 
Determining the effect of a 
system application (merged 
with COE) for adjusting dose 
in patients with renal 
insufficiency in drug 
prescribing and patient 
outcomes. 
8 -CDSS(default dose, 
frequency, 
recommendations 
displayed to the order-
entry user) 
Rates of 
appropriate 
prescription  
-Hospital and 
pharmacy costs 
-Dose appropriateness was 
67% in test vs. 54% in control  
-Mean length of hospital stay 
was 4.3 (4.5) days in test vs. 
4.5 (4.8) in control 
-No significant differences in 
estimated hospital and 
pharmacy costs. 
Nash  
(2005)  
USA 
NM CKD 
NM 
Prospective 
uncontrolled 
Inpatients 
Determining the impact of 
MSRS in addition CPOE to 
by detecting the 
NM MSRS (dose 
recommendation based on 
renal function) 
-Rate of over 
dosing 
-Decreased rate of over dosing 
of medications requiring 
adjustment 
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administration of excessive 
doses of medication in 
patients with CKD 
-Proportion of 
medication 
errors 
23.2% to 16.8% 
Bhardwaja  
(2011) 
USA 
32,917 
(3025/3100) 
CKD 
Randomized 
controlled 
Community 
To determine whether a 
computerized DRAP 
program could decrease the 
rate of medication errors in 
drug selection or dosing in 
patients with renal 
insufficiency 
15 -DRAP 
(alert pharmacists at the 
time of dispensing to 
possible errors in  drug 
selection and dosing ) 
 
-Proportion of 
medication 
errors 
- Proportion of medication 
errors was significantly lower 
in the intervention group than 
the control (33% vs 49%, 
P<0.001). 
Weinhandl 
(2013) 
USA 
Find full 
text 
51877 (43,013 
/8,864) HD 
NM 
Prospective 
Controlled 
Ambulatory 
To determine outcomes of 
integrated pharmacy 
program for haemodialysis 
patients  
 -Medication review 
-telephonic medication 
therapy management,  
-Rates of death 
and 
hospitalization. 
-Lower rates of death and 
hospitalization  
Wang  
(2008)  
Taiwan  
37 transplant 
NM 
Prospective 
uncontrolled 
Inpatients 
To investigate effects of 
clinical pharmacist joining 
transplant clinic to provide 
pharmaceutical care on 
treatment outcomes  
15 
 
 
-Medication review 
-Therapeutic 
recommendations 
 
PhR acceptance 
rate 
-More than ninety percentages 
of PhR were accepted 
-94.2% of the patients showed 
improved disease conditions in 
which the PhR was accepted. 
Via-Sosa 
(2013) 
Spain 
 
350 (176/174) 
CKD  
83.1(7.21) 
Prospective 
controlled 
Community 
To evaluate the effectiveness 
of the community 
pharmacist's intervention in 
improving dosing 
7 -Dosing review for drugs 
requiring adjustment 
-Recommendation to the 
physician 
-Prevalence of  
DRPs  
-Difference in the dosing 
inadequacy and mean drug-
related problems between the 
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inadequacy in elderly 
patients  
control and intervention group 
was increased after the 
intervention. (P < 0.001)  
 
Barnes 
(2014) 
USA 
146 CKD 
71.6 (12.2) 
Prospective  
Uncontrolled 
Ambulatory 
To evaluate pharmacist-
driven renal medication 
dosing intervention  
12 -Medication review 
-ensure all medications 
are prescribed correctly 
based on renal function 
-Provide recommendation 
to physician 
 
-Rate of use of 
aspirin, ACE-
Is/ARBs 
-PhR 
acceptance rate 
-Use of ACE-Is/ARBs and 
aspirin increased to 77% and 
82% from 73% and 72% 
respectively.  
- 65.2% recommendations 
were accepted by the 
physicians. 
Ribed 
(2013) 
Spain 
449 CKD 
NM 
Prospective 
uncontrolled 
Inpatient 
To evaluate a program 
implementing a dose 
adjustment alert system 
according to the patient's 
renal function. 
2 -Dosing and adjustment 
--Provide 
recommendation to 
physician 
-Rate of use of 
aspirin, ACE-
Is/ARBs 
-PhR 
acceptance rate 
- Recommendation acceptance 
rate of 70%. 
Joost 
(2014) 
Germany 
67 (35/32) TP 
54 (11.9) 
 51 (13.3) 
Prospective 
controlled  
Inpatient 
To investigate the impact of a 
pharmaceutical care 
programme on daily drug 
adherence during the first 
year after renal 
transplantation. 
24 -Medication review 
-counselling sessions  
(immunosuppressive 
drug therapy  
the mechanisms of 
transplant rejection,  
drug actions and dosing 
drug–drug interaction 
 -Drug 
adherence 
-Changes in 
HRQoL 
-Drug adherence improved 
significantly after the 
intervention (P = 0.014)  
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adverse effects  
written information 
material.  
adherence support,  
Jiang 
(2013) 
China 
NM 
CKD 
Prospective 
uncontrolled 
Inpatients 
To evaluate the effects of 
dosing adjustments 
performed by pharmacists on 
the length of intensive care 
unit (ICU) stay, ICU cost, 
and antimicrobial adverse 
drug events (ADEs). 
 -Drug dosing and 
adjustments 
-Length of 
intensive care 
unit (ICU) stay, 
-ICU cost  
-Antimicrobial 
adverse drug 
events (ADEs 
-Reduced length of ICU stay 
from 10.7 +/- 11.1 days to 7.7 
+/- 8.3 days (p = 0.037)  
-Cost savings of $3525 per 
septic patient  
-Decrease in ADE (P = 0.048). 
 
Jiang 
(2014) 
China 
103/106 
Dialysis 
61.3 (16.9) 58.9 
(17.3) 
Prospective 
uncontrolled  
Inpatient 
 
To examine the effectiveness 
of pharmacist dosing 
adjustment for critically ill 
patients receiving continuous 
renal replacement therapy 
(CRRT) 
12 -Dosage adjustment  
 
-PhR 
acceptance rate 
cost savings 
-90.98% of the 
recommendations were 
accepted by the physicians 
-Cost saving of US$2,345.98 
cost savings per critically ill 
patient receiving CRRT 
-Decline in adverse drug 
events (P<0.001).  
Gracia 
(2013) 
Spain 
No full text 
47 CKD 
79.2 (7.9) 
Prospective 
uncontrolled 
Inpatient 
Evaluate the outcomes of a 
pharmacist intervention for 
drug dosage adjustment of 
renal risk in patients with 
chronic kidney disease 
7 -Medication review 
Therapeutic 
recommendation 
-PhR 
acceptance 
81.5 % of interventions were 
accepted 
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(CKD) during their 
admission in a short stay unit 
(SSU). 
Diaz 
(2013) 
Spain 
171 CKD 
76.4 
Prospective 
uncontrolled 
Inpatient 
-Implementation of a 
computer-based, semi-
automated system to 
optimise the drug prescribing 
in patients with renal 
impairment  
 
3 -A system for drug dosage 
adjustment integrated into 
the Hospital computer 
provider order entry 
system. 
-Frequency of 
appropriate 
prescription and 
accepted 
recommendatio
ns 
-Increase in appropriate 
prescribing from 65% to 86% 
after intervention. (P=0.001).  
-60% of the recommendations 
were accepted. 
Borolossy 
(2014) 
Germany 
50 (25/25) HD  
11.5 (0.6)   
10.8 (0.64) 
Prospective 
Randomised 
controlled 
Ambulatory 
To evaluate the impact of 
interventions by the clinical 
pharmacist on the clinical 
outcome of children 
undergoing haemodialysis 
9 -Medication review 
-Start or discontinue a 
drug; increase 
or decrease a dose;  
-Patient education 
(disease, drug therapy) 
-Promote patients’ 
adherence 
-Serum levels of 
calcium (Ca), 
phosphorus (P), 
parathyroid 
hormone 
-Health-related 
quality of life  
 
Test group in comparison to 
controlled group showed a 
significant decline in 
-Systolic and diastolic blood 
pressure (P=0.0001),  
-Serum phosphorus level 
(P=0.006) and  
-Parathyroid hormone level 
(P=0.001)  
-Serum Ca*P product level of 
the test group (P=0.001) 
-Satisfaction with the renal 
treatment significantly 
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improved in the test group 
(P=0.0001)  
Cabello-
Muriel  
(2014) 
Spain 
249 (124/125) 
CKD 
81.2 (8.5) 
 82.4 (7.4) 
Prospective 
controlled 
Inpatient 
-To evaluate the 
effectiveness of a 
pharmacist-physician 
intervention program in 
managing patients with CKD  
6 -Medication review 
-Inform the physician 
about potentially 
nephrotoxic drugs 
-Alert the physician about 
the drugs requiring 
dosage adjustment 
-Propose a recommended 
dose adjustment. 
-GFR on 
admission and 
at discharge 
-Intervention lowered the 
percentage of potentially 
nephrotoxic drugs unadjusted 
to renal function from 26.7% 
(88 of 329) to 6.9% (23 of 
329). 
-Clinical impact of this 
improvement could not be 
analysed due to shorter study 
period. 
PD: Peritoneal dialysis PhR: Pharmacist recommendations, HC: Historical control, CrCl: Creatinine clearance, HRQOL: Health related quality of life, ADR: Adverse 
drug reactions, TRPs: Treatment related problems, RQLP: renal quality of life profile, P:Phosphate, Ca P:Calcium-phosphate, MTM: Medication therapy 
management, CDSS: Computerised decision Support System, COE : Computerized order entry , DRAP: Drug renal alert pharmacy, MSRS: Medication safety 
reporting system, MPE: Medication prescribing error, ACE-Is: Angiotensin-converting enzyme inhibitors, ARBs: Angiotensin II receptor blockers 
Table 8.2 Intervention focused on optimising drug therapy in CKD 
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Pharmacist intervention- Educational activities  
The most common educational intervention was providing verbal instructions to 
patients, which included counselling regarding disease, drugs, and lifestyle modifications, use 
of medication, management of complications and comorbidities and the importance of regular 
dialysis.150 244 329-332 Written educational materials or books were given to patients on request.329 
331 Pharmacists provided unstructured counselling, lasting for fifteen minutes on each 
alternating visits and this was successful in improving health related quality of life for 
haemodialysis patients. Quality of life was determined by the generic instrument World Health 
Organisation quality of life questionnaire which comprised of 26 items, that measures four 
domains: physical, psychological, social and environmental. Clinical pharmacists provided 
counselling, solely focused on medication, and this lead to significant improvement in patients’ 
medication knowledge and adherence.329 A cross over randomised trial332 conducted to 
evaluate the impact of educational interventions on medication knowledge in haemodialysis 
patients reported an increase in the knowledge level of patients after intervention. The 
pharmacist intervention comprised of a structured face-to-face interview session of 25-30 
minutes to assess the medication knowledge of the enrolled patients followed by appropriate 
counselling. The test group showed significant improvement in medication knowledge at week 
sixteen of the study. Chisholm et al333 addressed the impact of a clinical pharmacist service on 
transplant patients in terms of adherence with immunosuppressant agents. Adherence 
enhancement strategies were implemented in the intervention group where a pharmacist 
counselled patients regarding the drug therapy and the correct method for taking medications. 
The control group was exposed to routine clinical services only. Adherence rate in the 
intervention group was statistically higher than for the control group (p<0.001). Further, the 
test group had a longer duration of adherence than the patients in the control group (p<0.05)
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Reference 
Author 
Year 
Country 
Patient 
characteristics 
N(C/T) 
Age (Years) 
Mean (SD) 
Study design/ 
Settings 
 
Aim Duration 
(months) 
Intervention Key measurement Result 
Thomas  
(2009) 
India 
56 (28/28) HD 
47.5 
50.2 
Non-
Randomised 
controlled 
Ambulatory 
To assess the impact of patient 
counselling on HRQOL of HD 
patients 
6 -Patient education and 
training on diet , life 
style modification, 
medication and disease 
HRQOL Health related quality of life in 
test group showed a consistent 
improvement of 2% in six 
months 
Sathvik 
(2007) 
India 
90 (45/45) HD 
50.69 (13.69) 
47.29 (17.78) 
 
Crossover 
randomised  
Inpatients 
Evaluation of impact of 
pharmacist educational 
program on medication 
knowledge of the patients 
4 -Patient education and 
training 
MKAQ Improvement in MKAQ scores 
after intervention 
Chisholm 
(2001) 
USA 
24 (12/12) TP 
49.2 (10.2) 
Randomised 
controlled  
Ambulatory 
Assessment of impact of 
clinical pharmacy services on 
renal TP patients' adherence 
with immunosuppressive 
medications 
24 -Patient education and 
training 
-Drug therapy 
monitoring 
-Medication review 
Adherence rate Intervention group had higher 
mean CR, longer duration of 
adherence, faster achievement of 
target level of adherence 
Abraham 
(2012) 
India 
81 (46/35) HD 
48.2 (12.6) 
50.7 (12.1) 
Prospective 
controlled 
Ambulatory 
Estimation of effect of patient 
counselling in quality of life of 
ESRD patients  
12 -Patient counselling on 
disease, diet, exercise, 
lifestyle modification, 
use of medication and the 
World Health 
Organisation Quality 
of life scale 
-Improvement in physical 
psychological, environment and   
social domain (P<0.001) 
-Improvement in quality of life 
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importance of regular 
dialysis 
-Verbal and written 
materials provided 
-Delayed progression of renal 
failure 
Aburuz 
(2013) 
Jordan 
130 CKD  
56.3 (17.8) 
Prospective  
uncontrolled 
Inpatients 
To implement and evaluate the 
impact of pharmaceutical care 
service for hospitalised 
patients with CKD 
3 -Patient education on 
diet, smoking cessation 
and management of 
comorbidities and 
complications 
-Provide 
recommendation to 
physician 
-Nature and 
prevalence of TRPs 
-Clinical significance 
of TRPs 
-PhR acceptance rate 
 
-86% PhR accepted  
-17%TRPs resolved 
-5.5 % TRPs improved 
-37.4 % TRPs prevented  
-Better management of 
comorbidities 
Bayliss 
2011 
USA 
 
1769/233 
CKD 
68.29 (12.29) 
67.62 (11.28) 
Historical 
control 
Community 
To determine if 
multidisciplinary team (MDT) 
care slows the rate of 
decline in renal function 
4 yrs -Patient education on 
disease, medication, 
management of 
comorbidity and 
complications, diet. 
-Medication 
reconciliation  
-Nephrology consultation 
including medical 
recommendations for  
comorbidities and 
complications  
-Decline in GFR level 
-Values of LDL, 
HbA1c, and BP 
-Decline in mean GFR value in 
usual vs MDT group: 1.2 mL/min 
vs 2.5 mL/min (P< 0.0001) 
-Fewer chronic conditions in 
MDT patients 
-No differences in the BP, HbA1c, 
or LDL value. 
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Bertsche 
(2009) 
Germany 
 
 
68 CKD 
65.3 (13.8) 
 
Prospective 
Uncontrolled 
Inpatient 
To assess the effect of drug 
information counselling for 
clinicians on the 
appropriateness in drugs 
requiring dose adjustment in 
intensive-care patients 
3 -Calculate renal function 
-Determine the 
appropriate dose based on 
renal function 
-Provide 
recommendation to 
physician whenever drug 
adjustment is required 
-Prevalence of 
overdosed drugs 
before and after the 
intervention 
-Extent of overdose was reduced 
from 54% before to 31% after the 
intervention (P<0. 001). 
Rani 
(2013) 
India 
85 HD 
50.52 (13.28) 
 
Prospective 
uncontrolled 
Ambulatory 
To assess the effect of patient 
counselling in improving their 
medication knowledge and 
adherence 
3 -Patient counselling 
(disease, dialysis 
procedure, the drugs, diet 
and fluid restrictions) 
-Information leaflets  
-MKAQ (Medication 
knowledge 
assessment 
questionnaire) score 
-Brief Medication 
questionnaire (BMQ) 
-Significant increase in the 
medication knowledge from 
baseline (P= 0.000). 
-Significant increase in mean 
BMQ score indicating improved 
adherence (P=0.000). 
HD: Haemodialysis, HRQOL : Health related quality of life, MKAQ : Medication Knowledge Assessment Questionnaires, CP: Adherence rate, TP: Transplant patients, ESDR: End 
Stage Renal Disease 
Table 8.3 Intervention focused on patient education and training
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8.4.3 Outcomes of pharmacist intervention 
The outcomes that can be most influenced by pharmacists’ interventions are the 
clinical/physiological, humanistic, drug-related and economic outcomes. 
Clinical/physiological outcomes 
The protocol driven administration of erythropoietin managed by pharmacists resulted 
in a faster achievement of target haemoglobin level with use of lesser dose of erythropoietin.312 
Implementation of an anaemia management protocol along with epoetin and iron therapy dose 
monitoring/ adjustment resulted in significant elevation in haemoglobin and transferrin 
saturation value and an increase in the number of patients with target haemoglobin level.214 295 
299 303 307 311-314 A pharmacist-run anaemia education program providing medical therapeutic 
information to the patients along with information on using an administration device for self-
injection of epoietin resulted in improved patient adherence with an optimal haemoglobin level 
within two months.309 Similarly, pharmacist-provided patient education and training on 
medication along with implementation of serum phosphate management protocol lead to 
reduction in serum phosphate level.210 Drug use evaluation, providing drug information and 
therapeutic recommendations to the physician on renal anaemia in ESRD resulted in an 
increased trend of mean haematocrit in patients.310 Dose monitoring and adjustment for 
darbopoietin resulted in an increase in the number of patients exhibiting a haemoglobin target 
range.225 304 Conversion of erythropoietin administration from the intravenous to the 
subcutaneous route lead to improvement in the level of haematocrit.292 Preparation of IV 
calcitriol by the pharmacist for each patient on a daily basis led to a significant decrease in the 
number of patients with moderate to severe hyperparathyroidism.319 Clinical pharmacy 
services that included a pharmacist performing medication reviews with an emphasis on 
preventing or resolving medication-related problems and implementing adherence-enhancing 
activities, produced a significant decrease in systolic and diastolic blood pressure, along with 
an increase in the number of patients reaching target levels for blood pressure.317 318  
Pharmaceutical care services, which included ongoing medication review and 
providing appropriate pharmacotherapy recommendations, reinforcing patient adherence, and 
suggesting use of renin-angiotensin system inhibitors, had a positive impact on patients' blood 
glucose control along with an increase in the number of patients at target goals for blood 
pressure, glycosylated haemoglobin and cholesterol levels.301 316 The dyslipidaemia control 
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program consisting of ordering/assessment of lab tests, dose optimisation and providing 
recommendation to physicians resulted in reduction in total cholesterol level [mean (SD) 80(3) 
vs 96(5) mg/dl] along with increase in patients reaching target levels for low density 
lipoprotein.294 315 
Comprehensive clinical pharmacy services that included dose monitoring and 
adjustment, education and training on disease and medications, drug use evaluation to manage 
the multiple complications in haemodialysis patients also resulted in optimal serum calcium, 
parathyroid hormone, haemoglobin, cholesterol level etc.305 321 322 and  delayed progression of 
renal failure.334 Pharmacist intervention comprising of medication review and drug dose 
adjustment was effective in reducing the duration and rate of all causes for hospitalisation.220 
335   
An integrated pharmacy program for haemodialysis patients that included telephonic 
medication therapy management was associated with lower rates of death and 
hospitalization.327  There were fewer all cause hospitalisations [1.8(2.4) vs. 3.1(3.0)] and 
shorter hospitalized times (9.7 +/- 1.4.7 vs. 15.5 +/- 16.3 days) in the pharmaceutical care group 
compared with the standard care group in a randomised controlled study.220 The effort of 
pharmacists in optimising the dose for haemodialysis and transplant patients led to a significant 
reduction in occurrence of ADR and medication errors.119 300 
 
Humanistic outcomes 
Pharmacists conducted counselling on diet, life style modification, medication and 
disease for haemodialysis patients resulted in improvement in health related quality of life 
measured using the World Health Organisation Quality of life scale.334 Pharmacist mediated 
medication review and therapeutic recommendation lead to an increase in quality of life.219 
Implementation of adherence enhancement strategies like counselling transplant 
patients regarding drug therapy and the proper ways to take medication resulted in 
improvement in adherence rate.333 Furthermore, pharmacist dose monitoring and adjustment 
showed reduction in non-adherence. Counselling sessions focusing on immunosuppressive 
drugs, the mechanisms of transplant rejection, drug actions and dosing drug–drug interaction 
adverse effects and providing written information material and adherence support lead to an 
increase in adherence with medications.165 Similarly, in a study with a historical control group, 
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there was reduction in physician’s non-adherence with dosing guidelines by 27.5% after the 
pharmacists started monitoring patients drug therapy.119 Educational interventions comprising 
of a structured face-to-face interview session of 25-30 minutes to assess the medication 
knowledge of enrolled patients followed by appropriate counselling resulted in an increase in 
the knowledge level of patients.332 
Pharmacists provided therapeutic recommendations to the physicians in more than 50% 
of the trials. However, none of the studies had the complete (100%) acceptance of the 
recommendations. More than 90% of the therapeutic recommendations provided by the 
pharmacist were accepted by the physicians in eight studies.151 152 306 324 336 337 Nine studies had  
acceptance between 50-90%.119 293 298 323 328 338-341 Two studies had an acceptance rate of less 
than 50%.227 300 Physician acceptance of pharmacist recommendations resulted in changes to 
therapy in two studies.152 342 Few studies classified the impact of recommendations as-‘non-
significant, significant, very significant and extremely significant’ and greater than 50% of the 
recommendations were significant in all studies.151 324 341 In the patients group in which the 
physician accepted the pharmacist’s recommendations, patients showed improved disease 
conditions.324 337 
 
Drug-related outcomes 
The renal dosing service provided by the pharmacists led to an increase in appropriate 
dosing and a reduction in physician’s nonadherence with dosing guidelines and drug-related 
problems.119 293 300 342 343  In a prospective uncontrolled study with hospitalised patients with 
CKD, there was a 15% increase in appropriate renal drug dosing from 66.5% to 81.2% after 
pharmacist intervention.300 Dosing adjustments performed by pharmacists in critically ill 
patients lead to a decrease in adverse drug events.335 336 Use of decision support systems for 
adjusting the dose in patients with renal insufficiency resulted in an increase in dose 
appropriateness and a decreased rate of overdosing.135 308 326 340 The average weekly dose of 
erythropoietin was reduced after the route of administration was changed from intravenous to 
subcutaneous.292 Further, there was improvement in dosing of erythropoietin and iron.  
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Economic outcomes 
The implementation of pharmaceutical care programs for patients with CKD resulted 
in positive economic outcomes. A clinical pharmacist-managed medication assistance program 
in a renal transplant clinic produced substantial cost savings over this one-year study period. 
For each dollar spent in the pharmacist's time, a minimum of US $4 was returned to the 
institution.344 The drug cost reduced from US $50 per patients per treatment to US $30 after 
the pharmacists were involved in determining the erythropoietin based on monthly haematocrit 
levels.297 Pardo et al showed the savings of US $384.5 over a three-month period after 
pharmacists started monitoring the drug dose for elderly patients with renal impairment.296 Cost 
savings of US $2250 was observed within 8 months of implementation of dose adjustment 
programs in a prospective observational study.119 Similarly, there was cost savings of US 
$29,166 after a 6 week of implementation of a dose monitoring program for hospitalised 
patients with CKD.300 Drug dosing adjustments performed by pharmacists for intensive care 
unit patients lead to cost savings of US $3525 per septic patients.335 Drug dosing adjustments 
performed by pharmacists for critically ill patients receiving continuous renal replacement 
therapy resulted in cost savings of US $2345.98.336 The implementation of a erythropoietin 
management protocol led to reduction in erythropoietin dose per treatment, resulting in 
significant cost avoidance annually.307  
 
8.5 Discussion 
Overall, the pharmacist interventions appeared to have a positive effect on patient 
outcomes concerning physiological and biochemical parameters (blood glucose, lipid level, 
blood pressure, haemoglobin level etc.), incidence of adverse drug reactions, knowledge, 
satisfaction, adherence, quality of life in patients and the occurrence of drug-related problems. 
Most importantly, the pharmacist medication review appeared promising in decreasing the rate 
of over dosing of medications requiring adjustment. Drug use evaluation and monitoring was 
successful in reducing the usage of unnecessary drugs and improving physician adherence to 
dosing guidelines. Pharmacists management of comorbidities generally, but not always, had 
better outcomes in comparison to physician’s management. A total of 14 trials included data 
on the burden of costs to patients, none of which performed formal economic evaluations. All 
of the studies conducted a simple cost analysis, targeting the prescribing costs and yielded a 
significantly positive outcome. 
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Methodological Critique 
The primary concern regarding the methodology of the included studies would be the 
study design. The majority of the studies included in the analysis had an uncontrolled design. 
An uncontrolled design determines the relationship between the variables in the study but it 
restricts developing the casual relationship in general.345 The impact of pharmacist intervention 
can be measured only with the randomised controlled trials that reports clear descriptions of 
patient’s demographics and the intervention preformed. The lesser amount of randomised 
controlled trials performed creates limitations to the quantification of the results. Significant 
comparison could not be performed due to the diversity of the tools utilised in the studies. The 
average sample size in the studies was small therefore, the generalisation of the results to the 
greater population would not be convenient. The included studies lack full details regarding 
sample recruitment. Some studies did not report the sample size and one of the reasons for this 
might be attributed to the inclusion of the congress abstract in our reviews. Some studies lacked 
the date of data entry follow up time. It is recommended that outcomes that are clinically 
significant should be presented clearly and it is desired that the outcomes presentation be 
consistent with the economic, clinical, humanistic (ECHO) outcomes model to provide clear 
insight concerning the results.346 However, very few studies have followed this method.  
Two studies assessed medication knowledge of hemodialysis patients using a 
Medication Knowledge Assssment Questionnaire. In the first study, the administered 
questionnaire was developed and validated by the investigators332and the second study used 
the validated questionnaire from the first study.329 The content validity of the questionnaire 
was performed through a literature review, discussion among a panel of experts (nephrologist 
and clinical pharmacist), and a focus group discussion amongst patients. The questionnaire was 
pilot tested using a convenience sample of hemodialysis patients to assess reliability. 
Most of the interventions were carried out in hospital settings. Very few studies 
identified addressed patients with CKD in the community. Studies focusing on educational 
interventions identified by our search terms were conducted in haemodialysis patients. None 
of the studies tested patients with early stages of CKD. In fact, educational intervention is 
equally important for patients in this stage in order to prevent progression of CKD. Another 
weakness of the studies was that there was no clear definition of ‘usual care patients’ in the 
control groups. Most studies did not have a control group for comparison and there was no 
175 
 
 
baseline assessment of adherence which made it difficult to evaluate the effect of interventions. 
We could not perform a meta-analysis due to the heterogeneity of the studies. Quality control 
report of the literature review could not be presented, as the literature search and screening of 
the articles according to the inclusion criteria was carried out solely by the candidate.  
 
Findings in comparison with other studies 
The findings from this review are consistent with the results of similar studies.347-349 
However, the findings from our study are reinforced by the use of multiple databases, strict 
inclusion criteria and a comprehensive search strategy. Our search terms covered various 
descriptive studies that did not report the outcomes of intervention rather they reported the 
intervention process. We excluded such studies with the rationale that we cannot expect the 
intervention to always create positive results.350 
 
Conclusions and recommendations 
-Studies included in the review demonstrate that DRPs are very frequent and are 
increasing in patients with renal insufficiency. The most common DRPs found in the included 
studies were incorrect dose, adverse drug reactions, and inappropriate drug therapy. 
Cardiovascular drugs and anti-infective agents were the most common classes of medications 
causing DRPs. The decrease in DRPs frequency after pharmacist involvement reflects the need 
for the pharmacist to be involved in the treatment of CKD. Further, the high level of acceptance 
of pharmacists’ recommendations by physicians indicates the greater need for pharmacists to 
be involved in the care of renal insufficiency. 
-The included studies demonstrated that the pharmaceutical care implementation is 
related to tangible benefits on clinical, humanistic, economic and, drug-related outcomes in 
various stages of CKD, dialysis, transplant patients in different settings; ambulatory, transplant 
clinic, dialysis unit, community and hospital wards. Therefore, incorporation of pharmacist in 
the care of chronic kidney disease patients should be considered in health care policy decisions. 
-Patients with CKD, especially dialysis patients, have a very high economic burden 
related to the direct (hospital and drug cost) and indirect cost of treatment (abstinence from 
work) etc. The findings from the reviewed studies, demonstrates that providing pharmaceutical 
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care is a successful means for avoiding the costs associated with drug therapy, hospitalisation 
and DRPs etc. 
-CKD is believed to degrade the quality of life in patients. However, the awareness of 
the patients regarding diet and medication through counselling proved to be an effective means 
for increasing their quality of life. The counselling by pharmacists was more effective in 
improving the psychological domain and removing misconceptions about CKD. 
-The studies confirm that there is poor medication knowledge (name, indication and 
dosage regimen) on the part of the patients with CKD. The education provided by the clinical 
pharmacists resulted in considerable improvement to patient’s knowledge. There seems to be 
a need for the continued education of the patients so that they better understand the disease and 
the associated medications. A trained pharmacist could play a vital role in educating 
CKD/haemodialysis/transplant patients, which has obvious benefits for therapeutic outcomes. 
-Longer duration studies are required to evaluate the continuous clinical pharmacy 
activities. Appropriate care for patients with CKD must occur in the earliest stages, preferably 
before progression to more severe stages. Patients who received clinical pharmacy services in 
addition to routine clinical services had better adherence to treatment than patients who only 
received routine clinical services. The results of these trials suggests the need for a 
multidisciplinary team that includes a clinical pharmacist as a part of the care of patients with 
CKD. This is beneficial for achieving the desired therapeutic outcomes in patients with CKD. 
-This review supports the idea of incorporating a clinical pharmacist to improve 
therapeutic effectiveness, quality and safety of patient care. Implementing clinical pharmacy 
services for the care of patients with CKD can be tedious and difficult if the institution requires 
the provision of new resources. However, the advantage of pharmaceutical interventions as 
reported in the studies in this review is that most clinical pharmacy services leads to positive 
economic outcomes - a net hospital cost benefits/patients cost burden in terms of cost 
avoidance, reduced use and occurrence of ADRs.  
-However, more research is needed to better understand the role of the pharmacist in 
the community settings especially for the elderly with deteriorating renal function. Lastly, there 
is a need for multicentre, randomised controlled trials of a longer duration in larger populations 
to determine the benefits to the health care system for incorporating pharmaceutical care 
programs for patients with CKD. 
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-Most of the interventional studies are conducted in the USA and not a single 
interventional study was conducted in Australia. It would appear that there is a need for 
interventional studies in Australian settings.  
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Chapter 9 OVERALL DISCUSSION, FUTURE DIRECTIONS AND CONCLUSION  
CKD management guidelines are regularly disseminated by nephrology professional bodies 
and are designed to reduce the occurrence and progression of CKD, and to improve the quality 
of care. Despite the readily available evidence-based guidelines and standard drug information 
sources, there is suboptimal prescribing in patients with CKD. The need for dose adjustment 
in renal impairment often goes under-recognised, potentially leaving patients exposed to a 
higher risk of adverse drug effects. The five studies outlined in this thesis were conducted to 
quantify the extent of this problem in the Australian setting, to explore the factors that influence 
them and to recommend the areas that need intervention to improve the usage of high-risk 
medications in patients with CKD. 
The analysis of medication review cases revealed that both aged-care residents and 
community-dwelling older people are often prescribed renally-cleared medicines, outside of 
the recommended guidelines. Drugs like perindopril, fenofibrate, olmesartan, gliptins, 
metformin, bisphosphonates, strontium and ACE-inhibitors were the most inappropriately 
prescribed medications. Patients in aged-care were more likely to be prescribed medication 
inappropriately. Older age, and the presence of diabetes and heart failure were found to be 
associated with patients being prescribed medications inappropriately. 
There was a lack of renal dosing information in the standard information sources. 
Additionally, there was poor consistency in dosing recommendations and renal function 
severity terms used among the sources. This can adversely affect prescribing practices as it 
may confuse or mislead the prescriber and potentially cause them to refrain from using these 
information sources. 
Regular updating of the drug information sources is warranted, along with a need for 
all drugs that are to be used in patients with renal dysfunction to undergo at least one 
pharmacokinetic study in patients with varying degrees of renal impairment prior to marketing. 
An expiry date should be assigned for PIs in order to enforce upgrading the information with 
time. Uniformity in the categorisation of renal impairment and renal dosing information would 
be beneficial to reduce the possibility of inappropriate dosing. 
The marked discrepancies in doses rendered using various renal function estimating 
equations complicate the prescribing decision. There is need for a long-term multi-centre study 
in a diverse population to define the clinical effects of the discrepancies among the equations 
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for drug dosing. Use of a single kidney function estimate for detection, drug dosing and 
management of CKD would facilitate better health care delivery. It can potentially address the 
confusion associated with the existing practice of using different formulae for different 
purposes. 
Pharmacist-conducted drug usage evaluation and monitoring appeared promising in 
decreasing the rate of over dosing, usage of unnecessary drugs, and improving physician 
adherence to dosing guidelines. The problem of dose inappropriateness could be addressed to 
some extent, by provision of  HMRs and RMMRs as these have been found to be effective in 
reducing the use of potentially inappropriate medicine for elderly people in the community. 
The high level of acceptance of pharmacists’ recommendations by the physician indicates the 
greater need for pharmacists to be involved in the care of patients with CKD. Therefore, 
incorporation of the pharmacist in the care of patients with CKD should be considered in health 
care policy decisions.  
The GPs included in our study expressed relatively low awareness of CKD management 
guidelines, uncertainty around acceptable renal function tests, confusion surrounding the most 
correct test for renal dosing and a desire for intervention programs to improve CKD care. 
Additionally, the GPs expressed concerns over the inadequate and ambiguous renal dosing 
recommendations included in the drug information sources. Time constraints, risk of over-
diagnosis associated with automated eGFR, practitioner’s inertia and the logistics of getting a 
test before prescribing, were some of the challenges to ordering a kidney function test.  
Addressing these barriers to using the guidelines with concrete interventions at the 
levels at which they occur would help to improve the dosing in patients with CKD. A series of 
brief, individualised training sessions on available sources and updated information on renal 
dosing could help enhance skills to effectively access information sources. Designing and 
implementing a tool that integrates multiple information sources into a single interface, would 
decrease the time required to seek information and help prescribers consult multiple sources, 
each with a varying design and interface in a single platform. Decision support systems can be 
incorporated within the prescribing software, that could alert the provider to potentially order 
a renal function test. The alert could also provide references to guidelines and information 
sources that would guide dosage adjustment. Online medical education focusing on updated 
information can potentially address the confusion associated with the existing practice of using 
different formulae.  
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Guidelines that are unclear, controversial or based on opinion are less likely to be 
employed in clinical practice. Updating the information sources to present the key elements in 
an unambiguous format, in conjunction with efforts to build consensus among the standard 
information sources, may be necessary. GPs can accordingly incorporate the recommendations 
into practice.  
In conclusion, improved dissemination of existing guidelines, online education to 
increase awareness of available guidelines, and decision support systems to aid GPs in 
identifying renally-cleared drugs appear warranted. Formulating education and training 
programs for general practitioners and pharmacists geared towards recognising drugs that 
require caution in renal impairment and the patients at risk is required. Integrating non-
dispensing pharmacists within general practices could support the delivery of healthcare 
services and improve patient outcomes. Non-dispensing pharmacists in general practice can 
assist GPs in a range of areas such as medication management, and developing and managing 
drug safety monitoring systems. Particularly in CKD management, pharmacists can support 
GPs in prescribing by offering advice on renally cleared drugs, drugs to be avoided or used 
with caution in renal impairment and recommending alternate treatment options. Pharmacists 
co-located in general practice can design and deliver patient education sessions to facilitate 
increased medication adherence. Accredited pharmacists conducting HMR and RMMR 
services, contribute to reducing medication errors and adverse drug events and ensure the safe 
and effective use of medicines. These services assist GPs in making better judgments 
concerning patients who require additional medication monitoring and can reassure GPs that 
patients are being managed appropriately. Studies are needed to understand if such 
interventions could improve prescribing practices without substantial economic impacts or 
disrupting the general practice workflow. 
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Appendix 1. List of renally-cleared Drugs examined in the study 
Drugs/Usual maximum dose Dosage adjustment in relation to CrCl values 
Creatinine Clearance, mL/min Maximum dosing recommendation, mg 
Metformin 
500-3000 mg daily  
 
60–90 2000 daily 
30-60 1000 daily 
<30 Avoid use 
Glibenclamide 
 2.5–20 mg daily  
≤50 Avoid use 
Saxagliptin 
5 mg once daily 
<50 2.5 once daily 
Sitagliptin 
100 mg once daily 
30–50 50 once daily 
<30 25 once daily 
Vildagliptin 
50 mg twice daily 
<50 50 once daily 
Perindopril 
Perindopril arginine, 5 -10 mg once 
daily 
Perindopril erbumine, 4-8 mg once 
daily 
30–60 2.5/2 mg once daily 
15–30 2.5/2 mg alternate days 
<15 2.5/2 mg on day of dialysis 
Olmesartan 
20 -40 mg once daily 
<30 Avoid use 
Valsartan 
80-320 mg once daily 
<30 80 once daily 
Fenofibrate 
145 mg once daily 
20–60 96 once daily 
10–20 48 once daily 
<10 Avoid use 
Zoledronic acidb 
5 mg once per year 
<30 Avoid use 
Alendronate 
10 mg once daily or 70 mg once a 
week. 
< 35 Avoid use 
Ibandronic acid 
Oral 50 mg once daily 
IV 6 mg every 4 weeks 
30–50 Oral: 50 every second day, IV: 4 every 4 weeks 
<30 Oral:50 once each week, IV:2 every 4 weeks 
<10 Avoid use 
Risedronate 
5 mg once daily or 35 mg once a 
week or 150 mg once a month 
<30 Avoid use 
Clodronate 
1600-3200 mg daily  
50–80 1600 daily 
30–50 1200 daily 
10–30 800 daily 
<10 Avoid use 
Tiludronate 
400 mg once daily  
<30 Avoid use 
Strontium 
2000 mg once daily 
<30 Avoid use 
Teriparatide 
20 micrograms once daily  
<30 Avoid use 
Duloxetine 
30-120 mg once daily 
<30 30 once daily 
Bupropion 
150-300 mg once daily  
≤ 50 150 once daily 
Rivaroxaban 
 15 mg twice daily for 3 weeks, then 
20 mg once daily. 
<15 Avoid use 
Dabigatran 
 150 mg twice daily 
30-50 110 twice daily 
<30 Avoid use 
Pregabalin 30–60 300 in 1 or 2 doses 
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75-300 mg twice daily 15–30 150 in 1 or 2 doses. 
<15 75 as single dose. 
Gabapentin 
300-3600 mg daily  
50–79 600–1800 daily in 3 doses 
30–49 300–900 daily in 2/3 doses. 
15–29 600 daily in 2/3 doses. 
<15 300 daily 
Levetiracetam 
250-1500 mg twice daily  
50–79 500–1000  twice daily 
30–49 250–750 twice daily 
<30 250-500 twice daily 
Memantine 
5-20 mg daily. 
5–29 10 once daily 
Paliperidone 
3–12 mg once daily 
50–80 6 once daily 
30–50 3 once daily/Avoid injection 
10-30 3 once daily 
<10 Avoid use 
Pramipexole 
125 micrograms-1500 mg 3 times 
daily 
20–50 2.25 once daily 
<20 1.5 once daily 
Varenicline 
0.5-2 mg once daily  
<30 1 daily 
Solifenacin 
5-10 mg once daily 
<30 5 once daily 
Tolterodine 
1-2 mg twice daily 
<30 1 twice daily 
aAll recommendations are based on the Australian Medicines Handbook bIndication for 
osteoporosis 
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Appendix 2. Survey questionnaires 
 
Applicability, utility, and potential barriers to the use of the available guidelines and information 
sources for renal drug dosing purposes: A survey of General Practitioners 
 
We are requesting your assistance in completing this brief survey. The main purpose of this survey is to 
better understand general practitioners’ (GPs) views on applicability, utility, and potential barriers to the 
use of the available guidelines and information sources for renal drug dosing purposes in the primary care 
settings. The overall purpose is to make recommendations on how these might be improved, if deemed 
desirable.  
We are interested to know what information sources or guidelines you currently use for renal drug dosing 
purposes. We would like to know whether you perceive any barriers in accessing these guidelines or tools 
designed to help you with drug use in chronic kidney disease.  
This survey is being distributed to GPs in Australia, and is anonymous. Aggregated information from the 
survey will be released but individual responses will not be identifiable or linked to your email address. 
There are no anticipated risks associated with this research. Completion of the survey is completely 
voluntary and you may withdraw at any time. 
The information provided by you is strictly confidential. You or your practice will not be identified in any 
reports or publications that may result from this study. 
 
Thank you for your participation! 
 
Section A. Demographics and professional information 
1. Please select your gender. o     Female 
o     Male 
 
 
2. How many years have you been practising as a GP 
in the community setting? 
Years…..  
3. Is your practice setting primarily? o     Urban 
o     Suburban 
o     Rural 
o     Other……. 
 
 
4. What state do you predominantly practise in? o     New South Wales 
o     Northern Territory 
o     Queensland 
o     South Australia 
o     Tasmania 
o     Victoria 
o     Western Australia 
 
 
5.  Approximately how many different patients with 
Chronic Kidney Disease (CKD) do you see on average 
in a week? 
Number of patients….  
6. Do you use an electronic prescribing software or 
electronic health record system in your practice? 
o     Yes 
o     No 
 
 
Go to Section 8 
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7. Which prescribing software system are you 
currently using in your practice? 
o     Medical Director 
o     Best Practice 
o     ZedMed 
o     Genie 
o     MedTech32 
o     Practix and Profile 
o     Other…. 
 
Section B. Approach to drug dosing 
8. What is your preferred renal function measure for 
drug dosing purposes? 
o Serum creatinine 
o Laboratory eGFR 
o Estimated Creatinine Clearance-
calculated using kidney function 
estimating equation 
 
 
9. For the prescription of drugs in elderly patients, do 
you take into account 
o Estimated creatinine clearance 
o Serum creatinine level 
o Laboratory eGFR 
o Unsure 
 
 
10. Before prescribing to elderly patients, do you 
evaluate the renal function 
o For all new drugs for the patient 
o Only for certain drugs 
o Regularly even for a repeat 
prescription for chronic 
medications 
 
 
11. How practical or feasible it is for you to assess 
renal function before prescribing a renally excreted 
or nephrotoxic medicine? 
o Very practical or feasible 
o Fairly practical or feasible 
o Not practical or feasible 
o Unsure/no response 
 
 
12. Do you recognise any of these as factors that 
restrict you from ordering a kidney function test? 
Please select all that apply. 
o Limited time/more urgent 
patient issues 
o Cost associated for patient 
o Patient’s non-adherence 
o Do not believe it is necessary 
o Not recommended by existing 
CKD guidelines 
o Communication barriers with 
the patient 
o Fear of being perceived as 
‘over-servicing’ 
o Others…………. 
 
 
13. Has the availability of lab-provided eGFR 
changed the way you diagnose CKD? 
o Yes. 
How…………………………… 
o No. 
o Unsure 
 
 
14. Has the availability of lab-provided eGFR 
changed the way you perform drug dose adjustment? 
o Yes. 
How………………………… 
o No. 
 
185 
 
 
o Unsure 
 
15.  Do you think your referral practice to 
nephrologists has changed since the introduction of 
lab-provided eGFR? 
o Yes 
o No 
o Unsure 
 
 
16. Do you use Cockcroft-Gault equation for 
estimating Creatinine clearance for drug dosing 
purposes? 
o     Yes.  
o     No, I use laboratory eGFR.  
o     Other  
 
Go to question 16a 
Go to question 16b 
Go to Question 17 
16a. While using Cockcroft-Gault equation which 
patient weight do you use? 
o Actual body weight 
o Ideal body weight 
o Adjusted body weight 
o Unsure as I use the online 
calculators 
o Others……………… 
 
 
16b. While using laboratory eGFR for dosing, you 
use 
o eGFR exactly as provided by the 
laboratory 
o I take the lab eGFR provided and 
normalise it for the patient’s 
body surface area for all patients 
o I take the lab eGFR provided 
and normalise it for the patient’s 
body surface only for only 
patients with extremes of body 
weight 
o Unsure 
 
 
17.  Please indicate how strongly you agree with each 
of the following statements. 
 
Bisphosphonates can be used in all stages of CKD 
with correct dosage adjustment. 
 
ACEi/ARBs can safely be prescribed at all stages of 
CKD and should not be deliberately avoided just 
because GFR is reduced. 
o Strongly agree 
o Agree 
o Neutral 
o Disagree 
o Strongly disagree 
 
18. Please circle the appropriate number on the 5-
point scale: Not at all confident 1 to Very confident 5. 
 
How confident you are in identifying nephrotoxic 
drugs, renally-cleared drugs? 
 
How confident are you in determining the optimal 
dose for ACE inhibitors and/or ARB in patients with 
CKD? 
 
How confident you are on determining the optimal 
dose for bisphosphonates in patients with CKD? 
 
How confident you are on determining the optimal 
dose for glibenclamide, metformin and gliptins in 
patients with CKD? 
o 1 – Not at all confident 
o 2 
o 3 
o 4 
o 5 – Very confident 
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Section C. Barriers to using guidelines and how it can be overcome 
19.  How often do you experience difficulties in 
deciding on drug dosages for patients with declined 
renal function? 
o     Often or sometimes 
o     Rarely or never 
 
 
20. Which information source do you mostly use for 
guidance about renal drug dosing in your practice 
setting? Tick only one option. 
o     British National Formulary 
(BNF) 
o     MIMS 
o     Australian Medicines Handbook 
(AMH) 
o     Therapeutic Guidelines 
o     The Renal Drug Reference 
Guide 
o     Contact hospital pharmacist or 
consultant 
o     Contact local pharmacist 
o     None 
o     Other please 
mention…………… 
 
21.  How do you access them? o     Electronically 
o     Paper-based 
 
 
22. What is your rating of the clinical usefulness of 
the information source for assisting with drug dosage 
decisions for patients with CKD? 
o     Very useful 
o     Fairly useful 
o     Not useful 
o     Unsure/no response 
 
 
23. Can you comment on the 
guidelines/recommendation’s reliability? 
o     Very reliable 
o     Fairly reliable 
o     Not reliable 
o     Unsure/no response 
 
 
24. Are the guidelines easy to access? o     Yes 
o     No, it requires too much time 
navigating 
o     Unsure/no response 
 
 
25. Are the recommendations applicable to primary 
care settings? 
o     Very or fairly applicable 
o     Not useful 
o     Unsure/no response 
 
 
26. Has the Kidney Health Australia- “CKD 
management in general practice guidelines” been 
helpful in managing patients with CKD? 
o     Yes 
o     No, I am not familiar with them 
o     No, I am familiar with them, but 
they are not useful in my 
practice 
o     Unsure 
 
 
27. Do you feel any of the following limit accessing the 
guidelines/drug information sources or performing 
dose adjustment in patients with CKD? Please tick all 
that apply. 
o     Lack of time 
o     Lack of investment by health 
authorities for routine 
assessment of renal function 
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o     The information source: lack of 
information, ambiguous 
information 
o     Lack of hard evidence 
o     Not recommended by existing 
guidelines 
o     Evidence not related to context 
of primary care 
o     Too much evidence 
o     Do not believe reduced dose 
will improve patient outcome 
o     I don’t know where to look for 
the information 
o     Lack of easy access to 
guidelines 
o     Patient factors - attitudes, 
expectations of patients 
o     The need of lengthy discussions 
with patients 
o     Others.............................. 
 
28. Data from research suggests that inappropriate 
prescribing of renally-cleared drugs in patients with 
renal impairment is not uncommon. Which of the 
following factors do you feel may contribute to this? 
Please select all that apply. 
o Insufficient information on 
appropriate drug doses for the 
particular patient 
o     Insufficient access to dosing 
information during 
consultation 
o     GPs not making use of 
information they have on drug 
dosing 
o     GPs not making use of 
information about individual 
patients 
o     Lack of routine renal function 
assessment 
o     Lack of awareness on 
availability of information 
sources 
 
 
29. Which of the following interventions would most 
appeal to you to help optimise the medication for 
patients with CKD? Rank most important to least 
important as 1-6. 
o     Clinical decision support 
systems that assist with drug 
dosing decisions 
o     Academic detailing visits by a 
nephrologist 
o     Pharmacist-conducted 
medication reviews 
o     Online training and education 
o     Continuing medical education 
lectures 
o     Face to face and online learning 
modules 
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Appendix 3. Invitation for the survey 
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